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Producing single-sex litters can have a positive impact for many applications, including 
reducing disease-spreading vectors, increasing effective breeding populations for 
conservation, in agricultural biology, and in research; reducing unnecessary animal 
culling, in accordance with the Home Office 3Rs. In the laboratory mouse model, Mus 
musculus, males carry the sex chromosome complement XY. The daughters inherit the X 
chromosome, and the sons inherit the Y chromosome.  In this thesis I exploit the unique 
inheritance of the X and Y chromosome from the male heterogametic sex to investigate 
multiple methods of generating all-male or all-female litters. Co-inheritance of two 
alleles, one from the father and one from the mother, which only upon the presence of 
both alleles causes embryonic lethality, was called a bi-component system. I first 
performed a proof-of-principle strategy utilising two pre-existing mouse models, X-Cre 
and an inducible Rosa26-DTA. Diphtheria toxin A (DTA) expression was only active 
upon excision of a floxed-STOP cassette by Cre recombinase. Co-inheritance of the X-
Cre allele from the father, and Rosa26-DTA allele from the mother resulted in activation 
of the DTA and female-specific embryonic non-viability. In an alternative approach, I 
used CRISPR-Cas9 to generate mutations in a target housekeeping gene by co-inheritance 
of a Cas9 and sgRNA transgene. I first investigated the mutation efficiency of multiple 
sgRNAs in vitro, targeting an essential gene Topoisomerase 1. Highly-mutagenic sgRNA 
constructs were then carried forward to generate sgRNA-expressing mouse lines via 
recombination-mediated transgenesis. The sgRNA-expressing mice were mated with a 
pre-existing Rosa26-Cas9 mouse line. I showed that co-inheritance of the Cas9 and 
sgRNA transgene induced mutations in the target Topoisomerase 1 locus. Co-inheritance 
of the two transgenes also resulted in embryonic non-viability due to loss-of-function of 
Topoisomerase 1, whilst inheritance of a single transgene did not result in loss-of-
function mutations. Lastly, in order to generate sex-specific mutations by CRISPR-Cas9, 
I generated sex chromosome-linked Cas9 transgenes. I showed that the X-Cas9 transgene 
expressed Cas9 in vitro and in vivo, and in the future this line may be a useful tool for 
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Chapter 1. Introduction 
Sexual reproduction, the process of combining genetic information from two individuals 
into a single organism with a new genotype, is found in many species in the animal and 
plant kingdoms. The genetic information that will be inherited from the parents to the 
next generation is carried in a specific type of cell, called a gamete. In males, these 
gametes are called sperm. In females, the gametes are called oocytes. Fertilisation of an 
oocyte by a sperm results in the production of a zygote, the earliest form of the developing 
embryo, made up of just one cell. The zygote undergoes hundreds of cell divisions and 
cell differentiation processes to form a fully developed offspring.  
 
The chromosome complement that the embryo inherited from the parents at fertilisation 
will also predispose the embryo to developing male- or female-specific characteristics. 
These male- or female-specific characteristics are known as sexual dimorphisms. 
Examples of sexual dimorphisms include anatomical or physiological differences, such 
as muscle mass, height and gonadal differentiation. Furthermore, sex differences are not 
limited to anatomy and physiology, but have also been shown to influence behaviour, 
personality and even susceptibility to some diseases (Snell and Turner, 2018). The sex-
specific differences are largely dependent on which combination of sex chromosomes are 
inherited. The combination of sex chromosomes means that males and females inherit 
different chromosome complements and gene expression of these sex chromosomes 
induces downstream pathways to induce sex-specific primary and secondary 
characteristics.  
 
The sex-specific characteristics seen in male/female anatomy and physiology have been 
exploited since the domestication of agricultural animals in order to maximise output for 
food and economic purpose. Examples of artificial selection include breeding male cows 
with larger muscle mass for meat consumption, or females with greater milk production. 
The growing human population size means there is an ever-increasing requirement for 
the surplus of a specific sex to increase production in farming and agriculture. Methods 
of generating single-sex litters to maximise output, for example in dairy cows or layer 
hens in agriculture, are actively being researched. Importantly, an understanding of the 
Chapter 1 Introduction 
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regulation of genetic sex determination is required in order to influence Mendelian 
offspring sex ratios. The development of genetic tools to skew sex ratios is a major focus 
of this thesis.  
 
In this thesis, I will first introduce the concept of genetic sex determination, the 
nomenclature of the mammalian sex chromosomes, and theory of sex chromosome 
evolution. I will then give further background to the heterogametic XY system in 
mammals; specifically, the role of the X and Y chromosomes in mammalian 
development, and sex chromosome gene expression. Finally, I will give a brief history to 
the development of CRISPR-Cas9 genome editing tools, and current methods of 
generating single-sex litters. 
 
1.1 Sex determination  
Around 335 BC, Aristotle stipulated that the temperature of the father during conception 
would determine the sex of the offspring produced; a father significantly warmer than the 
mother would result in a male child, whilst a cooler father would result in female child. 
Environmental theories regarding sex determination remained extremely well regarded 
for hundreds of years, and in fact, temperature remains an important regulator of sex 
determination in some reptile species to this day (e.g. Kohno et al., 2014). However, in 
the early 1900s, the ground-breaking discovery of the sex chromosomes by Nettie Stevens 
and Edmund Beecher Wilson changed the way we understand the genetics of sex 
determination. Stevens showed that male and female mealworms have two slightly 
different chromosome complements. Female mealworms carried 20 chromosomes, but 
males carried 19 plus 1 distinctly smaller chromosome. She described how this very small 
chromosome could be uniquely traced to sperm that produce only male offspring 
(Stevens, 1905b, Stevens, 1905a). This was the first description of the male-determining 
Y chromosome and showed that mealworm males are the ‘heterogametic’ sex. 
Heterogamety refers to the production of gametes which carry one of two possible sex 
chromosomes (as well as the autosomes). If the male is the heterogametic sex, such as in 
humans and mice, the sex of the offspring is dependent on which sex chromosome is 
Chapter 1 Introduction 
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carried by the sperm that fertilises the oocyte. The homogametic sex produces gametes 
that all carry the same sex chromosome.  
 
In 1909, Wilson concluded that inheritance of a specific combination of sex chromosomes 
was the genetic cause of sex determination (Wilson, 1909). He called the large 
chromosome “X” and the smaller “male” chromosome “Y”. Therefore, males carried the 
sex chromosome complement XY. The X is inherited from the homogametic female that 
produces only X-carrying oocytes, and the Y from a Y-carrying sperm. Females carry the 
sex chromosome complement XX; an X from the oocyte and an X from a X-carrying 
sperm. This X/Y nomenclature is also used in the mammalian sex determination system. 
The nomenclature of the sex chromosomes was based on much earlier work by Hermann 
Henking in 1891 who called a large chromosome found in Pyrrhocoris apterus sperm 
“X”. In 1960, an international panel determined that the autosomes would be numbered, 
and the X and Y sex chromosomes would remain lettered (Lejeune et al., 1960).  
 
The X/Y nomenclature of the sex chromosomes is not used for all species. In birds, the 
heterogametic sex is the converse to mammals. Female birds have a sex chromosome 
complement ZW, producing two different sex chromosome-carrying gametes (Z or W). 
The male birds are the homogametic sex, with all gametes carrying a Z-chromosome. 
Male offspring therefore have the sex chromosome complement ZZ.  
 
The early work by Stevens and Wilson confirmed that inheritance of a Y chromosome 
meant that the embryo developed as male. However it was unknown whether male 
development was directly caused by the Y chromosome, or what the influence of carrying 
a single X versus the two X chromosomes in females was. In 1959, the human male-
determining factor was uncovered during two studies of human disorders of sex 
development (DSD); Turner syndrome (Ford et al., 1959) and Klinefelter syndrome 
(Jacobs and Strong, 1959). In both Turner syndrome and Klinefelter syndrome there is 
aneuploidy of the sex chromosomes. Turner syndrome patients have a single X 
chromosome (XO) whilst Klinefelter patients are trisomic, having two X chromosomes 
and a Y (XXY). Turner syndrome patients show female characteristics, despite having a 
single X whilst Klinefelter syndrome patients develop male characteristics, despite 
Chapter 1 Introduction 
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having two X chromosomes. This finding highlighted that, in humans, the presence of the 
Y chromosome, and not the copy number of the X chromosome, gives rise to male 
characteristics. The testis-determining factor (TDF) therefore must be a Y chromosome-
linked factor.  
 
The first suggested TDF was a eutherian Y chromosome-linked gene called ZFY (Zinc 
finger protein Y-linked; Page et al., 1987), however this gene was autosomal in 
marsupials, suggesting it was unlikely to have a role in sex determination (Graves, 2006). 
Sinclair and colleagues also showed that ZFY was not expressed in the somatic cells of 
the testis, confirming that ZFY was unlikely to have a role in sex determination (Palmer 
et al., 1989). In 1990, a gene on the Y chromosome that encodes for male characteristics 
was discovered in humans. During a study of sex-reversed men, Sinclair et al discovered 
that the patients all had a translocation of the Y chromosome. Common to all of the 
patients was a small Y-linked gene contained within this translocation, called SRY (Sex-
determining region on the Y; Sinclair et al., 1990). In the same year, the homologous Sry 
gene was discovered in the mouse (Gubbay et al., 1990). In 1991, experimental studies 
confirmed that Sry was an essential male sex-determining gene. Koopman et al showed 
that when a Sry transgene was introduced into female mouse embryos containing the 
usual complement of two X chromosomes, the females showed male developmental 
characteristics, such as testes (Koopman et al., 1991). Moreover, SRY was also found to 
be on the Y chromosome in marsupials (Foster et al., 1992). SRY/Sry is only present in 
eutherian and metatherian mammals. The platypus, a monotreme, has no SRY gene. They 
have five X chromosomes and five Y chromosomes, which are more similar to the bird 
ZW than to human XY sex chromosomes (Veyrunes et al., 2008). However, one potential 
TDF in protherians (e.g. platypus) is a Y-linked gene AMH (Anti-Mullerian hormone; 
Cortez et al., 2014), which is thought to have a role in sex-determination in many fish 
species (Hattori et al., 2012). The function of SRY/Sry in mammalian sex determination 
will be described further in 1.4. 
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1.2 Evolution of the XY sex chromosomes   
Although the concept of genetic sex determination first arose in the early 1900s, it was 
not until some years later, in 1914, when Hermann Muller hypothesised how the sex 
chromosomes may have arisen during evolution, based on studies in Drosophila. Muller 
theorised that the sex chromosomes were unable to pair and undergo crossing-over during 
meiosis. Therefore the X and Y chromosome accumulated recessive deleterious 
mutations that were kept heterozygous due to a lack of recombination, and were therefore 
effectively neutral (Muller, 1914). Gradually, the number of recessive lethal mutations 
accumulated, resulting in the wildtype locus being lost from the population and the 
mutations become fixed. Muller hypothesised that the process of recombination and 
crossing-over was advantageous for the population and therefore sexual reproduction was 
preferable over asexual reproduction (Muller, 1914, Muller, 1964, Muller, 1932). The 
process of irreversible accumulation of deleterious mutations was coined “Muller’s 
Ratchet” (Felsenstein, 1974). 
 
In 1967, Susumo Ohno’s hypotheses built on the concept that sex chromosomes 
originated from a pair of autosomes that originally could undergo normal pairing and 
recombination. Ohno suggested that a random mutation had occurred on one of the two 
autosomes, meaning the pair of chromosomes were then heteromorphic (Ohno, 1967). 
The gene containing this mutation is described as the early sex-determining gene and the 
chromosome became the “proto-Y” (grey line, Figure 1). The occurrence of this male-
specific sex-determining gene on the proto-Y resulted in the surrounding proto-Y genes 
being selected for male-specific function (dark blue lines, Figure 1). The accumulation of 
male-function genes in this region inhibited recombination between the X and Y at this 
position (light blue, Figure 1). Ohno theorised that a gene duplication and inversion event 
of the Y-linked region containing the sex-determining gene further supressed crossing-
over between the proto-X and proto-Y (“Ohno’s hypothesis”; Ohno, 1967). The lack of 
recombination of the proto-X and proto-Y meant that deleterious mutations occurring at 
gene loci (red lines, Figure 1) were then lost by degeneration of the Y chromosome due 
to genetic drift. Over millions of years, this degeneration and loss of Y chromosome-
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linked genes has led to a massive reduction in the Y chromosome size compared to the 
X, and the Y is extremely gene-poor (Figure 1).  
 
The ‘modern-day’ XY sex chromosomes, evolving over the last 166 million years (Snell 
and Turner, 2018, Bellott et al., 2014); Figure 1), now encompass only a small region  of 
continuous sequence homology between the two chromosomes, known as the 
pseudoautosomal region (PAR; purple, Figure 1). The PAR is thought to have arisen 
during an autosomal translocation event, as many of the genes contained within the PAR 
in eutherians are still autosomal in metatherians (Toder and Graves, 1998, Park et al., 
2005, Waters et al., 2007). The human and mouse C57BL/6 PAR have very limited 
homology (Disteche et al., 1992) and humans have two separate PARs that lie at each end 
of the sex chromosomes (Cooke and Smith, 1986). In the mouse, the single PAR contains 
only five protein-coding genes (Mueller et al., 2013, Bellott et al., 2014). The presence 
of the PAR allows the X and Y chromosomes to pair during meiosis (Burgoyne, 1982, 
Ellis and Goodfellow, 1989). Deletion of the PAR results in failed X-Y pairing during 
meiosis and male infertility (Mohandas et al., 1992, Matsuda et al., 1992). The genes 
contained within the PAR are not susceptible to mechanisms of dosage compensation, as 
they are retained in two copies in males and females (Ellis and Goodfellow, 1989, Ross 
et al., 2005, Burgoyne, 1982).  
 
To further understand the evolution of the modern X and Y chromosome, comparisons of 
gene content between three major groups of mammals; eutherians, metatherians and 
monotremes was performed. In all three groups, a region of the X chromosome is 
maintained, called the ‘ancient’ region. This conserved region contains homology to the 
chicken autosome 4 (Nanda et al., 1999, Ross et al., 2005, Bellott et al., 2010, Fridolfsson 
et al., 1998, Bellott et al., 2017). In eutherian mammals, the X chromosome has also 
gained additional autosomal regions fused to the X chromosome (“X-added regions”, 
XARs), generating a larger X compared with marsupials and monotremes. This XAR 
contains homology to the chicken autosome 1 (Nanda et al., 1999, Ross et al., 2005, 
Bellott et al., 2010, Fridolfsson et al., 1998, Bellott et al., 2017). These extra regions have 
therefore arisen on the X chromosome since the divergence of eutherians and marsupials, 
approximately 166 MYA (Bellott et al., 2014). The XAR contains many genes shared by 
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the X and Y, suggesting that there was also additions to the Y chromosome (“Y-added 
region”, YAR). Most likely, these additions also arose by translocations of autosomal 
regions and they have remained autosomal in marsupials and monotremes (Graves, 1995, 
Graves et al., 2006, Toder and Graves, 1998). Furthermore, modern-day mammalian and 
bird sex chromosomes have likely arisen as separate evolutionary events, shown by 
genomic and transcriptomic studies (Bellott et al., 2014, Bellott et al., 2010, Graves et al., 
2006, Cortez et al., 2014). The chicken ZW sex chromosomes contain homology to the 




Figure 1. Evolution of the sex chromosomes 
The modern X and Y sex chromosomes are thought to have arisen from an ancestral pair of 
autosomes approximately 166-148 million years ago (Snell and Turner, 2018, Bellott et al., 2014). 
One of these chromosomes, the proto-Y, acquired a spontaneous mutation (white line), in the 
early ‘sex-determining’ region. Accumulation of mutations on the sex specific proto-Y (dark blue 
lines) thereby resulted in inhibition of recombination between the proto-X and proto-Y. The 
proto-X is thought to have gained a new, fused region, translocated from an autosome (green); 
the X-added region (XAR). The inhibition of recombination resulted in the proto-Y gaining 
deleterious mutations (red lines) that are unable to be lost by recombination, thereby resulting in 
rapid degeneration of the proto-Y chromosome. Eventually, the Y chromosome was significantly 
degenerated, containing many multicopy, ampliconic, or male-specific genes. The modern day 
sex chromosomes contain only homology at the pseudoautosomal region (PAR; light purple). The 
X chromosome is thought to be made up of 5 evolutionary strata (coloured numbers).  
 
Y-chromosome degeneration has resulted in retention of significantly fewer protein-
coding genes compared to the X chromosome (Skaletsky et al., 2003). Given that so few 
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Y-linked genes remain, there has been much speculation about whether these persisting 
Y-chromosome genes have been retained by chance, or whether they have an essential 
male-specific function (Lahn and Page, 1997).  This will be discussed further in 1.4. 
Another major consequence of the Y-chromosome degeneration was the unequal X-
chromosome gene expression output between males that contain one X chromosome, and 
females that contain two X chromosomes. The system of female X chromosome 
inactivation (XCI) and X chromosome upregulation (XUR) ensures equal expression 
from the X chromosome in males and females, and in balance with diploid autosomes. 
The X chromosome and autosome balance is called “dosage compensation” and was 
hypothesised by Susumo Ohno (Ohno, 1967). Dosage compensation is described in 
greater detail in 1.3. 
 
1.3 X-chromosome functions in the germline 
Autosomal genes spend an equal amount of time in males and females, as both of the 
sexes are diploid. Therefore, if a mutation arises, any recessive effects can be neutral in 
a heterozygous genotype. However for the sex chromosomes it is more unbalanced. When 
the male is the heterogametic sex, such as in humans, the X chromosome is present two-
thirds of the time in females, but only one-third of the time in males (Rice, 1984). If a 
mutation arises on the hemizygous X chromosome in males, there is no wildtype allele to 
mask the mutated allele, and this mutation could result in a fitness benefit or cost. If the 
effect is beneficial to the male, it may be fixed and spread through the population. If the 
effect has a fitness cost, it may be deleterious and lost in the population. Therefore, 
recessive mutations on the X chromosome may be under greater selection compared to 
the autosomes. This comparatively increased rate of selection on the X is called the 
“faster-X” effect (Vicoso and Charlesworth, 2009, Vicoso and Charlesworth, 2006).  
 
The “faster-X” may have a higher rate of selection acting on the chromosome compared 
to autosomes when recessive mutations occur, but this rate can also be influenced by 
mutations in sex-biased genes. If a sex-biased autosomal gene gains a mutation that 
provides a fitness benefit for females, but not for males, it will only increase in the 
population if the advantage is significantly higher than the disadvantage. However if the 
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mutation occurs in an X-linked gene that provides a fitness benefit for females, it is more 
likely to be passed on to the next generation, because the X chromosome is present more 
often in females (two-thirds versus one-third in males). On the converse, X-linked 
mutations that are beneficial for males but have a fitness cost for females, can also become 
fixed quickly, as the fitness effect is expressed in single X-carrying males, and is hidden 
by heterozygosity in females. Overall, there is a sexual antagonism between sex-bias 
genes. The X chromosome can accumulate these male-specific or female-specific 
beneficial mutations, resulting in an accumulation of sexual antagonism of sex-specific 
genes carried on the X chromosome relative to the autosomes. This is known as Rice’s 
hypothesis (Rice, 1984, Vicoso and Charlesworth, 2006).  
 
Although the X is present more in females, many male-specific genes on the X 
chromosome are exclusively expressed in pre-meiotic and/or post-meiotic germ cells in 
the testis (Hurst, 2001, Wang et al., 2001, Lercher et al., 2003, Khil et al., 2004). A screen 
for spermatogonial-expressed genes in the mouse showed that a disproportionately high 
number are X chromosome-linked (Wang et al., 2001). Of the genes expressed in pre-
meiotic germ cells, many are single copy (Wang et al., 2001). Conversely, many of the 
testis-specific genes expressed in post-meiotic germ cells are highly ampliconic, referring 
to duplications of regions that are greater than 10kb in length and share greater than 99% 
sequence similarity. These ampliconic genes contribute approximately 13% of the X 
chromosome in humans, and 17% in the mouse (Mueller et al., 2013, Mueller et al., 2008, 
Ross et al., 2005). Many of the X-linked amplicon genes are cancer testis antigens 
(CTAs). CTA genes are highly expressed in multiple cancer types and in spermatogonia 
(Stevenson et al., 2007, Simpson et al., 2005). Many of the CTA gene families on the X 
chromosome are organised into complex inverted repeats (Simpson et al., 2005). As many 
as 10% of genes on the human X chromosome are in CTA families (Ross et al., 2005).  
 
During male germ cell meiosis, the X chromosome (and Y chromosome) are silenced, in 
a process called meiotic sex chromosome inactivation, MSCI (Turner, 2007). It has 
therefore been suggested that the post-meiotic germ cell genes have been amplified on 
the X chromosome in order to achieve sufficient expression levels post-MSCI, when the 
majority of X-linked genes remain silenced (Mueller et al., 2008, Turner, 2007), and that 
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the amplified X-genes may be essential for spermiogenesis and sperm elongation. 
Further, in the mouse, functional pseudogenes have been copied onto autosomes from the 
X chromosome by retrotransposition (Adra et al., 1988). Transposition onto an autosome 
may allow escape from MSCI. Unlike single copy and multi copy genes, ampliconic 
genes do not share homology between humans and mice and appear to have been acquired 
independently (Mueller et al., 2013).  
 
Furthermore, X-linked genes that have testis-specific function have also been shown to 
be expressed very highly in the brain compared to other somatic tissues (Zechner et al., 
2001, Nguyen and Disteche, 2006). Over 100 X-linked genes have been implicated in 
patients with intellectual disabilities (Skuse, 2005, Ropers, 2010).  
 
The X chromosome also contains genes that have essential female functions. As earlier 
described, the X chromosome consists of ‘ancient’ regions that are shared by eutherians 
and metatherians, and ‘added’ regions which are unique to eutherians. Genes contained 
within the ancient region of the human and mouse X chromosome are usually female-
biased and highly expressed in the ovary and placenta (Khil et al., 2004). The ovary-
specific X-linked genes are dosage sensitive; XO (Turner syndrome) females who have 
a single X present ovarian dysgenesis, supporting theories that these ovary-specific X-
linked may be required in two copies.  
 
Rice’s hypothesis highlights that sexual antagonism may allow genes that have a role in 
male- or female-specific function to become accumulated, either on the X chromosome 
or via translocation to an autosome. This is a different evolutionary force to Ohno’s 
hypothesis, which predicted equal dosage of sex chromosome-linked genes between 
males and females, thereby suggesting that gene amplification would be unlikely. 
Therefore, X-linked genes may be under different evolutionary forces dependent on gene 
function. 
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1.3.1 Dosage compensation 
Females carry two X chromosomes, whilst males have a single X. Therefore, the X-linked 
protein-coding genes are present in twice the copy number in females, compared to males. 
Ohno hypothesised that a mechanism of dosage compensation is employed to balance the 
X chromosome output between males and females and prevent ‘aneuploidy-like’ effects 
in male cells (Ohno, 1967). The unbalanced gene dosage in males could be simply 
combatted by up-regulating all X-linked genes two-fold, to match the X chromosome 
output of female cells. However, a consequence of the two-fold X-linked gene 
upregulation is a two-fold increase in X chromosome to autosome output in females. This 
problem of dosage is thereby solved in ‘two-steps’. Firstly, X-linked genes in male and 
female cells are up-regulated (X-upregulation; XUR), resulting in an X chromosome to 
autosome (X:A) ratio of ‘1’ in males, and ‘2’ in females. The output of the X chromosome 
is therefore balanced with the diploid autosomes, in males. This process of XUR will be 
described in further detail in 1.3.2. In females, the second step, X chromosome 
inactivation (XCI) occurs. In this process, one X chromosome is transcriptionally 
silenced, bringing the overall X chromosome gene expression level back to ‘1’, 
equivalent to the autosomes. This will be discussed further in 1.3.3 and 1.3.4. 
 
1.3.2 X-chromosome upregulation 
Ohno hypothesised that the single male X chromosome would need to balance with 
autosomal gene output, by upregulating X-linked genes two-fold. The extent of XUR is 
calculated by dividing the medium expression of X-linked genes (X) by the medium 
expression of autosomal genes (A); giving the X:A ratio. An X:A=1 indicates that the X-
linked genes have been upregulated, in keeping with Ohno’s hypothesis. An X:A=0.5 
suggests that the X-linked gene output has not been upregulated and is half the autosome 
output. The X:A ratio also takes into account the number of active X chromosomes 
compared to the autosomes. Lyon and Grumbach hypothesised that cells are able to 
‘count’ the number of active X chromosomes (Lyon, 1962, Grumbach et al., 1963). Cells 
are therefore able to maintain a single active X chromosome with the expected X:A ratio, 
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even if the females have a single X (XO, Turner syndrome) or have multiple Xs (e.g. 
XXY, Klinefelter syndrome).  
 
Evidence for XUR first arose from analysis of the gene Clcn4. In Mus musculus this gene 
is autosomal, whilst in a different mouse species, M. spretus, the gene is X-linked. Adler 
et al showed that expression of Clcn4 in M. spretus is twice that of M. musculus. The 
two-fold up-regulation of Clcn4 in M. spretus was the first indication that X-linked genes 
undergo XUR (Adler et al., 1997). Subsequently, XUR has been assayed at the whole 
chromosome level. Two studies utilised microarrays to support Ohno’s hypothesis of 
XUR (Gupta et al., 2006, Nguyen and Disteche, 2006). However an RNAseq study 
reported the opposite; with X:A ratio of approximately 0.5, thereby rejecting Ohno’s 
hypothesis (Xiong et al., 2010). A reanalysis of this RNAseq data was performed more 
recently, filtering out non- and lowly-expressed genes. These original RNAseq studies by 
Xiong et al, were performed in somatic tissue, and therefore highly enriched and 
ampliconic X-linked genes which are only expressed in the testis and ovary were included 
in the analysis. The inclusion of these lowly-expressed genes artificially lowered the X:A 
ratio. When the lowly expressed genes were excluded in the reanalysis, the X:A ratio 
confirmed XUR (X:A~1) and upheld Ohno’s hypothesis (Deng et al., 2011, Kharchenko 
et al., 2011, Lin et al., 2011, Yildirim et al., 2011). Sangrithi et al also showed that in 
somatic tissue, when all genes were included, the X:A ratio were below one. When the 
authors removed genes that were lowly expressed, the X:A ratio equalled at least one, 
showing that male and female somatic tissue undergo XUR (Sangrithi et al., 2017). 
Studies showed that XUR preferentially affects genes with housekeeping function and X-
linked gene products that interact with autosomes (Pessia et al., 2012). The expression 
and dosage of these genes therefore needs to be tightly regulated (Birchler, 2012, Pessia 
et al., 2012, Pessia et al., 2014, Sangrithi et al., 2017, Sangrithi and Turner, 2018).  
 
Other studies have performed slightly different analyses, for example by comparing the 
ratio of the modern X chromosome to the proto-X using human and chicken 
chromosomes (Lin et al., 2012), or by only comparing protein-coding genes that are 
known to be dosage-sensitive (Pessia et al., 2014). These studies confirmed that XUR 
affects X-linked genes that encode protein complexes that interact with autosomal genes. 
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By comparing modern X-linked genes that have autosomal orthologues in the chicken, 
these studies also showed that there is downregulation of autosomal genes that interact 
with X-encoded proteins (Julien et al., 2012, Lin et al., 2012, Pessia et al., 2012). In 2019, 
studies in bovine embryos, which undergo random XCI at the blastocyst-stage (Bermejo-
Alvarez et al., 2011) confirmed evidence for XUR with X:A ratios of one in somatic and 
germline cells (Duan et al., 2019, Ka et al., 2016, Jiang et al., 2014). 
 
1.3.3 X-chromosome inactivation 
XCI reduces genetic output of the two X chromosomes in females from two to one by 
transcriptionally silencing a single X. Major breakthroughs in understanding XCI came 
during the 1960s. Mary Lyon observed that female mice heterozygous for a mutation in 
an X-linked gene show variability in coat colour. She speculated that these patches of 
different colour had arisen as a clonal growth of a specific type of cell that had undergone 
silencing of a single X chromosome (Lyon, 1961). Lyon’s Law is the first description of 
dosage compensation by X chromosome silencing in females. Russell and Bangham also 
showed that similar coat colour patterns occur in mice with autosomal translocations of 
the heterozygous X chromosome coat colour loci (Russell and Bangham, 1961).  
 
Lyon theorised that XCI occurs in three stages; initiation, spreading and maintenance 
(Lyon, 1988) and that XCI may be initiated at a specific region of the X chromosome, 
termed the X-inactivation centre (XIC). Rastan and Robertson (1985) showed that two 
XIC X-linked regions must be present in order for random XCI to occur (Rastan and 
Robertson, 1985). This finding suggested that the XIC had a role in ‘choosing’ which X 
chromosome is silenced prior to the onset of XCI. As well as the process of ‘counting’ 
the number of X chromosomes by the X:A ratio, it is thought that the XIC may also 
function in ‘sensing’ (Augui et al., 2007a). Sensing is very similar to counting but takes 
into account the potential of extra X chromosomes to undergo XCI.  
 
In the 1990s, many studies utilised translocations of the X chromosome to pinpoint the 
exact location of the X-linked XIC (Brockdorff et al., 1991, Leppig et al., 1993, Kay et 
al., 1993). Once the XIC region was narrowed down, a candidate gene for XCI was 
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discovered in 1991. Brown et al discovered a non-coding RNA (ncRNA) that was found 
to have female-specific expression in human somatic cells (Brown et al., 1991, Brown et 
al., 1992) and was situated within the XIC. The ncRNA was called XIST (X-inactive 
specific transcript). The following year, the mouse homologue Xist was discovered 
(Borsani et al., 1991, Brockdorff et al., 1992, Kay et al., 1993). Studies utilising RNA 
fluorescence in situ hybridisation (RNA-FISH) showed that the XIST/Xist RNA molecule 
specifically coats the inactive X (Xi) and can be detected as an RNA cloud in the nucleus 
(Clemson et al., 1996, Brown et al., 1992, Engreitz et al., 2013, Simon et al., 2013). To 
elucidate how XIST/Xist may function to silence the inactive X chromosome, Penny et al 
deleted a region of one of the Xist alleles in female embryonic stem cells (ESCs) and 
proved that Xist is an essential requirement of XCI. Further, targeting Xist in ESCs 
resulted in an XCI skew, inducing Xist expression from the non-targeted allele (Penny et 
al., 1996). An Xist cDNA transgene integrated onto an autosome induced silencing of the 
autosomal genes, showing that Xist was functional to silence genes that were not X-linked 
(Wutz and Jaenisch, 2000). Lee et al utilised a yeast artificial chromosome (YAC), where 
the Xist gene was contained within a 450kb region. The YAC was transfected into XY 
mouse ESCs. Upon differentiation of the ESCs, results showed that the Xist transgene 
was able to induce silencing in many of the genes in the surrounding YAC region (Lee et 
al., 1996, Lee and Jaenisch, 1997). These results confirmed Xist as an essential gene for 
XCI. 
 
Activation and expression of Xist generates a ncRNA which is spliced and polyadenylated 
before coating the Xi in cis (Brockdorff et al., 1991, Borsani et al., 1991, Clemson et al., 
1996, Brown et al., 1992, Engreitz et al., 2013, Simon et al., 2013). To investigate some 
of the other factors regulating Xist expression, studies have generated loss-of-function 
mutations in candidate genes and assessed the effect on XCI (Pontier and Gribnau, 2011). 
There are several X-linked genes that are proposed to have a role in Xist activation. One 
example is the X-pairing region (Xpr) which mediates interactions between the two XICs 
in XX cells (Augui et al., 2007b). Another example is Rnf12/RLIM (Ring finger protein, 
LIM domain interacting), a protein-coding gene (Jonkers et al., 2009) which is thought 
to regulate X chromosome counting and activate Xist directly. Overexpression of Rnf12 
in either male or female cells triggers ectopic XCI (Jonkers et al., 2009), and Rnf12 knock-
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out in females shows reduced XCI (Barakat et al., 2011). A third example is Jpx (Enox). 
Jpx (Just proximal to Xist) encodes for a ncRNA and may enable Xist expression by 
interfering with Tsix (X-inactive specific transcript antisense; Tian et al., 2010, Jonkers 
et al., 2009). Tsix is an anti-sense RNA that represses Xist activity (Lee et al., 1999) 
thereby maintaining the transcriptional activity of the active X (Stavropoulos et al., 2001, 
Shibata and Lee, 2004, Sado et al., 2006, Ohhata et al., 2006). Deletion of the Tsix 
promoter in one allele of XX cells in vitro results in skewed XCI (Lee and Lu, 1999, Lee, 
2002, Migeon et al., 2002, Stavropoulos et al., 2001) but does not result in ectopic Xist 
upregulation (Morey et al., 2001). A homozygous deletion of Tsix however, does appear 
to result in increased Xist expression (Lee, 2005) and the authors suggest Tsix has a role 
in X-chromosome counting. Once Xist is expressed, it is thought to recruit chromatin 
remodelling complexes to the Xi. One example of these proteins is PRC2 (Polycomb 
repressive complex 2), which trimethylates lysin 27 on histone H3 (H3K27; Marks et al., 
2009, Marks et al., 2015), an epigenetic mark associated with inactive chromatin. The 
XIC region upstream of Xist, containing Jpx and Xpr, amongst others, is also highly 
enriched in H3K9 dimethylation and H3K27 trimethylation (Heard et al., 2001, 
Rougeulle et al., 2004).  
 
Once XIST/Xist is expressed, the ncRNA coats the X chromosome in cis. Lyon proposed 
that “long interspersed nuclear elements” (LINEs), which are highly repetitive elements 
abundant on the mouse X chromosome, may facilitate Xist spreading (Lyon, 1998). 
Bailey et al showed that the mouse X chromosome is enriched in LINEs compared to the 
autosomes, and that there is significant clustering of these elements around the XIC 
(Bailey et al., 2000). They hypothesised that this enrichment of LINEs on the X 
chromosome may allow for propagation of XCI along the chromosome (Bailey et al., 
2000). Chromosome silencing due to Xist-containing translocations are significantly less 
efficient at Xist spreading compared with on the X chromosome. This suggests that these 
LINE-poor regions have slower Xist spreading (Sharp et al., 2002). Ross et al also showed 
that the human X chromosome was significantly enriched for LINEs. They confirmed 
that the XIC was highly LINE rich, although interestingly the Xist locus was 
comparatively LINE poor (Ross et al., 2005).  
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1.3.4 Imprinted X inactivation in the mouse pre-implantation embryo 
After fertilisation of the mouse oocyte to form the single-cell zygote embryo, successive 
rounds of cell division give rise to the 2-cell (E1.5), 4-cell (E2.0) and 8-cell (E2.5) stages 
of the pre-implantation embryo. At the 2-cell stage, embryonic genes become 
transcriptionally active, in a process called embryonic genome activation (EGA; Flach et 
al., 1982, Bernstein and Mukherjee, 1972). Prior to EGA, embryonic development relies 
on a store of mRNAs deposited in the embryo by the maternal oocyte. The maternally-
loaded mRNAs are degraded after EGA (Clegg and Piko, 1983, De Leon et al., 1983, 
Wassarman and Kinloch, 1992). After the 8-cell stage, the embryo undergoes compaction 
and asymmetric divisions, giving rise to the morula-stage (16-32 cells, E3.0) embryo. 
Individual cells of the morula-stage embryo are morphologically indistinct (Ducibella and 
Anderson, 1975). The totipotent blastomeres (individual cells of the embryo) become 
lineage specified as the embryo develops, due to the expression of different factors. By 
E3.0 to E3.5, the late-morula to early-blastocyst-stage, the blastomeres have been lineage 
specified to form either the inner cell mass (ICM) or the trophectoderm (TE; Figure 2). 
This lineage specification is the first cell-fate decision. By E4.0-4.5, the late blastocyst-
stage, the embryonic cells have further diverged into three lineages (Gardner, 1985, 
Dietrich and Hiiragi, 2007, Rossant and Tam, 2009). Cells of the ICM become either 
epiblast (Epi) or primitive endoderm (PE, Figure 2). The Epi is marked by expression of 
transcription factor Nanog (Chazaud et al., 2006, Chambers et al., 2003, Mitsui et al., 
2003), whilst the PE is marked by expression of Gata6 (GATA-binding factor 6; Chazaud 
et al., 2006). The pluripotency factor OCT4 (Octamer-binding transcription factor 4, 
encoded by Pou5f1; POU class 5 homebox 1) is highly expressed in ICM cells, 
maintained in Epi cells, and downregulated in PE cells (reviewed in e.g. Chazaud and 
Yamanaka, 2016). Cells of the Epi are destined to become the embryo-proper, whilst cells 
of the PE will become the yolk sac. The trophectoderm (TE) cells, marked by Cdx2 
(Caudal type homeobox 2) expression (Strumpf et al., 2005, Ralston and Rossant, 2008, 
Niwa et al., 2005) surround the blastocyst (Figure 2) and will form the extra-embryonic, 
placental tissues.  
 
During the period of mouse pre-implantation development prior to the first cell-fate 
decision, XCI is imprinted in all blastomeres, i.e. an X chromosome is inactivated in a 
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parent-of-origin specific manner. The imprinting results in the paternally-inherited X 
chromosome (Xp) always being transcriptionally silenced in XX female mouse embryos 
(Takagi and Sasaki, 1975, Okamoto et al., 2004, Okamoto et al., 2005). The phenomenon 
of imprinted Xp XCI is not unique to pre-implantation mouse embryos, but also occurs 
in the somatic cells of metatherian mammals (Sharman, 1971). Mouse pre-implantation 
Xp XCI was originally thought to be a result of retained Xp silencing after MSCI (Huynh 
and Lee, 2003). However MSCI is Xist-independent (Turner et al., 2002, Turner et al., 
2006) and there is Xp transcriptional activity at the 2-cell stage, at the onset of EGA 
(Okamoto et al., 2005). A 1997 study by Marahens et al showed that if Xist is deleted 
from the paternal X chromosome, females were severely underdeveloped. However if 
Xist is deleted from the maternal X, females developed normally (Marahrens et al., 1997) 
confirming the role of Xist in imprinted Xp XCI. Furthermore, Xist was shown to be 
upregulated at approximately the 2-4 cell stage, closely after XCI is initiated, supporting 
the role of Xist in Xp XCI (Okamoto et al., 2005, Okamoto et al., 2004, Zuccotti et al., 
2002). Nuclear transfer studies had suggested that imprinted XCI is activated by a 
repressive mark that silences maternal Xist, established during oogenesis (Tada et al., 
2000). Key studies were published in 2017, when Inoue et al discovered that the 
epigenetic mark H3K27me3 was responsible for autosomal imprinting (Inoue et al., 
2017a). A follow-up study again by Inoue et al showed that the Xist locus is coated with 
H3K27me3 marks during oogenesis. The H3K27me3 repressive mark is maintained 
throughout pre-implantation development on the maternal X chromosome, and loss of 
H3K27me3 allows ectopic Xm Xist expression (Inoue et al., 2017b, Inoue et al., 2017a). 
 
At the blastocyst-stage, E4.0-4.5, the paternally-silenced X chromosome in the Epi is 
reactivated and Xist coating is lost (Mak et al., 2004, Okamoto et al., 2004). This leads to 
a brief window during embryonic development when cells of the Epi contain two active 
X chromosomes (XaXa, (Mak et al., 2004), Figure 2). Following this period of XaXa in 
the blastocyst Epi, the cells of the Epi undergo random XCI mediated by Xist, similarly 
to XCI in humans and rabbits (Okamoto et al., 2011). Conversely, cells contributing to 
the TE and PE that form the extra-embryonic lineages maintain imprinted XCI, and the 
Xp remains transcriptionally silenced (Takagi and Sasaki, 1975), (West et al., 1977); 
Figure 2).  






Figure 2. Mouse pre-implantation embryonic development 
After fertilisation of the X-carrying oocyte (maternal X; Xm) by an X-carrying sperm (Xp), a 
female (XX) zygote is generated. XCI in the pre-implantation mouse embryo is imprinted. Xist is 
expressed from the Xp and spreads in cis along the Xp, transcriptionally silencing the 
chromosome. This XCI is maintained up until the early blastocyst-stage. At the later blastocyst-
stage both X chromosomes are briefly reactivated in the epiblast (Epi). This cell type can be used 
for generating embryonic stem cells. In the primitive ectoderm (PE) and trophectoderm (TE), 
imprinted Xp silencing is maintained. The cells of the epiblast then undergo random XCI.  
 
Although XCI in mice is imprinted, specifically only silencing the paternal X 
chromosome in pre-implantation embryos, and trophectoderm-derived lineages, does not 
occur in other mammals. In humans and rabbits there is no imprinted XCI but is instead 
random in early embryonic development (Okamoto et al., 2011). Whether random or 
imprinted however, XCI has been observed in all mammalian species studied to date 
(Ohno et al., 1959, Lyon, 1961, Heard et al., 1997).  
 
In summary, XUR and XCI are essential during development for balanced X-
chromosome gene dosage between males and females. However the mechanism of XUR 
and XCI is an important consideration when generating genetic tools. For example, 
transgenes on the X chromosome may be susceptible to XUR and XCI. This is of 
particular note when generating paternal X-linked transgenic mouse models, as they may 
be subject to Xp XCI.  The generation of X-linked transgenes will be discussed in greater 
detail in Chapter 3 and Chapter 6.  
 
Chapter 1 Introduction 
 33 
1.3.5 X-linked genes that escape XCI 
XCI balances gene dosage between males and females. However there are a number of 
X-linked genes that ‘escape’ XCI, and are not transcriptionally silenced.  
 
In 1962, Mary Lyon suggested that genes present in the PAR would escape XCI (Lyon, 
1962). While this has been confirmed (Berletch et al., 2010, Berletch et al., 2011, 
Disteche et al., 2002), it is now known that the X-linked escapees are not limited to the 
PAR (Berletch et al., 2010, Berletch et al., 2011). Up to 3% of genes on the mouse X 
chromosome consistently escape XCI (Berletch et al., 2011), with a further 4% presenting 
expression patterns representative of XCI escape in a tissue-specific manner (Carrel and 
Willard, 1999, Yang et al., 2010, Disteche and Berletch, 2015, Berletch et al., 2015, 
Tukiainen et al., 2017, Garieri et al., 2018). In the mouse, escape genes are located across 
the entire X chromosome, but the majority appear to be localised to the XAR. These 
escape genes lack Xist coating and appear to lack repressive histone marks that are 
characteristic of silenced X-linked genes e.g. H3K27me3 (Simon et al., 2013, Goto and 
Takagi, 2000, Yang et al., 2010, Marks et al., 2015). In the human, there are a higher 
number of escapees compared to the mouse, and the escapees are more highly 
concentrated to the human XAR. Approximately 15% of X-linked genes consistently 
escape XCI in humans, with a further 10% escaping XCI in a tissue-specific manner and 
are highly diverse (Carrel and Willard, 2005). Escapee genes are hypomethylated at CpG 
islands compared to non-escape genes and this CpG island hypomethylation has been 
used to identify further putative escapees (Lister et al., 2013, Cotton et al., 2015, Schultz 
et al., 2015).  
 
1.4 The Y chromosome 
The degeneration of the Y chromosome has led to significantly less protein-coding genes 
on the Y than the X chromosome (Bellott et al., 2014). In humans, only 3% of ancestral 
genes have survived (Bellott et al., 2010, Skaletsky et al., 2003), whereas 98% of X 
chromosome genes have remained (Mueller et al., 2013). The degeneration of the Y 
chromosome gained traction in mainstream media; citing the predicted extinction of 
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males due to the loss of all protein-coding genes on the Y chromosome in the next 5-10 
million years (Graves, 2004, Aitken and Marshall Graves, 2002). The concept of the 
“impeding demise” hypothesis is that the human Y chromosome would lose 
approximately five protein-coding genes that originally had X-homologues every one 
million years (Graves, 2004, Aitken and Marshall Graves, 2002). In 2005, Hughes et al 
showed that this was not the case. They performed comparative sequencing analyses 
between chimpanzee and human, which diverged approximately six million years ago. 
The impending demise hypothesis would predict that the chimpanzee should have many 
more Y chromosome linked genes that have since been lost in the human. Their findings 
contradicted the impending demise hypothesis and showed that there had been very little 
Y-gene loss during the six million years of human evolution (Hughes et al., 2005). Further 
studies by Hughes et al again showed that although Y-decay was initially extremely rapid, 
the degeneration since the divergence of humans has practically stopped, and the Y 
chromosome has undergone recent acquisition and amplification of testis-specific genes 
(Hughes et al., 2012, Hughes et al., 2010). Studies by Bellott et al and Cortez et al, 
confirmed that the Y chromosome gene loss had practically stopped since the divergence 
of monkeys, chimps and humans (Bellott et al., 2014, Cortez et al., 2014). It is thought 
that the genes retained on the Y chromosome have essential biological functions, such as 
transcription, translation and protein stability (Bellott et al., 2014, Lahn and Page, 1997). 
 
The degeneration and divergence of the Y chromosome resulted in a large region of the 
Y that is unable to pair with the X, known as the male-specific region on the Y 
chromosome, MSY (Skaletsky et al., 2003). In humans, the MSY is flanked by the two 
PARs, where pairing and meiotic recombination normally occurs. The MSY contains 
highly ampliconic genes and repetitive elements, preventing accurate sequencing of the 
region. In 2003, Skaletsky et al performed the first sequencing of the human MSY by 
“single-haplotype iterative mapping and sequencing” (SHIMS). Their data showed that 
the MSY is made up of three main types of euchromatic sequences. Firstly, X-transposed 
units; which are highly sequence-similar to X chromosome genes. Secondly; X-
degenerate genes, which occurred on the ancestral autosomes and degenerated during sex 
chromosome evolution. Lastly, ampliconic genes, which contribute approximately 30% 
of the MSY euchromatic sequence, and are multi-copy gene families. Of the ampliconic 
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gene families, two are thought to have originated on the early Y chromosome, whilst 
seven are thought to have been transposed from autosomes.  Of the nine ampliconic gene 
families, at least six are proposed to have a role in testis-function (Skaletsky et al., 2003). 
The SHIMS method of sequencing and mapping the complex Y chromosome has since 
been used to evaluate primate Y, human X and chicken Z chromosomes (Bellott et al., 
2014, Bellott et al., 2010, Skaletsky et al., 2003, Mueller et al., 2013, Hughes et al., 2012, 
Hughes et al., 2010, Hughes et al., 2005) and ancestral regions of the Y chromosome in 
eight mammalian species for comparative studies (Bellott et al., 2014).  
 
The most extensive sequencing and annotation of the mouse MSY was performed in 2014 
by Soh et al (Soh et al., 2014). The mouse MSY has undergone extensive degeneration 
from loss of ancestral genes, and gain of genes by transposition from the autosomes. The 
study showed that the mouse MSY is highly euchromatic (89.5Mb, 99.9%). This is 
contrary to suggestions that the mouse Y chromosome would be very small and 
heterochromatic (Bachtrog, 2013, Charlesworth and Charlesworth, 2000, Graves, 2006). 
In the 89.5Mb of euchromatic sequence, Soh et al described two types of genes; ancestral 
Y-genes and acquired Y-genes. The ancestral genes made up 2Mb of the euchromatin, 
and originated from the ancestral autosomes. The remaining 87.5Mb consisted of 
acquired sequence and was almost entirely ampliconic. Of this 87.5Mb of acquired 
sequence, the majority (86.4Mb) was located on the Y chromosome long arm (Yq). Yq 
amplicons fall into three large gene families; Sly (Sypc3-like Y-linked), Srsy (Serine-rich, 
secreted, Y-linked) and Ssty (Spermiogenesis specific transcript on the Y; Soh et al., 
2014). On the Y chromosome short arm (Yp), there are twelve families of protein-coding 
genes, including Sry (Sex-determining region Y), Uty (Ubiquitously transcribed 
tetratriopeptide repeat containing, Y linked) and Eif2s3y (Soh et al., 2014). These three 
genes in particular will be discussed in greater depth. Sry and Eif2s3y have essential 
functions in fertility, and may be useful targets for generating single sex litters in the 
future. Eif2s3y and Uty are expressed in embryonic stem cells and therefore provide 
useful Y-chromosome expression markers throughout this thesis.   
 
The results of the Soh et al study showed that the mouse MSY has greatly diverged from 
the human and primate MSY through the huge amplification of three gene families. Only 
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2Mb (2.2%) of ancestral shared genes are retained on the MSY (Soh et al., 2014). The 
highly-amplified gene families have a specific role in male germ cell development. A 
reduction in copy number of these multicopy genes results in a sex skew, producing more 
females than males (Conway et al., 1994). The same effect is also seen upon knock-down 
of Sly (Cocquet et al., 2009, Cocquet et al., 2012). The authors suggest therefore that the 
amplification of these gene families on the MSY is due to sex-linked meiotic drive, which 
can also result in degeneration and loss of single-copy ancestral genes. Another theory 
for ampliconic Y-linked gene families is that the amplicons allow for intrachromosomal 
rearrangements and therefore prevent further Y-degeneration (Rozen et al., 2003). 
Therefore, the amplified gene families may have arisen due to genomic competition 
between the X and Y chromosome during spermatogenesis (Bachtrog, 2014). 
 
1.4.1 Sry 
Of the twelve protein-coding genes on the mouse Y chromosome short arm, the gene Sry 
is considered the “testis-determining” factor. The human SRY gene was discovered in 
1990 (Sinclair et al., 1990) and the homologous gene Sry was discovered in mice shortly 
after (Gubbay et al., 1990). Integration of an Sry-containing transgene into XX female 
mice resulted in sex reversal (Koopman et al., 1991).  
 
Sry is a single-exon gene and member of the SOX (Sry-related high motility group 
(HMG) box) family of transcription factors (Gubbay et al., 1990). The SOX family have 
a variety of functions during embryogenesis and in differentiation (Kamachi and Kondoh, 
2013). The HMG box controls the essential function of the transcription factors by 
binding DNA and inducing a bend (Harley and Goodfellow, 1994, Harley et al., 1994). 
Many XY female patients have mutations in Sry encoding for the HMG domain, 
highlighting the essential function of this region. Human and goat SRY/Sry transgenes 
that have been inserted into XX mice function equivalently and the mice develop as XX 
males (Pannetier et al., 2006, Lovell-Badge et al., 2002). Although the HMG domain is 
highly conserved amongst species, the remaining sequence conservation of Sry is 
extremely poor (Kashimada and Koopman, 2010).  
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Sry expression in the mouse is extremely tightly regulated within the gonad. During 
embryogenesis, Sry expression is first detectable by E10.5 in the genital ridge somatic 
cells. Expression peaks at E11.5 and is lost by E12.5 (Koopman et al., 1990, Kashimada 
and Koopman, 2010, Jeske et al., 1995). In humans, SRY is more widely expressed. 
Quickly after Sry is upregulated in the mouse gonad, a second gene, Sox9 (SRY-Box 9) 
is also upregulated. Unlike Sry expression which is only active for a short period of time, 
Sox9 expression is maintained beyond E12.5. Sox9 knock-out in XY mice (Chaboissier 
et al., 2004, Barrionuevo et al., 2006), and Sox9 overexpression in XX mice (Bishop et 
al., 2000, Vidal et al., 2001), both show sex-reversal phenotypes. These studies have 
implicated upregulation of Sox9 in male sex-determination. Sekido and Lovell-Badge 
discovered the “testis-specific enhancer of Sox9 core” (TESCO), a 1.4kb region upstream 
of the Sox9 transcriptional start site. They showed that SRY with SF1 (Steroidogenic 
factor 1) bind directly to TESCO and induce upregulation of Sox9, highlighting evidence 
for Sry being a transcriptional activator (Sekido and Lovell-Badge, 2008). Deletion of 
TESCO in mice results in a reduction of Sox9 expression (Gonen et al., 2017). Deletion 
of a Sox9 upstream regulatory element called Enhancer 13 results in XY females (Gonen 
et al., 2018).  
 
1.4.2 Eif2s3y 
The hunt for the ‘testis-determining factor’ resulted in the discovery of the Y chromosome 
linked gene Sry. XX females containing Sry transgenes are sex-reversed and show male 
phenotypic characteristics (Koopman et al., 1991, Koopman et al., 1990). However the 
XX sex-reversed mice are infertile because they do not produce mature sperm. A study 
in 2001 by Mazeyrat et al showed that the essential Y-linked factor for mouse 
spermatogenesis is a subunit of the gene Eif2, called Eif2s3y. They utilised a mouse line 
containing a Y chromosome short arm partial deletion. Males carrying the deletion do not 
undergo spermatogenesis. They systematically introduced a number of Y-linked genes as 
transgenes. Upon introduction of Eif2s3y, spermatogenesis was restored (Mazeyrat et al., 
2001). In 2009, studies by Yamauchi et al showed that male mice that lack the entire long 
arm of the Y chromosome can still produce offspring when sperm are injected into 
oocytes via “intracytoplasmic sperm injection” (ICSI), suggesting that genes on the Yp 
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are responsible for spermatogenic function. XO mice that contain an Sry gene and an 
Eif2s3y transgene are able to produce round-spermatids. Yamauchi et al (2014) showed 
that upon injection of Eif2s3y transgenic XOSry round spermatids into oocytes by “round 
spermatid oocyte injection” (ROSI), the oocytes were successfully fertilised. Successfully 
cleaved embryos were transferred into pseudopregnant recipient females and live 
offspring were obtained (Yamauchi et al., 2014). These studies show that Y chromosome 
contribution of just two genes, Sry and Eif2s3y, is sufficient to generate live offspring by 
assisted reproductive technologies.  
 
1.4.3 Uty 
The role of Sry and Eif2s3y in male-specific development has been clearly defined. 
However for some Y chromosome-linked genes the role in development is more 
uncertain. An example of this is Uty. The Y chromosome linked Uty transcript is 5.5kb 
(Greenfield et al., 1998, Greenfield et al., 1996) and encodes a histone demethylase that 
demethylates the trimethylation on H3K27me3 (Walport et al., 2014). In humans, Uty is 
expressed in multiple tissue types, including the spleen and thymus, and male-specific 
tissue such as the prostate and testis (Yang et al., 2018). Studies have suggested that Uty 
may be involved in a gene regulatory network underlying development of prostate tissue 
and that dysregulation of Uty may predispose men to prostate cancer (Dutta et al., 2016).  
 
The role of the X and Y chromosome genes in female and male development, and the 
impact of the sex chromosomes in factors such as susceptibility to disease, is an ever 
increasing field of research. The advent of CRISPR-Cas9 genome editing has provided 
an ease in which to investigate even more deeply the role of sex chromosome-linked 
genes, generate targeted X- and Y-linked transgenics, and begin to tackle previously 
unanswered questions regarding the role of the sex chromosomes outside the gonad. 
However the high complexity of the Y chromosome continues to provide a challenging 
environment in which to perform genome editing. This will be discussed in further detail 
in 6.1. 
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1.5 Development of CRISPR-Cas9 as a genome editing tool 
“Clustered regularly interspersed short palindromic repeat” (CRISPR) based genome 
editing has revolutionised diverse fields of biological research. Consisting of two 
components; a Cas9 endonuclease and single guide RNA (sgRNA); the technology is 
quickly and easily manipulated to target many genes or genomic regions. Furthermore, 
the range of techniques in which CRISPR-Cas9 genome editing is now utilised has 
expanded far beyond simple knock-out insertion/deletion mutations. The expansion of 
the CRISPR-Cas9 toolbox now includes variants such as catalytically “dead” or “active” 
Cas9 to fine-tune expression of genes, and/or regulate chromatin and epigenetics.  
 
1.5.1 A brief history of CRISPR-Cas 
CRISPRs were originally discovered in 1987 in E. coli. “CRISPRs” refer to repetitive 
elements interspersed with non-repetitive sequences called spacers (Ishino et al., 1987). 
Although discovered in the genome of many bacterial and archaeal species, the non-
repetitive spacers were homologous to viral and mobile genetic element DNA (Bolotin et 
al., 2005, Mojica et al., 2005, Pourcel et al., 2005). It was found that Cas (CRISPR-
associated) genes are very closely linked to CRISPR elements, are highly conserved, and 
encode putative nuclease and helicase domains (Doudna and Charpentier, 2014, Bolotin 
et al., 2005, Haft et al., 2005, Jansen et al., 2002, Pourcel et al., 2005). Many hypothesised 
that the Cas genes are expressed upon phage invasion and target the invading viral DNA 
for DNA cleavage (Bolotin et al., 2005, Pourcel et al., 2005, Mojica et al., 2005). The 
integrated spacer sequence from a previous viral infection of the bacteria guides the Cas 
endonuclease to the newly invading virus (Doudna and Charpentier, 2014, Makarova et 
al., 2006, Barrangou et al., 2007, Marraffini and Sontheimer, 2008). However it was not 
until 2011 that the precise mechanism of Cas-regulated adaptive immunity was 
discovered.  
 
Upon invasion by the virus or phage, the host bacteria expresses a non-coding pre-
CRISPR RNA (pre-crRNA) which is processed to produce the mature CRISPR RNA 
(crRNA) from the spacer sequence. The mature crRNA molecule consists of a region that 
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is complementary to the viral DNA, and a repeat rich-region. RNA sequencing of 
Streptococcus pyogenes revealed the expression of a second RNA, called the trans-
encoded small RNAs (tracrRNA; Deltcheva et al., 2011). These small tracrRNAs contain 
complementarity to the repeat rich region of the crRNA. The tracrRNA also has a vital 
role in the maturation of the pre-crRNA to the mature crRNA by the activity of host 
factors RNase III and Csn1 protein, another CRISPR-associated protein (Deltcheva et al., 
2011). Doudna and colleagues discovered that all phage spacer sequences inserted into 
the bacterial host genomes also contained a similar sequence motif, called the protospacer 
adjacent motif (PAM; Jinek et al., 2012, Doudna and Charpentier, 2014). The precise 
sequence of the motif varied in different bacterial species with different Cas genes, but 
was consistent within species. The PAM sequence in the viral sequence is recognised by 
the Cas nucleases. In 2012, Jinek et al showed that the crRNA and tracrRNA could be 
produced as one chimeric single guide RNA (“sgRNA”) by fusion of the two RNAs. This 
meant that a sgRNA could be synthetically produced to target virtually any region of the 
genome, provided a PAM sequence was present at the target site. A schematic of 
discovery and development of CRISPR-Cas technology to become a genome editing tool 
is described in more detail in 1.5.2 and summarised in Figure 4. 
 
Thousands of studies have used CRISPR-Cas9 genome editing technology and the 
majority of these have utilised a Cas gene derived from S. pyogenes, called SpCas9 . S. 
pyogenes Cas9 is from the type II CRISPR system (contained with class II systems), 
commonly occurring in bacteria (class II also contains type IV, V and VI). Class I systems 
(type I and III) are more commonly used by Archaea. The use of the S. pyogenes CRISPR-
Cas9 system is predominantly because of the simplicity of the sgRNA and single Cas9 
protein (Doudna and Charpentier, 2014, Jinek et al., 2012, Gasiunas et al., 2012), and the 
ease of design; the recognised PAM is a trinucleotide NGG in the 5’ to 3’ direction, 
providing a large number of target possibilities in the mammalian genome. The crRNA 
component of the sgRNA is designed to be complementary to the target sequence (usually 
20 nucleotides long) upstream of the PAM site, generating a simple “two component” 
system (Doudna and Charpentier, 2014, Jinek et al., 2012).  
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However there is also a growing interest in using other CRISPR-Cas systems, such as 
Cpf1 proteins (e.g. from Acidaminococcus and Lachnospiraceae) which generate a 
staggered end DNA double strand break (DSB), compared to the blunt end generated by 
SpCas9. There is also a growing number of Cas9 enzymes harnessed from other bacterial 
systems, such as Staphylococcus aureus (SaCas9), and Campylobacter jejuni (CjCas9). 
These species have smaller Cas9 gene sequences, making them easier to package into 
different viral vectors. The main disadvantage of these newer systems is the higher 
complexity of the required PAM sequence (5’ to 3’; SaCas9: NNGRRT, and CjCas9: 
NNNNACAC), reducing the number of available targets in the genome.  
 
Irrespective of which CRISPR-Cas system is harnessed to generate DNA DSBs, the 
endogenous cell machinery repairs the DNA break in a manner similar to when DNA 
DSBs occur endogenously. Dependent largely on the stage of the cell cycle, the DNA 
DSB is usually repaired in one of two ways. The first possibility of repair mode is by non-
homologous end joining (NHEJ; Figure 3a), the second is by homology directed repair 
(HDR; Figure 3b). The mechanism of these two main methods of DNA repair is described 
in more detail below. 
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Figure 3. Schematic of CRISPR-Cas9 genome editing modes of producing mutations 
CRISPR-Cas9 induced mutations, guided by a sgRNA to a 20 nucleotide target region 
immediately adjacent (5’) to a protospacer adjacent motif (PAM) trinucleotide NGG. The Cas9 
endonuclease cuts at the -4 nucleotide position (red X) inducing a blunt end double stranded DNA 
break in the genomic DNA. The cleavage is repaired by one of two main mechanisms (a) non-
homologous end joining (NHEJ) to generally produce a knock-out mutation, or (b) homology 
directed repair (HDR) to generate a knock-in.  
 
1.5.1.1 Non-Homologous End Joining 
DNA DSBs are repaired using endogenous cellular DNA-repair pathways. DNA DSBs 
induced by introduction of exogenous CRISPR-Cas9 components are repaired using the 
same DNA DSB-repair mechanisms. One mechanism of DNA repair is by non-
homologous end-joining (NHEJ). NHEJ is the predominant form of DNA repair because 
there is no requirement for the presence of a repair template, such as a sister chromatid. 
Due to this lack of requirement for any kind of repair template, the mode of NHEJ is not 
limited to any particular stage of the cell cycle (Lieber, 2010, Maruyama et al., 2015). 
The mechanism of repair by NHEJ can be broken down into four steps: 1) recognition of 
the DNA DSB and assembly of the NHEJ complex at the break site. 2) bridging the DNA 
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DSB and stabilising the broken ends. 3) further processing of the break site. 4) ligation 
of the DNA strands. These steps are described in further detail below. 
 
In order to repair the DNA DSB by NHEJ, firstly the broken ends are recognised by 
proteins Ku70 and Ku80 (also known as Ku86/Xrcc5; X-ray repair complementing 
defective repair in Chinese hamster cells 5) which form a heterodimer. This protein 
complex forms a ring-like structure which slides onto the DNA at the DSB, thereby 
binding the backbone of the DNA (Walker et al., 2001). This protein complex then acts 
as a scaffold to recruit further proteins to form the NHEJ complex. These factors include 
DNA-PKcs (DNA-dependent protein kinase), XRCC4 (X-ray repair cross 
complementing 4), DNA ligase IV, XLF (XRCC4-like factor) and APLF (Aprataxin and 
PNKP like factor; Davis and Chen, 2013). Ku70/Ku80 recruits DNA-PKcs to form an 
active complex in the presence of DNA (Gottlieb and Jackson, 1993), inducing DNA-
PKc kinase activity. XRCC4 directly interacts with the Ku70 subunit (Mari et al., 2006), 
whilst DNA ligase IV interacts with the heterodimer (Costantini et al., 2007, Hsu et al., 
2002). Further processing enzymes are then recruited to the DNA DSB. More recently, 
studies suggested that APLF may function to stabilise the whole NHEJ complex (Grundy 
et al., 2013, Rulten et al., 2011).  
 
The NHEJ complex holds the DNA DSB ends in close proximity, forming a paired-end 
complex that stabilises the DSB. Essentially, it is the recruitment of DNA-PKcs by the 
Ku70/Ku80 heterodimer that enables the formation of the complex holding the two DSB 
ends in a stable formation (Cary et al., 1998, Weterings and van Gent, 2004). 
Furthermore, the XRCC4-XLF components may form a filamentous structure that further 
plays a role in bridging the broken ends (Malivert et al., 2010, Callebaut et al., 2006). To 
process the DSB site further, additional processing enzymes are recruited by the 
Ku70/Ku80, including Artemis, PNKP (Polynucleotide kinase 3-phosphatase), APLF, 
Polymerases µ and l, WRN (Werner syndrome RecQ like helicase), Aprataxin and Ku 
(reviewed in (Davis and Chen, 2013). For example, Artemis, possibly activated by 
phosphorylation, is known to have nucleolytic activity by nicking 5’ overhangs (Li et al., 
2014a, Chang et al., 2015). Polymerase µ fills in DNA gaps by polymerising from a 
template strand using dNTPs and rNTPs (Nick McElhinny and Ramsden, 2003). 
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The paired end complex then ligates the DNA DSB ends together, repairing the DNA 
break. XRCC4 stabilises DNA ligase IV which induces the activation of DNA ligase IV 
by adenylation (Grawunder et al., 1997). The adenylated active DNA ligase IV ligates 
the processed ends across the DSB site, to form the repaired dsDNA helix (Grawunder et 
al., 1997, Gu et al., 2007a, Gu et al., 2007b).  
 
The NHEJ repair mechanism is essential for intentional introduction of mismatches at the 
DNA DSB site when using CRISPR-Cas9 for genome editing. The continual DNA DSBs 
at target sites caused by CRISPR-Cas9 requires a constant NHEJ repair. Due to the lack 
of repair template, NHEJ is therefore error-prone. Eventually, the NHEJ will introduce 
mismatches or errors at the target site. These errors could be introduction of nucleotides 
(“insertion”) or loss of some nucleotides (“deletion”), together known as “indels”. The 
mutation could also be replacement of a single nucleotide (single nucleotide variant, 
SNV), resulting in a mutation at that target site. There is a two-thirds chance of generating 
a frame-shift mutation by NHEJ due to disruption of a trinucleotide codon. Frame-shift 
mutations are more likely to produce loss-of-function phenotypes when occurring in the 
reading-frame of a protein-coding gene. Introduction of indel mutations in the target DNA 
will prevent further CRISPR-Cas induced DSBs, as the sequence recognised CRISPR-
Cas components is no longer intact. The use of CRISPR-Cas9 tools to generate loss-of-
function mutants in a variety of mammalian cell types is described further below (see 
1.5.2).  
 
1.5.1.2 Homology Directed Repair 
Unlike NHEJ, which does not require a DNA template, homology directed repair (HDR) 
requires a repair template. Due to the requirement for a repair template, usually the sister 
chromatid, HDR is limited to the S and G2 phases of the cell cycle (Maruyama et al., 
2015, Zhao et al., 2017, Escribano-Diaz et al., 2013). Therefore, HDR is a significantly 
less common mode of DNA DSB repair (Chu et al., 2015, Maruyama et al., 2015).  
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The model of DNA DSB repair by homologous recombination (HR) was first postulated 
in 1983 (Szostak et al., 1983) with a description of DNA DSB repair via a double Holliday 
junction, based on the Holliday junction model by Robin Holliday (Holliday, 2007). 
Current understanding of HR proposes there are several steps to induce DNA DSB repair 
(reviewed in (Jasin and Rothstein, 2013). Initially, the DSB is resected at the 5’ end to 
generate a 3’ overhang (Kass and Jasin, 2010, Symington and Gautier, 2011). The DSB 
ends are processed by a complex of Mre11/Rad50/Xrs2 (MRE11 homolog, double strand 
break repair nuclease/RAD50 double strand break repair protein/X-ray sensitive), termed 
the MRX complex in Saccharomyces cerevisiae (Usui et al., 1998), or 
Mre11/Rad50/Nbs1 (MRE11 homolog, double strand break repair nuclease/RAD50 
double strand break repair protein/Nibrin), the MRN complex, in mammals (Dolganov et 
al., 1996, Trujillo et al., 1998). In mammals, CtIP (CtBP-interacting protein, homologous 
to Sae2 in yeast) is recruited to DSBs in G2/S phase and recruits RPA (Replication protein 
A) and ATR (Ataxia telangiectasia and Rad3 related) to the DSBs (Sartori et al., 2007). 
If the 5’ overhang is extensive, there is further recruitment of ExoI (Exonucolease 1), or 
a complex of Sgs1/Dna2 (Mimitou and Symington, 2008, Zhu et al., 2008). Completion 
of strand resection and production of the 3’ overhang allows for strand invasion and repair 
by DNA synthesis. The invading DNA strand then displaces one strand of the double 
stranded DNA duplex and pairs with the remaining single stranded DNA, resulting in the 
formation of ‘hybrid’ DNA known as a displacement loop (“D loop”). The recombination 
intermediate is then resolved to complete the DNA repair process. The Ku complex, 
which has an essential role in NHEJ, may block DSB-end resection and inhibit HR. This 
is supported by evidence that Ku knock-out increases the efficiency of HR (Pierce et al., 
2001). 
 
HDR of DNA DSBs has been utilised experimentally to insert exogenous DNA sequences 
into the genome. Knock-in by HDR was originally shown in studies that utilised 
endonucleases such as I-SceI with a known DNA cleavage sequence. A I-SceI expression 
vector was introduced into cells contemporaneously with a plasmid containing repeats of 
homologous sequence. DNA DSBs were introduced in the target chromosome, and not 
in the plasmid (Rouet et al., 1994, Jasin et al., 1985). The genomic DSB was repaired 
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either by the plasmid, by the sister chromatid or by error-free ligation of the cleavage site 
(Rouet et al., 1994).  
 
The strategy of HDR to generate a ‘knock-in’, such as LoxP sites or fluorescent reporters 
has been developed to produce many genome engineered laboratory animal models. The 
sequence of interest is flanked by large lengths of sequence homologous to the target 
region in the genome. With the advent, in 2013, of CRISPR-Cas9 for genome editing in 
mammalian cells (Cong et al., 2013, Mali et al., 2013, Jinek et al., 2013), it is now 
relatively easy to generate knock-in transgenes. In this strategy, the CRISPR-Cas9 
components targeting a gene of interest can be introduced simultaneously with a repair 
template containing homology regions flanking the transgene (“homology arms”). In this 
way, the gene is targeted for DNA DSBs, whilst also providing a template to repair the 
DNA break. HDR is also being used to generate targeted single nucleotide changes in a 
very precise manner. Applications, examples and developments of generating transgenics 
by HDR are described further in 1.5.2.  
 
1.5.2 Utilising CRISPR-Cas in vitro and in vivo to generate transgenic lines 
CRISPR-Cas9 tools are now in place to generate knock-out by NHEJ and knock-in 
transgenics by HDR at a target locus with relative speed and ease, as well as more 
complex regulation of gene expression. To generate indel mutations for loss-of-function 
studies, the Cas9 and sgRNA are introduced in vitro or in vivo. For HDR experiments, 
the Cas9 and sgRNA targeting the locus of interest are contemporaneously introduced in 
vitro or in vivo with a repair template. Use of CRISPR-Cas9 for gene editing began in 
2013 (Jinek et al., 2013, Cong et al., 2013, Wang et al., 2013b, Mali et al., 2013, Yang et 
al., 2013a), and is being increasingly widely-adopted, with design and strategy becoming 
ever more efficient and optimised. 
 
The first three studies in 2013 that harnessed CRISPR-Cas9 genome editing did so in 
mammalian cells, highlighting a breakthrough in transferring a bacterial immunological 
response system into a mammalian context. Jinek et al transfected human HEK293T cells 
with human codon-optimised SpCas9 fused to eGFP for visualisation of transfection, and 
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an sgRNA targeting a gene CLTA (Clathrin light chain A). The results of this study 
showed a 6-8% mutation efficiency at CLTA. Jinek et al suggested that the efficiency of 
indel mutation could be improved by complexing sgRNA and Cas9 prior to transfection, 
to increase the stability of the sgRNA (Jinek et al., 2013). Cong et al also used human 
codon-optimised SpCas9, fused to multiple nuclear localisation signals (NLS) to increase 
the efficiency of Cas9 localisation to the nucleus. The SpCas9 was co-transfected in 
human 293FT cells with three further factors: separate tracrRNA and pre-crRNA, and 
RNaseIII, targeting the gene EMX1 (Empty spiracles homeobox 1). RNaseIII was 
described in a study by Deltcheva et al (2011) as an essential component required for the 
maturation of pre-crRNA to crRNA (Deltcheva et al., 2011). Cong et al showed that 
addition or removal of RNase III in the transfection mixture had no noticeable effect on 
mutation efficiency, suggesting that mammalian cells can use endogenous RNases for 
maturation of the pre-crRNA into crRNA. Conversely, removal of either the tracrRNA or 
pre-crRNA resulted in no indel mutations induced at EMX1.  This study highlighted a 
minimal three-component capacity for generating mutations at a target locus (Cong et al., 
2013). Cong et al also showed that mutations could be generated in a target gene at a 
higher efficiency by transfection of a single plasmid that expresses both the Cas9 and 
sgRNA, instead of as separate components, improving the simplicity of CRISPR-Cas9 
based genome editing (Cong et al., 2013). Mali et al (2013) was the first example of 
generating a knock-in by HDR. They utilised a human HEK293T cell line that contains a 
eGFP reporter. Expression of the eGFP reporter is inhibited due to the presence of a stop 
codon at the beginning of the coding sequence. Mali et al transfected the HEK293T cells 
with an sgRNA and Cas9 targeting eGFP, alongside a repair template that removes the 
stop codon. Integration of the repair template by HDR thereby induces eGFP expression 
and results showed that the eGFP positive cells were successfully selected by 
fluorescence activated cell sorting (Mali et al., 2013). 
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Figure 4. Timeline of CRISPR-Cas technology development 
A timeline highlighting key discoveries in the development of CRISPR-Cas9 as a technology for 
genome editing. Originally discovered as a immunological defence mechanism against invading 
phage, the action of Cas endonucleases targeting specific sequences, guided by chimeric sgRNAs 
has been harnessed to target virtually any region of the genome in mammalian cells in vitro, and 
in vivo.  
 
Further studies in 2013 expanded the toolbox of CRISPR-Cas9 genome editing by 
development of tools that allowed for targeting of multiple genes at once, called 
“multiplexing” (Ran et al., 2013a, Wang et al., 2013b). Wang et al introduced five 
different sgRNAs (plus Cas9) targeting the genes Tet1, Tet2, Tet3 (Tet methylcytosine 
dioxygenase 1, 2, 3), Sry and Uty into mouse ESCs, and mutations were generated in all 
targeted genes (Wang et al., 2013b). A single plasmid vector was generated by Ran et al 
which contained two sgRNA scaffolds for expression of two sgRNAs from a single 
vector. This could be used for multiplexing of different genes, or for two sgRNAs 
targeting the same gene, resulting in large deletions of the intervening sequence (Ran et 
al., 2013a). Large deletions of the target gene has the potential to increase the likelihood 
of a loss-of-function mutation.    
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In many of these early studies, the aim was to generate a mutation in a target gene by 
CRISPR-Cas9 induced DNA DSBs. The DNA DSB is repaired by NHEJ and is error-
prone, producing an indel mutation. Recently, evidence has shown that the mutational 
outcome at a specific target site can be predictable (see 1.5.3; Chakrabarti et al., 2019, 
van Overbeek et al., 2016, Allen et al., 2018). Nevertheless, repair by NHEJ carries a risk 
of variability, large indels, and/or complex rearrangements (Kosicki et al., 2018) which 
can make genotyping challenging. To increase the accuracy of assessing genetic 
modifications, researchers are utilising the HDR mode of DNA DSB repair, to either 
make small precise nucleotide changes, or to introduce exogenous DNA. The sequence 
of interest to be integrated into the target genome is flanked by homology arms, which 
are homologous to the target genome. This sequence of interest could be very small, for 
example a single nucleotide to replace the existing nucleotide in the target gene. The 
sequence could also be large, for example LoxP sites to generate conditional knock-outs, 
or fluorescent reporter genes for gene-tagging. The repair template (or “targeting vector”) 
is introduced in vitro or in vivo alongside Cas9 and an sgRNA targeting the gene of 
interest.  
 
Targeting experiments have traditionally used dsDNA plasmids as the repair template to 
insert transgenes. Plasmids are often large, supercoiled DNA and can be challenging for 
packaging the DNA into cells for HDR. The early study by Wang et al (2013) showcased 
a different type of repair template for introducing very specific point mutations at a target 
locus. They co-injected target sgRNAs, Cas9 mRNA and single stranded oligonucleotides 
(ssODNs) to generate a knock-in (Wang et al., 2013b). The use of ssODNs is gaining 
traction for inserting small transgenes, for example point mutations, as the DNA is 
smaller and easier to package into cells (e.g. Wang et al., 2013b). Quadros et al (2017) 
also performed knock-in experiments using long single-stranded oligonucleotide 
(lssODN) repair templates, termed “Easi-CRISPR”. The efficiency of knock-in with 
lssODNS was extremely effective, with efficiencies of 100% (Quadros et al., 2017). The 
ssODNs/lssODNs can be manufactured either in-house by molecular biology techniques, 
or synthetically, providing a quick and easy repair template for small knock-in 
experiments. However lssODNs generated synthetically are restricted to the maximum 
size private companies can manufacture with high fidelity.   
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HDR can also be utilised to knock-in large transgenes into a target gene, for example to 
generate fluorescent reporter ‘tagged’ proteins. Gene-tagging can be useful for visualising 
the expression domains of a protein-coding gene. Yang et al, (2013) highlighted examples 
of generating fluorescent reporter knock-ins for tagging a number of essential embryonic 
pre-implantation genes, marking different lineages. In this study, reporter alleles for 
genes Nanog (mCherry), Sox2 (SRY-box 2; V5) and Oct4 (eGFP) were generated using 
a ‘one-step’ knock-in system in mice (Yang et al., 2013a). For large insertions such as 
fluorescent reporters (e.g. Yang et al. 2013), or replacement of genes/exons with 
antibiotic selection cassettes (e.g. Spiegel et al., 2019), CRISPR-Cas9 HDR targeting 
strategies usually make use of dsDNA plasmid repair vectors. The targeting vector length 
with long homology arms is usually greater than that possibly produced by lssODN 
synthesis.  
 
The design of the homology arms (HAs) in gene targeting experiments is an essential 
consideration. A study by Richardson et al in 2016 aimed to produce a trinucleotide 
change in a target gene by CRISPR-Cas9 HDR. They used lssODN repair templates with 
varying lengths of 5’ and 3’ HAs, complementary to either the target or non-target strand. 
They observed that repair templates with homology to the non-target strand produced a 
successful knock-in at a greater efficiency than at on-target strands by HDR (Richardson 
et al., 2016) also observed in other studies (Lin et al., 2014, Yang et al., 2013b). 
Asymmetric HAs produced the highest rate of integration by HDR compared to 
symmetric HAs, particularly when the longer HA is on the PAM-proximal side of the 
DSB (Richardson et al., 2016). Furthermore, the closer the HAs align to the DNA DSB 
position, the higher rate of repair template insertion (Cong et al., 2013, Mali et al., 2013, 
Paquet et al., 2016, Kwart et al., 2017). In order to have homology arms as close as 
possible to the DSB point, the target sgRNA sequence may also be contained within the 
homology arm. Having the sgRNA sequence contained within the homology arm is 
disadvantageous for two reasons. Firstly; the CRISPR-Cas9 system may induce DNA 
DSBs in the repair template, inhibiting accurate HDR. Secondly, the repair template may 
be successfully integrated by HDR, but lost again due to CRISPR-Cas9 targeting of the 
HDR allele. To circumvent issues with CRISPR-Cas9-induced DNA DSBs in the repair 
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template, a silent mutation can be introduced into the PAM sequence in the homology 
arm-containing sgRNA sequence, called a ‘blocking mutation’ (Paquet et al., 2016). 
Despite considerations of homology arm length and proximity to the sgRNA target site, 
the efficiency of HDR is poor compared to the NHEJ (Chu et al., 2015, Maruyama et al., 
2015). Addition of chemicals that inhibit NHEJ, such as SCR7 which functions by 
inhibiting DNA ligase IV (Ma et al., 2016, Maruyama et al., 2015, Srivastava et al., 2012), 
or that increase the rate of HDR, such as RS-1, which enhances RAD51 DNA binding 
(Jayathilaka et al., 2008, Song et al., 2016, Pinder et al., 2015), have been shown to 
improve HDR rates in some cell types but they have not widely employed in many 
species.   
 
1.5.3 Predicting CRISPR-Cas9 mutational outcomes 
Since the adaption of CRISPR-Cas for genome editing, researchers are now investigating 
further the structure and endonuclease action of Cas enzymes, in particular SpCas9. 
Structural studies of Cas9 have been essential in the understanding of how and where 
DNA DSBs are induced at the target site, and how the location of the DSB affects the 
mutational outcome at the target locus.  
 
SpCas9 is bilobed, containing an a-helical recognition (REC) lobe, and a nuclease (NUC) 
lobe, bridged by an a-helix (Jinek et al., 2014, Nishimasu et al., 2014, Sampson and 
Weiss, 2013). The NUC lobe has two major nuclease domains; the RuvC and HNH 
domains.  The DNA DSB endonuclease function of both the RuvC and HNH domains is 
Mg2+ dependent (Jinek et al., 2012, Gong et al., 2018). The HNH domain induces DNA 
cleavage at the DNA strand that is complementary to the 20 nucleotide crRNA sequence, 
whilst the RuvC domain cleaves the opposite DNA strand (Jinek et al., 2012, Gasiunas et 
al., 2012). The bilobed Cas9 endonuclease induces a blunt DSB at a specific point, 
between nucleotides 3 and 4 in the 5’ direction (“-4”) to the PAM site (red X, Figure 3; 
Shen et al., 2013). A mutation in either the HNH or RuvC domain results in a DNA single 
strand break (SSB). These Cas9 variants are nickases (“Cas9n”). A mutation in both 
RuvC and HNH domains results in complete loss of the endonuclease cleavage activity 
(Jinek et al., 2012, Gasiunas et al., 2012). 
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The discovery that Cas9 endonuclease induces a blunt DNA DSB at the -4 position 
opened up research avenues into predictions of precise CRISPR-Cas9 induced mutational 
outcome. In 2016, a study by van Overbeek et al used 96 sgRNA sequences for different 
targets and assessed the indels at each target (van Overbeek et al., 2016).  Although the 
number of sgRNA targets was small, this study was the first to suggest that mutational 
outcome was non-random. In 2018, a larger-scale study by Allen et al utilised over 40,000 
synthetic constructs to assess mutation outcome. Each construct contained both the 
sgRNA expression cassette, and the sgRNA target sequence. The constructs were 
introduced into Cas9-expressing cell lines and the target loci sequenced. This study 
showed there is increased probability of the mutational outcome at a certain sites being 
predictable, based on the surrounding sequence (Allen et al., 2018). Chakrabarti et al 
(2019) improved on these studies with precise predictions of specific nucleotide indels. 
They showed that there is much higher likelihood of the mutation at the target site being 
a mononucleotide insertion if the -4 position is an A or T nucleotide. If the -4 position 
contains a dinucleotide of two C nucleotides, the most commonly predicted outcome is a 
mononucleotide deletion of one of the C nucleotides. Lastly, if the -4 position is a G 
nucleotide, the outcome is much more unpredictable, with varying types of indels at the 
target site (Chakrabarti et al., 2019). These results were similarly presented in a study by 
Shen et al (2018), who highlighted that in 5-11% of sgRNA target sites in the human 
genome, the repair outcome is predictable (Shen et al., 2018). These significant results 
highlight the importance in strategizing sgRNA design and target site location. 
 
1.6 The requirement for specific sexes in the modern world – health, 
agriculture and pest control 
Animals and animal products have been selected for use in many aspects of modern day 
living. This includes in health applications and life sciences; for example development of 
medicines such as antibiotics and other essential drugs. Farm animals have been through 
generations of breeding for desired genetic traits. This has been for a variety of different 
qualities, from reproductive ability, to growth efficiency and food production. This 
process of ‘artificial selection’ or ‘selective breeding’ has ensured the most productive 
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genetic traits are carried forward to the next generation. The male in the ‘herd’ therefore 
contributes highly to the genetic contribution of the population on average, as generally 
the agricultural population is made up of very few, possibly only one, male, and many 
more females. Often a surplus of female agricultural animals are required compared to 
their male siblings. This requirement for females has resulted in widespread culling of 
the unrequired males. Examples of these are in the layer hen and dairy cow industries, 
where there has been extensive development of methods to generate single-sex litters, in 
an attempt to reduce the need for post-natal culling of the unrequired sex.  
 
Another positive reason to generate single-sex litters is that of adhering to the United 
Kingdom Home Office “3Rs”, for reduction, replacement and refinement. This policy 
aims to reduce unnecessary animal culling in laboratories across the UK. Many research 
groups studying sex-specific biology will also produce many animals of the unrequired 
sex, which are usually culled post-natally. A genetic method for reducing the number of 
the unrequired sex being born would have positive implications for reducing this animal 
culling issue. 
 
1.6.1 Layer hens 
In the layer hen industry, egg production for food is entirely from females, and the male 
chicks are culled shortly after birth. Estimates of exactly how many male chicks are culled 
per year vary, but are thought to be between 6-7 billion (Krautwald-Junghanns et al., 
2018). This is an extreme example of where the requirement for females outweighs the 
requirement for males, and is generating a vast animal welfare issue with charities such 
as the RSPCA (Royal Society for the Prevention of Cruelty to Animals) and PETA 
(People for the Ethical Treatment of Animals).  
 
Over the years, a number of non-invasive methods have been developed to reduce the 
extent of post-natal male chick culling. Hyperspectral imaging can be used on mid-
incubation eggs where the males and females have different feather colours (Gohler et 
al., 2017), whilst morphometric quantification such as egg shape (Yİlmaz-Dİkmen and 
Dİkmen, 2013, Krautwald-Junghanns et al., 2018, Galli et al., 2018) or egg odour 
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(Webster et al., 2015) which is different between males and females, has also been 
described. However these techniques have not been widely employed.  
 
Invasive methods to determine the sex of the developing chick embryo are generally more 
accurate, and more widely utilised as they are based on detection of female- or male-
specific molecules (Clinton et al., 2016). The different sexes are determined by 
quantification of hormone levels in the extracted allantoic fluid. Weissmann et al (2013) 
showed that detection of differential levels of estrone sulfate in extracted allantoic fluid 
was sufficient to determine the sex of the developing embryo. Interestingly, 
measurements of testosterone gave significantly more ambiguous results. On average, 
female allantoic fluid contained levels of estrone sulfate at 0.312ng/ml, whereas male 
fluid was 0.110ng/ml. However the levels of estrone sulfate could only be detected at day 
9, as there was not enough fluid present at day 7 for accurate detection of hormones 
(Weissmann et al., 2013). The chick embryo gestation period is 21 days, and they develop 
pain perception at approximately day 10.5 (Weissmann et al., 2013). Therefore invasive 
methods at day 9 are extremely close to the onset of pain perception. This carries a risk 
of causing distress and damage to the developing chick and may induce non-viability in 
severe cases (Rosenbruch, 1994, Rosenbruch, 1997). To access the allantoic fluid for 
extraction, a section of the shell and inner membrane has to be removed, in a process 
called “windowing”. Damage to the inner protective membrane reduces the health and 
hatching rate of the developing chick (Fineman et al., 1986, Speksnijder and Ivarie, 2000) 
and exposes the developing chick to potential pathogens from the outside environment 
before hatching (Brown et al, 1965).  
 
A different method to sex developing chicks was published in 2018 (Galli et al., 2018). 
This method relies on physiological differences between male and female chicks, but is 
a significantly less invasive procedure, as the inner membrane is not damaged. The 
method is based on a previously published invasive procedure study by Galli et al that 
quantified molecular sex differences in embryonic blood. The original study successfully 
detected male/female sex differences but also induced a reduced embryonic viability rate 
of approximately 10% due to inner membrane damage (Galli et al., 2017, Galli et al., 
2016). In the 2018 study, Galli et al performed optical spectroscopy at near infrared 
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radiation with Raman microscopy on day 3.5 chick embryos, upon windowing of the 
shell, but leaving the inner membrane intact (Galli et al., 2018). They quantified spectral 
excitation and fluorescence intensity from exposed extra-embryonic blood vessels. 
Results showed that female chicks have a fluorescence intensity significantly lower than 
males, on average. The study also highlighted that the procedure had no effect on the 
chick hatching rate. Furthermore, the analysis could be performed at embryonic day 3.5 
embryos, a significant advantage over earlier invasive day 9 analyses. Once the chicks 
were born, they were phenotypically sexed, and this result was compared to the predicted 
sex from the embryonic analysis. Results showed that the embryonic optical spectroscopy 
predicted sex correctly in over 90% of chicks (Galli et al., 2018). Although the data shows 
significant overlap in the spectral range for male and females, the authors propose a 
mathematical correction to more accurately segregate males and females.  
 
1.6.2 Dairy cows 
Similarly to the layer hen industry, the dairy industry also requires many more females 
than males. The most extensively researched method to generate greater numbers of 
female offspring is by bull sperm ‘sexing’. The process of sperm sexing selectively 
separates X- and Y-carrying sperm. The X-carrying sperm can then be used for assisted 
reproduction technologies (ART) such as in vitro fertilisation (IVF) of female dairy cows 
to increase the likelihood of generating XX female offspring.   
 
The most developed method of sexing sperm is by flow cytometry. Sperm-sorting by flow 
cytometry was first described in 1982 by Pinkel et al who developed the technology in 
order to separate Y- and O- carrying sperm from the vole (Microtus oregoni; Pinkel et 
al., 1982). The first flow cytometer used for sexing sperm for agriculture was called the 
“Beltsville sperm sexing technology” (Johnson et al., 1989, Johnson and Clarke, 1988, 
Johnson et al., 1999). The flow cytometry-sorted sperm were used for ART and shown to 
be highly successful for rabbits (Johnson et al., 1989), pigs (Johnson, 1991, (Kawarasaki 
et al., 1998, Rath et al., 1997), cattle (Seidel, 1997), and sheep (Johnson, 1995, Catt et al., 
1996). A limitation of the Beltsville flow cytometer was that the X- and Y-bearing sperm 
heads had to be removed from the tails. Tail removal ensured that the sperm heads would 
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be correctly orientated to be sorted by flow cytometry. The movement of attached tails 
disorientated the sperm and they could not be detected by the cytometer lasers and 
therefore would be incorrectly sorted. Although the tail-less sperm were immobile, the 
sperm heads were able to fertilise oocytes (Johnson and Pinkel, 1986, Johnson et al., 
1987, Johnson and Clarke, 1988). However sperm-head oocyte injection was not 
immediately translatable to an agricultural context. A key development in the technology 
was a flow cytometer with a nozzle that applied forces to the motile sperm (with tails), 
orientating them correctly. The process of sperm orientation resulted in an increased 
sorting efficiency from 30% to 60% for sperm with tails (Rens et al., 1998, Johnson et 
al., 1989, Johnson et al., 1999). The development in the sorting technology allowed for 
mature sperm to be sorted, frozen and thawed for used in a standard IVF techniques.   
 
To detect the sperm being sex-sorted by flow cytometry, DNA has to be stained. In early 
developments of the technology, this required removal of the sperm membrane in order 
for the stain to access the nucleus. This process killed the cells therefore they could not 
be used for ART (Johnson and Pinkel, 1986). The staining method was improved by 
Johnson et al, in the late 1980’s. Johnson et al used Hoechst 33342 for sperm staining 
which did not require the membranes to be removed (Johnson et al., 1987, Johnson and 
Clarke, 1988, Johnson et al., 1989), thereby reducing damage to the sperm. Upon staining 
bovine sperm with Hoeschst 33342, the DNA content of the X-carrying sperm is 3.8% 
higher than the Y (Johnson et al., 1999) allowing for clear separation of the two sperm 
types by flow cytometry. The efficiency of sorting bovine sperm by flow cytometry is 
high, with efficiency of pure X-carrying and Y-carrying sperm at around 90% (Seidel, 
2012). However, flow cytometry sorted-sperm used for cattle ART has been shown to 
reduce birth rates, compared to non-sorted sperm (Dejarnette et al., 2011, Frijters et al., 
2009, Seidel, 2007). Furthermore, the birth rate is not improved by increasing the  sperm 
number used for the ART procedure (Dejarnette et al., 2011). It is thought that the reduced 
birth rate is due to residual Hoescht 33342 dye from the sorted-sperm interfering with 
pre-implantation embryonic development (Garner, 2009). However, offspring that are 
successfully produced from sorted-sperm ART do not appear to show any developmental 
defects (Tubman et al., 2004, Seidel, 2007). 
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As well as the reduction in live births associated with sorted sperm, there are also practical 
and socioeconomic disadvantages associated with flow cytometry sperm-sorting. Flow 
cytometers are expensive to buy and maintain, and are time-consuming in sort-time and 
post-sort procedure. Sperm that are sex-sorted by this technique must be sorted fresh to 
ensure maximum accuracy of sex selection by DNA content. Cells are sorted one at a 
time, resulting in an extremely time-consuming process. Furthermore, post-sorted sperm 
must be frozen down appropriately for use downstream in ART (Seidel, 2007). 
 
Given the time, expense and the reduction in live birth rate, there is now an increasing 
interest in improving non-flow cytometry based methods for sperm sex-selection. An 
example of a non-flow cytometry method was published in a study in 2019 by Chowdhury 
et al. The authors developed a method whereby a monoclonal antibody (termed 
“WholeMom”) binds bovine Y-chromosome sperm epitopes, resulting in an aggregation 
of the Y-sperm heads. This allows the non-affected X chromosome sperm to be freely 
motile to fertilise the oocytes in vivo (Chowdhury et al., 2019). Another study published 
in 2019 by Umehara et al inhibited the motility of mouse X-carrying sperm by ligand 
activation of Toll-like receptor 7/8 (TLR7/8) which is expressed only in X-sperm. They 
separated X- and Y-carrying sperm by differences in motility. Following IVF with Y-
carrying (“fast”) sperm, 83% of pups born were male. IVF with X-carrying (“slow”) 
sperm produced 81% female offspring (Umehara et al., 2019).  
 
Developing a genetic method whereby the unrequired sex is never produced, would 
drastically reduce the animal welfare impact whilst reducing the costs and time associated 
with current sex-sorting methods.  
 
1.6.3 Pest control 
Whilst reducing the number of males produced in the layer hen or dairy cow industry is 
beneficial, on the converse, reducing the number of females may be beneficial for pest 
control. Reducing the number of breeding females could be used to control populations 
of invasive rodent species such as rats or mice or the malaria (Plasmodium)-carrying 
female mosquitos (Anopheles). The Plasmodium parasite is transmitted uniquely via 
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female Anopheles mosquitos. Therefore many research groups are investigating methods 
to generate male-bias populations. Strategies for reducing the number of breeding females 
in both rodents and mosquitos take advantage of natural Mendelian inheritance 
segregation, and aim to distort the expected sex ratios using gene drive methods, 
described further in 1.6.3.1. 
 
1.6.3.1 Gene drive 
The concept of gene drive (originally called “genetic underdominance”) was first 
postulated independently by Alexander Sergeevich Serebrovsky and Chris Curtis. They 
determined that chromosomal translocations could spread quickly through a population 
if they caused heterozygous inferiority, by populations selecting for homozygosity 
(Curtis, 1968, Serebrovsky A, 1969). The notion of skewing sex ratios by non-Mendelian 
inheritance was then described by Bill Hamilton in 1967, who suggested that sex ratios 
could be distorted by a mechanism of Y-linked bias (Hamilton, 1967). With the advent 
and ease of CRISPR-Cas9, it is now possible to control population dynamics by in vivo 
self-driven genome editing to distort offspring sex ratios. CRISPR-Cas9 gene drives 
could be used as a method of pest and vector control, and species such as the mosquito, 
are useful models of gene drive, due to the high reproductive rate and short life span.  
 
An early study aiming to skew mosquito offspring sex ratios was published in 2007 by 
Windbichler et al. A mosquito Y chromosome (the male determinant) was edited to carry 
a I-PpoI endonuclease transgene that targets the X chromosome for destruction 
(Windbichler et al., 2007, Burt, 2003). The endonuclease transgene was later edited to 
restrict I-PpoI expression to male meiosis (Galizi et al., 2014, Burt, 2003, Windbichler et 
al., 2007, Windbichler et al., 2008). During meiosis, I-PpoI selectively destroyed X-
carrying gametes, resulting in the viability of only Y chromosome carrying sperm and 
vastly reducing XX offspring numbers. In 2016, a study by Galizi et al used CRISPR-
Cas9 to target repetitive ribosomal sequences on the X chromosome, driven by a 
spermatogenesis specific promoter, resulting in shredding of the X and extreme male bias 
(Galizi et al., 2016). The non-viability effect is at the gametic level, therefore there is no 
effect on fertility of the population, but reduced availability of X-carrying male gametes.  
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One of the first examples of pre-CRISPR-Cas9 genetic modification for gene drive is 
using homing endonucleases, a selfish genetic element found originally in bacterial 
systems (reviewed in e.g.(Belfort and Roberts, 1997). This gene drive element takes 
advantage of endogenous DNA repair mechanisms. The homing endonuclease induces 
DNA DSBs, followed by insertion of the gene drive element as a repair template, into the 
cleaved allele by HR. This results in rapid conversion of the gene drive allele from 
heterozygosity to homozygosity. This strategy for mosquito population control was first 
described in 2011, whereby a gene for the homing endonuclease I-SceI was inserted into 
the mosquito genome (Windbichler et al., 2011) and the fly genome (Chan et al., 2011) 
and was inherited by offspring at above-Mendelian frequency.  
 
Since 2013, CRISPR-Cas9 has increased the efficiency of synthetic gene drive systems. 
The Cas9 endonuclease, guided by a sgRNA, induces a DNA DSB in a target gene. 
Endogenous HDR uses the Cas9-sgRNA transgene as the repair template (Figure 5). 
Therefore the Cas9-sgRNA transgene is converted from heterozygosity to homozygosity 
and spreads through the population at above-Mendelian frequency. The Cas9-sgRNA 
transgene is designed to target female fertility or viability genes, thereby reducing the 
female population and suppressing population growth (Esvelt et al., 2014, Gantz and Bier, 
2015). Successful CRISPR-Cas9 gene drive systems have been shown in multiple 
species, including Saccharomyces cerevisiae (DiCarlo et al., 2013), Anopheles stephensi 
(Gantz et al., 2015) and Anopheles gambiae (Hammond et al., 2016). 
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Figure 5. CRISPR-Cas9 gene drive 
CRISPR-Cas9-based gene drive promotes inheritance of a Cas9-sgRNA transgene at a rate above 
Mendelian frequency. A dsDNA plasmid repair template contains a Cas9-sgRNA allele that 
targets an essential viability or fertility gene. The repair template is integrated into the target 
viability/fertility gene by HDR, producing a heterozygous Cas9-sgRNA genotype and a ‘gene 
drive chromosome’. Expression of the Cas9-sgRNA transgene induces HDR at the second allele, 
converting the transgene from heterozygosity to homozygosity. The homozygous allele therefore 
spreads through the population at above Mendelian frequency.  
 
Many of the mechanisms used to reduce pest populations has been on non-mammalian 
models. However in order to reduce mammalian pest populations, for example invasive 
rodent species, a tool needs to be developed in the mouse model. A study in 2018 by 
Grunwald et al, generated a transgenic mouse line expressing a sgRNA construct and 
mCherry reporter, with no Cas9 gene. The sgRNA targeted the Tyrosinase (Tyr) gene. 
They hypothesised that mating the sgRNA-mCherry transgenic mouse line to a Cas9-
expressing mouse line would ‘activate’ the gene drive. Activation of the gene drive 
system would convert the sgRNA-mCherry allele from heterozygosity to homozygosity, 
named a “CopyCat element”, and thereby induce a homozygous knock-out in the Tyr 
gene. Knock-out of Tyr results in mice with a white coat colour, and mCherry transgene 
expression. Furthermore, they limited Cas9 expression to the germline by using a floxed-
STOP Cas9 mouse line (Rosa26-LSL-Cas9 (Platt et al., 2014) or H11-LSL-Cas9 (Chiou 
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et al., 2015)) and a germline promoter driving Cre.  Germline-specific expression of Cas9 
theoretically maximised the likelihood of HDR during germ cell mitosis/meiosis and 
therefore conversion of the sgRNA-mCherry allele to homozygosity. Despite Cas9 
expression being limited to the germline, the study showed that the efficiency of 
Mendelian inheritance of the CopyCat allele was relatively poor, ranging from 0% to 
72%. The majority of the offspring had mutations at the Tyr locus by NHEJ, without 
integration of the CopyCat element (Grunwald et al., 2019).   
 
1.6.3.2 The disadvantages of gene drive 
An important consideration in the mechanism of nuclease-based gene drive systems, such 
as CRISPR-Cas9, is the possibility of generating mutations that block progression of the 
gene drive system. This gene drive inhibition could be due to naturally occurring variants, 
appearing as single nucleotide polymorphisms (SNPs), blocking DSBs at the sgRNA 
recognition site. Inhibition of the gene drive mechanism could also be induced by 
CRISPR-Cas9 induced mutations at the target locus. The process of gene drive by 
CRISPR-Cas9 transgenes relies on the repair mechanism of HDR to convert the 
heterozygous transgene to homozygosity and therefore spread through the population at 
above-Mendelian frequency. However, if DNA DSBs at the target allele are repaired by 
NHEJ prior to HDR, indel mutations occurring at the locus would inhibit further DSBs 
by the gene drive system (Champer et al., 2017, Hammond et al., 2017, Hammond et al., 
2016, Gantz and Bier, 2015, Gantz et al., 2015). Recent studies using mathematical 
modelling have suggested that the current CRISPR-Cas9 gene drive systems designed for 
reducing female mosquito numbers would quickly lose transmission within the 
population due to arising mutations at the target site and would therefore require 
continuous intervention (Unckless et al., 2017, Hammond et al., 2016). Furthermore, poor 
efficiency of gene drive in mouse models, such as that described in Grunwald et al (2018), 
means that the alleles could take a long time to spread through the population, leaving 
plenty of time for genetic resistance to occur.  
 
There are a number of strategies that are currently being investigated that potentially 
could be implemented to prevent mutational resistance occurring in CRISPR-Cas9 gene 
drive (reviewed in e.g. Hammond and Galizi, 2017). One example that has gained traction 
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is the use of multiple sgRNAs complementary to the target gene of interest (Esvelt et al., 
2014). In this strategy, if resistance occurred at the target gene by NHEJ-induced 
mutation, multiple other target sites are still intact for HDR of the drive allele. Another 
way to circumvent issues associated with CRISPR-Cas9 gene drive resistance is by 
harnessing an endogenous selfish genetic element found in mice called the t-haplotype. 
The t-haplotype is a naturally occurring gene drive element on mouse chromosome 17 
(Willison and Lyon, 2000). Homozygous males are embryonic lethal, however 
heterozygous male mice pass on the t-haplotype element to offspring at above-Mendelian 
frequency (Bauer et al., 2005). Researchers are investigating the use of a t-haplotype 
variant which induces sterility in the males instead of non-viability, leaving females 
unaffected (Lyon, 2003). 
 
1.6.4 Skewing sex ratios using a bi-component system 
In 2018, Zhang et al highlighted a method of pest control in a lepidopteran species, using 
a model of Bombyx mori (silkworm). Silkworm species use a WZ/ZZ sex determination 
system and the female is the heterogametic sex (WZ chromosome complement). The 
authors generated a Cas9 knock-in line, linked to the W chromosome (W-Cas9). The W-
Cas9 transgene is uniquely inherited by female offspring. Furthermore, a second 
transgenic line was generated, expressing an sgRNA targeting the Bmtra2 (Bombyx mori 
transformer-2) gene. Bmtra2 is an essential gene and is embryonic lethal when knocked-
out. Mating of the W-Cas9 and sgRNA expressing lines resulted in female-specific 
mutations in Bmtra2, inducing Bmtra2 loss-of-function and non-viability of the female 
progeny (Zhang et al., 2018). This study was the first example of a CRISPR-Cas9 bi-
component system to induce sex-specific non-viability by knock-out of an essential gene. 
 
In 2019, a study by Yosef et al used a bi-component CRISPR-Cas9 method to generate 
single-sex litters in mammals. They generated a Y chromosome-linked sgRNA-
expressing mouse line, targeting essential genes Atp5b (ATP synthase subunit beta), 
Casp8 (Caspase 8) and Cdc20 (Cell division cycle 20). They theorised that mating the Y-
sgRNA lines with autosomal linked-Cas9 mouse lines would result in offspring male-
specific non-viability due to inheritance of both CRISPR-Cas9 components and loss-of-
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function mutations in the essential genes. Inheritance of the Y-sgRNA and autosome-
Cas9 transgenes significantly skewed the sex ratio of offspring, however there was not a 
complete loss of males. In the Y-Cas9 by Cas9 mating, 113 pups were born, 9 of which 
were male (8%). Six of the males did not survive through to weaning (Yosef et al., 2019). 
Although this study was the first study to utilise a bi-component system in the mouse 
model, the single-sex skew of litters was incomplete, and further improvements could be 
made.  
 
In summary, there are multiple different methods associated with producing an offspring 
sex-skew with distinct advantages and disadvantages. Many are currently being utilised 
to produce single-sex litters and reduce unrequired animal culling, but they are often time-
consuming and expensive. A possible cost-effective method to generating single-sex 
litters may be to utilise CRISPR-Cas9 components in a bi-component system. A single 
Cas9-expressing male in the ‘herd’ can be used for fertilisation (e.g. by IVF/ART) of 
many sgRNA-expressing females. Inheritance of both CRISPR-Cas9 components in a 
sex-specific manner results in embryonic non-viability of the target unrequired sex.  
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1.7 Aims 
CRISPR-Cas9 genome editing has provided an unprecedented ease by which to generate, 
characterise and evaluate mutations at a target locus. Utilising the two components of the 
CRISPR-Cas9 technology, Cas9 and sgRNA, the aim of this thesis is to generate stable, 
knock-in transgenic embryonic stem cell and mouse lines that express these two 
components separately. Upon doing so, the “bi-component” technology can be harnessed 
to generate targeted mutations, utilising the unique inheritance of the male heterogametic 
sex chromosomes to ensure mutagenesis occurs in a sex specific manner. Inheritance of 
both components in an individual induces knock-out of an essential gene, via CRISPR-
Cas9 mutagenesis, resulting in embryonic non-viability. This thesis makes use of the 
mouse laboratory model, however the technology has translational potential in 
agriculture, conservation and in animal welfare in conjunction with the Home Office 3Rs.   
 
Overall, the thesis has four major results chapters: 
 
1. In results chapter 1, I aim to investigate a “proof of principle” system with pre-
existing transgenic mouse lines to ask whether it is biological possible to generate 
single-sex litters.  
2. In results chapter 2, I aim to screen sgRNAs in vitro to determine efficiency of 
mutagenesis, characterising the dynamics and spectrum of mutations at the target 
locus. I then aim to generate a stable transgenic mouse line expressing a highly 
mutagenic sgRNA.  
3. In results chapter 3, I aim to develop the “bi-component” system of genetically 
segregating Cas9 and the sgRNA in vivo, assessing the mutations at the target 
locus in pre-implantation, non-viable embryos.  
4. In results chapter 4, I aim to generate stable transgenic embryonic stem cell and 
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Chapter 2. Materials & Methods 
2.1 Mouse Lines 
2.1.1 Breeding and maintenance 
All animals  were  maintained  with  appropriate  care  according  to the United Kingdom 
Animal Scientific Procedures Act 1986 and the ethics guidelines of the Francis Crick 
Institute. All mice used were Mus Musculus. Wildtype mice were C57BL/6J and 
transgenic mice were maintained on a C57BL/6J background. When targeted embryonic 
stem cells were used to generate the sex chromosome-linked transgenic lines, the targeted 
lines were C57BL/6N and were injected into C57BL/6J albino embryos. Chimeric mice 
and germline transmitting genetically modified mice were then maintained on a 
C57BL/6J background. The TARGATT attPx3 mice were generated using C57BL/6N 
embryos and were backcrossed to C57BL/6J for at least seven generations prior to 
purchase from Charles River for zygotic microinjection at the Crick institute. The mice 
were kept in IVC cages with automatic watering systems and air management systems 
which controls air flow, temperature and humidity. Animals were checked on a daily basis 
by the Biological Research Facility (BRF) staff. All of the breeding units are Specific 
Pathogen Free (SPF).  
2.1.2 Timed matings 
Male and female mice were co-housed from approximately 17:00 by the addition of a 
male mouse to the female cage. The females were checked for the presence of a vaginal 
plug the following morning, each day, indicating a mating had taken place. If a plug was 
visible, this day was considered embryonic day (E) 0.5. 
2.1.3 Embryo collections 
Following the presence of a vaginal plug (see 2.1.2) plugged females were culled 
according to Schedule 1 Killing (S1K) methods, according to the required embryonic age. 
The uterine horns were dissected into dPBS (Dulbecco’s Phosphate Buffered Saline, 
Gibco, ThermoFisher Scientific, USA) and individual horns flushed with 1ml of FHM 
(Follicle Holding Medium, Appendix A) using a 1ml syringe and needle, under a Leica 
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light dissecting microscope (Leica, Germany), into FHM in a clean dish. Embryos were 
transferred into individual drops of FHM using a StripperÒ (Origio, Denmark) pipette. 
2.2 Molecular Biology 
2.2.1 Genomic DNA extraction 
Genomic DNA was extracted using different methods depending on tissue or cell type 
and downstream processes.  
2.2.1.1 Mouse ear biopsies 
Genomic DNA was extracted from mouse ear biopsies for PCR genotyping. 150µl 50mM 
NaOH was added to biopsies and heated at 95°C for 90 minutes. The samples were cooled 
to room temperature before addition of 15µl 25mM Tris HCl pH8 and centrifugation for 
5 minutes at 13,000rpm.  
2.2.1.2 Embryonic stem cells from 96-well plates 
Genomic DNA was extracted from embryonic stem cells (ESCs) for PCR genotyping of 
CRISPR-Cas9 targeted lines. The ESCs were grown to confluency in 96 well plates. 
Excess medium was removed by plate inversion, and the ESCs were washed once with 
150µl dPBS. The dPBS was removed by plate inversion. The ESCs were lysed in 50µl 
Bradley Lysis buffer (Appendix A). Proteinase K (final concentration 1mg/ml) was added 
to the lysis buffer immediately before addition of the buffer to the ESCs. The plate was 
sealed with parafilm before heating in a humidified incubator overnight at 60°C. The 
following day, the plate was cooled to room temperature before DNA precipitation by 
addition of 100µl ice-cold EtOH/NaCl (100% EtOH 394ml, 5M NaCl 6ml). The plate 
was incubated at room temperature for 30 minutes, followed by centrifugation at 
3,000rpm for 20 minutes. The plates were inverted to remove excess liquid and DNA 
pellets were washed with 150µl ice-cold 70% EtOH twice. The supernatant was removed 
by inversion. Plates were air-dried and the DNA resuspended in 30µl EB (elution buffer; 
Appendix A). 
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2.2.1.3 Embryonic stem cells or mouse tissue 
To produce larger volumes of genomic DNA, phenol-chloroform DNA extraction was 
carried out. In general, phenol-chloroform extraction was used for >6cm plates of 
confluent ESCs, or approximately 100mg of mouse tissue (fresh, or snap frozen 
immediately upon collection). The ESCs were dissociated into single cells and 
centrifuged (as in 2.6.3) before resuspension in 705µl Bradley Lysis buffer (see 2.2.1.2) 
with Proteinase K. Tissue pieces were thawed on ice, macerated and resuspended in 705µl 
Bradley Lysis buffer with Proteinase K. The samples were incubated overnight at 55°C. 
The next day, 10µl of 100ug/ml RNase A was added to the samples for 1 hour and 
incubated at 37°C. Following RNase A treatment, 750µl phenol was added to the samples 
before rotation for 15 minutes. The samples were then centrifuged at 15,000g for 5 
minutes. The upper phase was collected into a fresh tube and 750µl phenol-chloroform 
added, the samples inverted and centrifuged at 15,000g for 5 minutes. The upper phase 
was collected into a fresh tube and 750µl chloroform-isoamyl alcohol added, the samples 
inverted and centrifuged at 15,000g for 5 minutes. The upper phase was collected into a 
fresh tube, and 750µl isopropanol added, the samples inverted and centrifuged at 1,000g 
for 15 minutes. The DNA pellet was washed with 1ml of 70% EtOH twice, and dried at 
room temperature for approximately 5-10 minutes. The DNA was resuspended in EB. 
2.2.2 Polymerase Chain Reaction (PCR) 
Unless otherwise stated, PCR genotyping reactions were carried out in a total volume of 
25µl using MyTaq Red Mix (2X, Bioline, UK) with standard thermocycling conditions 
according to manufacturer’s instructions. Amplification of large products (>1kb), or if 
PCR amplicons were required for downstream cloning applications; Q5 Hot Start High-
Fidelity DNA polymerase was used, according to manufacturer’s instructions (New 
England Biolabs (NEB), USA).  
 
Correct product amplification was confirmed by agarose (Agarose, Sigma-Aldrich, USA) 
gel electrophoresis. The agarose powder was melted in 1x TAE buffer (Tris-acetate-
EDTA), cooled and stained with SybrSafe (ThermoFisher Scientific, USA) before 
casting. Purple loading dye (6X, NEB, USA) was added to PCR samples at a final 
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concentration of 1X for visualisation under ultraviolet light. The PCR products were run 
alongside a 1kb GeneRuler DNA ladder (ThermoFisher Scientific, USA). The agarose 
gels were run at approximately 90V for 45 minutes, or until clear band separation. PCR 
amplicons on the agarose gel were visualised using BioRad ChemiDoc XRS+ Imaging 
System. Primers (listed in Appendix B) were designed using publicly available tool 
Primer3 [http://primer3.ut.ee/;(Untergasser et al., 2012, Koressaar and Remm, 2007, 
Koressaar et al., 2018)] or previously published sequences, and used at a final 
concentration of 10µm. Unless otherwise stated, all primers were synthesised by Eurofins 
Genomics (Germany).  
2.2.3 MiSeq PCR 
Unless otherwise stated, MiSeq PCR reactions were carried out in a total reaction volume 
of 25µl using Q5 High-Fidelity 2X Master Mix (Qiagen, UK). MiSeq primers were 
designed using Primer3, with additional adaptor sequences (Appendix B), to amplify 
products <500bp and used at a final concentration of 5µm. PCR products were amplified 
under standard thermocyling conditions, according to manufacturer’s instructions 
(Qiagen, UK). The MiSeq PCR amplicon was confirmed by gel electrophoresis before 
purification using solid phase reverse immobilisation (SPRI) beads (made in house). 
Downstream library amplification was carried out with Illumina TruSeq indexing primers 
(Illumina, USA; see 2.9.1 below). 
2.2.4 RNA extraction 
The ESCs were grown to confluency on pre-coated plates (see 2.6.1) in 2i+LIF culture 
conditions, as standard (see 2.6.3). Medium was aspirated, followed by washing with 
dPBS. The dPBS was aspirated and the adherent ESCs were lysed in 1ml TRI Reagent 
(Sigma-Aldrich, USA). The lysis was transferred to a microcentrifuge tube and 
centrifuged at 12,000g for 10 minutes at 4°C. The cleared upper phase was transferred to 
a new microcentrifuge tube and 200µl chloroform (Sigma-Aldrich, USA) added. The 
solution was mixed by shaking for 15 seconds, followed by centrifugation at 12,000g for 
15 minutes at 4°C. The aqueous upper phase was transferred to a new microcentrifuge 
tube and RNA was precipitated by addition of 500µl isopropanol, incubation at room 
temperature for 10 minutes, followed by centrifugation at 12,000g for 10 minutes at 4°C. 
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The supernatant was removed and pellet washed with 75% EtOH, followed by 
centrifugation at 7,500g for 5 minutes at 4°C. The pellet was air dried before resuspension 
in RNase-free water. 
2.2.5 cDNA synthesis 
The RNA and reverse transcriptase reagents were thawed, briefly centrifuged and kept 
on ice until use. cDNA synthesis was performed according to cDNA synthesis 
manufacturer's instructions (Thermo Scientific Maxima First Strand cDNA Synthesis Kit, 
USA). For downstream qPCR reactions, 200ng of RNA was used per cDNA synthesis 
reaction. For downstream RT-PCR reactions, a reverse transcriptase minus (-RT) 
negative control was always included to confirm absence of genomic DNA 
contamination.  
2.2.6 Quantitative PCR (TaqMan probes) 
After cDNA synthesis, the 20µl product was diluted 1:10 in water. Unless otherwise 
stated, each qPCR reaction was made to a total volume of 10µl (5µl TaqMan 2X 
Universal PCR Master Mix (Applied Biosystems by ThermoFisher Scientific, USA), 
0.5µl TaqMan probe (ThermoFisher Scientific, USA), 2.5µl water, 2µl of diluted cDNA). 
Each DNA sample was tested in triplicate and normalised to a housekeeping gene control, 
usually Gapdh, unless otherwise stated. All TaqMan probes used are listed in Appendix 
C. 
2.2.7 TOPO XL cloning 
Standard PCR reactions were done according to protocols for large PCR products, using 
Q5 Hot-Start High-Fidelity DNA polymerase (see 2.2.2). Presence of amplicons was 
initially confirmed by agarose gel electrophoresis. PCR products were used immediately 
for downstream TA cloning reactions according to manufacturer’s instructions (TOPO® 
XL PCR Cloning Kit, ThermoFisher Scientific, USA).   
2.2.8 Transformations and plasmid isolation 
Chemically competent E. coli cells (90µl aliquot; made in house), were thawed on ice 
immediately prior to transformation. The cloning reaction was added directly to the 
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competent cells (made in house, UK) and incubated on ice for 30 minutes. Samples were 
then heated at 42°C on a heat block for 1 minute, followed by cooling on ice for 2 minutes. 
810µl S.O.C (super optimal broth with catabolite repression, made in house; Appendix 
A) was added, and followed by heating in a shaking incubator for 30 minutes at 37°C, 
200rpm. Pre-prepared LB agar (lysogeny broth) plates containing an antibiotic (either 
ampicillin, 100mg/ml or kanamycin, 50mg/ml) were pre-warmed at 37°C during this 
incubation step. Following shaking, the tubes were centrifuged at 1,000g for 5 minutes 
and the supernatant removed. The cell pellet was resuspended in minimal volume, spread 
on the plates and incubated overnight at 37°C. Individual colonies were picked the 
following day into 2ml of liquid LB with antibiotic (either ampicillin, 100mg/ml or 
kanamycin, 50mg/ml) and placed in a shaking incubator overnight at 37°C. The following 
day, the plasmid DNA was isolated using a mini-prep kit according to manufacturer’s 
instructions (Qiagenprep Spin Miniprep Kit, Qiagen, UK). For larger quantities of 
plasmid, colonies were picked into 50-200ml of liquid LB with antibiotic and placed in a 
shaking incubator at 37°C overnight. The plasmid DNA was then isolated using a maxi-
prep kit according to manufacturer’s instructions (GenElute HP Plasmid Maxiprep Kit, 
Sigma-Aldrich, now Merck, USA).  
2.3 Protein Biology 
2.3.1 Protein extraction 
Protein extraction buffer (in RIPA (radioimmunoprecipitation assay) buffer; both 
Appendix A) was pre-prepared and kept on ice until use. For protein extraction from 
ESCs, the cells were firstly lysed into a single cell suspension, before centrifugation and  
resuspension in 50-100µl protein extraction buffer. For protein extraction from mouse 
tissue, the tissue was collected on ice, cut into small pieces and snap frozen in liquid 
nitrogen in screw-cap tubes (thereafter kept at -80°C). A single piece of tissue 
(approximately 100mg) was thawed on ice, and resuspended in 100-200µl protein 
extraction buffer. For both ESCs and mouse tissue, the resuspended samples were kept 
on ice for 30-40 minutes with occasional mixing to ensure complete homogenisation, 
followed by centrifugation at 8,000rpm at 4°C for 10 minutes. The supernatant was 
transferred to a clean 1.5ml Eppendorf tube and kept on ice until use. 
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2.3.2 Protein quantification 
Protein concentration was quantified using a bicinchoninic acid (BCA) assay using 
bovine serum albumin (BSA, 2mg/ml) serially diluted and the protein samples diluted 
1:10 in duplicate. An Ensight Multimode Plate Reader, by PerkinElmer with software 
Kaleido 2.0 was used for colorimetric quantification. 
2.3.3 Western blot 
The protein samples (10-100µg) were diluted in water and Laemmli buffer (Appendix A) 
and heated to 98°C for 10 minutes, followed by brief centrifugation. The samples and 
ladder were loaded into gel wells, inserted into the BioRad tank and covered by running 
buffer (Appendix A). The gel was run at 50V until the samples left the wells, followed 
by running at 120-150V for 45-60 minutes. The membranes were prepared by soaking in 
transfer buffer (Appendix A). The gel and membranes were then inserted into the transfer 
tank and run at 60-140V for 45-90 minutes. The membranes were then blocked in 
blocking buffer (Appendix A) for 60 minutes. Following blocking, the membranes were 
incubated with a primary antibody (diluted in blocking buffer) overnight at 4°C. The 
following day, the membranes were washed 3x in TBS+0.1% Tween followed by 
incubation with a secondary antibody (diluted in TBS+0.1% Tween), at room temperature 
for 45-60 minutes. The membranes were washed 3x in TBS+0.1% Tween before soaking 
in ECL for imaging. All antibodies used in western blots are listed in Appendix D. 
Western blots were carried out by Valdone Maciulyte (senior LRS, Turner lab). 
2.4 Southern Blot 
Genomic DNA was extracted from either ESCs or mouse tissue by phenol-chloroform 
DNA extraction (see 2.2.1.3). Resulting genomic DNA (10µg) was digested overnight 
with restriction enzymes (listed in Appendix E) and purified the following day by 
standard phenol-chloroform DNA precipitation, and washing with 70% EtOH. Digested 
and precipitated DNA was loaded (10µg/lane with 6X loading dye at final concentration 
1X) onto a 1% agarose gel (stained with SybrSafe). Bromophenol blue was loaded in one 
lane for monitoring later colour changes. The agarose gel electrophoresis was run at either 
30V overnight or 50V for 5 hours.  




The agarose gel was then depurinated by washing in depurination buffer (Appendix A) 
with gentle agitation until the bromophenol blue turned yellow (approximately 10 
minutes). The agarose gel was rinsed in water, followed by washing in denaturation buffer 
(Appendix A) with gentle agitation for 30 minutes (the bromophenol blue turned blue). 
The denaturation buffer was then replaced with  neutralisation buffer (Appendix A) and 
was washed with gentle agitation for 30minutes. The agarose gel was then rinsed with 
water to remove all traces of the neutralisation buffer.  
 
A glass sheet was placed across a metal tray that contained 20X SSC. On top of the glass 
sheet, Whatman filter paper (3MM, Sigma-Aldrich) was placed, lying across the glass 
sheet and into the container acting as a wick. The neutralised agarose gel was then blotted 
by placing the gel upside down on top of fresh Whatman filter paper , on top of the glass 
sheet. On top of the gel and filter paper, was a positively charged nylon membrane, 3 
filter papers and 2 inches of paper towels. A heavy weight (~1.5-2kg) was placed on top 
and the blot left to transfer overnight.  
 
The following day, the DNA was fixed by cross-linking by placing 4 Whatman sheets in 
a tray with 10X SSC (enough to cover the sheets), followed by the membrane (DNA 
facing up) and the tray was placed in a Stratalinker UV crosslinker (auto cross-linking, 
1200U joules, ~2 minutes). The membrane was then dried, rinsed twice in purified water 
and then dried again.  
 
The probe was synthesised according to manufacturer’s instructions (PCR DIG Probe 
Synthesis Kit, Roche), and 2µl run on 2% agarose gel to confirm DIG labelling, followed 
by purification using a PCR purification kit (e.g. Qiagen, UK), eluting in 30µl. For 
hybridisation, hybridisation buffer (Appendix A) was pre-heated to an optimal 
temperature (Topt; according to DIG Easy Hyb manufacturer’s instructions, Roche) for 
hybridisation of the specific probe. The membrane, with DNA facing the inside, was then 
placed inside a bottle containing pre-heated hybridisation buffer and incubated for 30 
minutes at Topt. The probe was diluted in 50µl purified water and boiled at 98°C for 10 
minutes. The probe was then cooled quickly on ice for 10 minutes. Salt was added to the 
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ice to cool the probe faster. The pre-heated hybridisation buffer was added to the probe 
(0.5-4µl) in a separate container. The pre-hybridisation solution in the bottle containing 
the membrane was discarded and quickly replaced with the hybridisation buffer 
containing the probe. The bottle was then incubated in the hybridisation oven at Topt 
overnight.  
 
The following day, the membrane was rinsed twice in 2X SSC/0.1% SDS for 5 minutes 
at room temperature. The membrane was then washed twice in 0.1X SSC/0.1% SDS at 
65°C for 15 minutes, in the hybridisation bottle, using the hybridisation oven. The 
membrane was then rinsed in water.  
 
For blocking and detection, 10X blocking buffer (Appendix A) was filtered with a 
0.45µm filter disc and used to make 1X blocking buffer in maleic acid. The membrane 
was incubated in 1X blocking buffer, with gentle agitation for 30 minutes (up to 3 hours). 
The membrane was then incubated in antibody solution (DIG antibody in 1X blocking 
buffer, 1:50,000). The membrane was then washed twice in washing buffer (Appendix 
A) for 15 minutes. The membrane was then equilibrated in detection buffer, for 5 minutes 
on a shaker. CSPD (a chemiluminescent substrate, Roche) was diluted 1:1000 in 2ml 
detection buffer, and applied to the membrane for 5 minutes. The film was developed in 
a dark room to visualise the DNA bands. All southern blots were carried out by Valdone 
Maciulyte.  
2.5 Preparation of CRISPR Components 
After generation of CRISPR components, the resulting plasmids were transformed into 
chemically competent E. coli cells, the plasmid isolated (see 2.2.8) and Sanger sequenced 
(Genewiz, UK).  
2.5.1 sgRNA design, cloning and synthesis 
The 20mer crRNA component of each sgRNA sequence was designed using publicly 
available tools (crispr.mit.edu, Zhang lab) and sgRNAs with a predicted high on-target 
activity were selected. Oligonucleotides, with the addition of BbsI or BsaI overhangs, 
(synthesised by Eurofins Genomics, Germany) were annealed and ligated into sgRNA-
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mCherry (“pLethal”), pX330, a gift from Feng Zhang, Addgene plasmid #42230 (Cong 
et al., 2013), pX459v2 a gift from Feng Zhang, Addgene #62988, (Ran et al., 2013b) 
and/or pX458, a gift from Feng Zhang, Addgene #48138, (Ran et al., 2013b) using BbsI 
or BsaI. All oligonucleotides are listed in Appendix B.  
2.5.2 Targeting vectors 
2.5.2.1 Cas9-eGFP  
To generate the Hprt X-Cas9 (X chromosome) and Y-Cas9 (Y chromosome) targeting 
vectors whereby expression of Cas9 and eGFP is linked via a T2A peptide under a CMV 
early enhancer/chicken b-actin (CAG) promoter, pX458 (Ran et al., 2013b) was 
modified. The 5’ and 3’ homology arms were cloned using unique restriction enzyme 
sites by standard directional cloning techniques. The LoxP-PGK-neomycin-LoxP 
cassette was inserted using Gibson assembly using unique restriction sites according to 
manufacturer’s instructions (NEBuilder HiFi DNA Assembly Cloning Kit, NEB, USA).  
2.5.2.2 sgRNA-mCherry (“pLethal”) 
To generate the sgRNA and mCherry expressing plasmid, pX333, a gift from Andrea 
Ventura, Addgene #64073 (Maddalo et al., 2014), containing two tandem U6 promoters 
was modified. The Cas9 gene sequence was replaced by the mCherry sequence using 
standard directional cloning techniques (AgeI and EcoRI restriction enzymes), under a 
Cbh promoter. The sgRNA oligonucleotides (Appendix B) were cloned into the pLethal 
plasmid using restriction enzyme sites BbsI and BsaI for U6 promoter 1 and 2, 
respectively.  
2.5.2.3 attB-sgRNA-mCherry-attB (TARGATT) 
The tandem U6-sgRNA cassettes and Cbh-mCherry components of the pLethal plasmid 
were cloned into TARGATT plasmid #3 (Applied StemCell, USA; (Zhu et al., 2014, 
Tasic et al., 2011) using restriction enzyme sites SpeI, XbaI and NotI by standard 
directional cloning. The sgRNA-mCherry sequence was then flanked by attB sequences 
contained in the TARGATT plasmid for integrase mediated recombination into the H11-
attPx3 mouse line (Applied StemCell, USA; (Zhu et al., 2014, Tasic et al., 2011).  
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2.6 Embryonic Stem Cell Culture 
2.6.1 Preparation of cell culture plates 
All ESCs were plated on laminin unless otherwise stated. Tissue culture grade plasticware 
(Nunc, ThermoFisher Scientific, USA) was coated with poly-L-ornithine (0.01% in 
water) for 1 hour (2.5ml per 6cm plate) at 37°C. The solution was aspirated, plates washed 
twice with 1x dPBS (1ml per 6cm plate), followed by addition of laminin solution 
(10ng/ml in dPBS; 2.5ml per 6cm plate) for 1 hour at 37°C (Hayashi and Saitou, 2013). 
The solution was aspirated immediately prior to plating ESCs. 
2.6.2 Deriving embryonic stem cell lines 
Blastocyst-stage embryos were collected (see 2.1.3 above) and plated individually in 
wells of a 24-well plate in 500µl pre-warmed 2i+LIF (Appendix A) and cultured in a 
37°C, 5% CO2 incubator. After 1 week, a further 1ml 2i+LIF was added. After 
approximately 3 weeks, any expanded blastocysts were dissociated into single cells by 
placing in 15µl TrypLE (Gibco, ThermoFisher Scientific, USA) and incubation for 4 
minutes at 37°C , followed by quenching with 2i+LIF and dissociation by gentle 
pipetting. The single cell suspension was plated into one well of a pre-coated (see 2.6.1 
above) 4-well plate and passaged as in 2.6.3. 
2.6.3 Passaging and maintenance 
The required number of plates were coated ahead of time (see 2.6.1 above) and the 2i+LIF 
pre-warmed. The 2i+LIF from plates containing actively growing ESCs was aspirated. 
The adherent ESCs were washed once with 1x dPBS, followed by addition of TrypLE 
(1ml per 6cm plate) and incubated at 37°C for 3 minutes, until all the ESCs had detached. 
The TrypLE was quenched by addition of 2ml 2i+LIF (1:2 TrypLE:2i+LIF), and the 
ESCs were dissociated into single cells by gentle pipetting. The resulting ESC suspension 
was cell-counted using the EVE hemocytomer (EVE by Cambridge Bioscience, UK). The 
required volume of cell suspension was centrifuged at 200g for 3 minutes, the supernatant 
aspirated, and the pellet resuspended in 1ml 2i+LIF before plating with further 2i+LIF 
and incubating at 37°C, 5% CO2. The ESCs were passaged every 2-3 days to prevent 
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occurrence of abnormal karyotypes and generally passaged at a ratio of 1:4 plates at each 
new passage. 
2.6.4 Freezing 
Freezing solution (Appendix A) was made and chilled at 4°C prior to freezing ESCs. The 
ESCs were dissociated into single cells and centrifuged (as in 2.6.3 above. The 
supernatant was aspirated and ESCs resuspended in 250µl per cryovial. The freezing 
solution was added to the resuspended cells at a ratio of 1:1 (250µl cell suspension: 250µl 
freeze solution). The total volume (500µl) was transferred into each cryovial and kept at 
-80°C in freezer boxes overnight. The following day, the cryovials were transferred to 
liquid nitrogen for long term storage. 
2.6.5 Thawing 
Plates were coated ahead of time (see 2.6.1) and the 2i+LIF pre-warmed. The cryovials 
containing frozen ESCs were warmed at 37°C for approximately 2-3 minutes, until 
visibly thawed. Once thawed, 1ml 2i+LIF was added to each cryovial, drop-wise. The 
cell suspension was transferred to a 15ml falcon tube, and a further 4ml 2i+LIF added 
slowly. The cell suspension was centrifuged at 200g for 4 minutes, the supernatant 
aspirated, the pellet resuspended in 1ml 2i+LIF and ESCs plated. 
2.6.6 Fluorescence Activated Cell Sorting (FACS) 
The ESCs were dissociated into a single cell suspension and centrifuged (see 2.6.3 above). 
The ESC pellet was then resuspended in FACS medium (Appendix A) and the cell 
suspension passed through a 40µm filter. The ESCs were sorted on the Aria Fusion Cell 
Sorter.  
2.6.7 Standard transfections 
In general, 1x106 single cells were plated on pre-coated 6-well plates in 2i+LIF (see 2.6.1 
and 2.6.3). Following plating, C57BL/6J or C57BL/6N background ESCs were 
transfected with Lipofectamine 3000 (ThermoFisher Scientific, USA) according to 
manufacturer’s instructions (Opti-MEM by ThermoFisher Scientific, USA), with 1µg of 
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plasmid (typically at concentration 1µg/µl) per well. The lipofection reaction was 
incubated for 15 minutes at room temperature before addition to plated cells. The 
CRISPR-Cas9 transfections were based on published protocols (Ran et al., 2013b). 
2.6.8 Generating knock-in lines by CRISPR-Cas9 homology directed repair 
(HDR) 
For each targeting experiment, 2x106 C57BL/6N (line B6N6; generated in-house by 
GeMS) single ESCs were transfected using Lipofectamine 2000 (ThermoFisher 
Scientific, USA; 22µl lipofectamine 2000, 478µl Opti-MEM, according to 
manufacturer’s instructions) with the addition of 2ug pX330 sgRNA expressing plasmid, 
and 2ug of repair template plasmid (targeting vector). The solution was incubated at room 
temperature for 20 minutes prior to addition to cells. The lipofectamine-DNA mix was 
added to C57BL/6N ESCs, prepared as a single cell suspension, and incubated at room 
temperature for 10 minutes before seeding ESCs in 6-well plates pre-coated with feeders 
on gelatin. To select for transgenic clones, 2 days post-transfection, neomycin antibiotic 
was added (270mg/ml) for 8-10 days. The X-Cas9 (X chromosome targeting) and Y-Cas9 
(Y chromosome targeting) knock-in transfections on serum+LIF conditions were done by 
the Genetic Manipulation Service (GeMS), part of the Science Technology Platforms at 
the Francis Crick Institute.  
2.7 Microinjections 
2.7.1 Zygote (TARGATT) 
H11-attPx3 TARGATT female mice (Applied StemCell, USA, (Zhu et al., 2014, Tasic et 
al., 2011) were superovulated and oocytes harvested. The oocytes were in vitro fertilised 
by sperm collected from C57BL/6J male mice. The TARGATT targeting vector (attB-
sgRNA-mCherry-attB) and C31f integrase were microinjected into the pronuclei of 
zygote stage embryos. The embryos that successfully divided to the 2-cell stage were 
transferred into pseudopregnant females. All pronuclear microinjection and surgical work 
was undertaken by the GeMS. 




Correctly targeted ESCs (see 2.6.8) were trypsinised into a single cell suspension and 
resuspended in 100µl KSOM (Potassium supplemented simplex optimised media, 
Appendix A; Lawitts and Biggers, 1993). Approximately 10 single cells were injected 
into blastocyst-stage albino C57BL/6J embryos. The injected blastocysts were then 
transferred to pseudopregnant females. Chimerism of resulting pups born was assessed 
by percentage black coat colour. All blastocyst microinjection and surgical work was 
undertaken by the GeMS. 
2.8 In Vivo Imaging 
Mouse pups were imaged for presence of fluorescence transgenes at age 3-4 days using 
the IVIS Lumina XR (Caliper LifeSciences) with "Living Image 4.4" software. To 
investigate expression of mCherry positive pups, the excitation filter was set to 535nm 
and the emission filter to dsRed. 
2.9 Next Generation Sequencing (NGS) 
2.9.1 MiSeq library preparation 
The purified MiSeq amplicon (see 2.2.3 above) was carried forward for library 
preparation, according to the Illumina MiSeq library prep manufacturer’s instructions 
(Nextera Index Kit V2). The resulting indexed library then underwent a second round of 
purification using Agencourt AMPure beads (Beckman Coulter, USA). The purified 
library was then quantified, normalised and pooled before submission to the Advanced 
Sequence Facility (ASF, part of the Science Technology Platforms at the Crick institute) 
for sequencing on the MiSeq for 2x250bp sequencing. The library indexing, purification 
and pooling steps were carried out by the GeMS.  
2.9.2 MiSeq data analysis  
The resulting Fastq files were collapsed using the FastX Toolkit (v0.0.13) and aligned to 
the reference genome (Mm10) using blastn, by the ASF and Bioinformatics and 
Biostatistics facility (BABS, part of the Science Technology Platforms at the Crick 
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institute). The MiSeq reads were analysed using a previously published R package; 
CrispRVariants (Lindsay et al., 2016) to evaluate individual sgRNA mutation 
efficiencies. The bioinformatic analysis of the MiSeq reads in order to generate the 
mutation efficiency was carried out by Jasmin Zohren (post-doc, Turner lab).  
2.9.3 Whole genome sequencing (WGS) library preparation 
Genomic DNA was extracted from embryonic stem cells by phenol-chloroform DNA 
extraction (see 2.2.1.3). A quality control (QC) step was performed using Tapestation 
Analysis Software 3.1 (Agilent Technologies) by the ASF. Samples that passed the QC 
step were then carried forward for library preparation, using the KAPA library 
preparation kit (KAPA Biosystems, Roche) according to manufacturer’s instructions. The 
library preparation step was carried out by the ASF.  
2.9.4 Whole genome sequencing data analysis 
The whole genome sequencing FastQ reads were trimmed using Trim Galore! to remove 
adaptor sequences. Post-trimming, the reads were aligned using BWA. To analyse the 
karyotype of targeted embryonic stem cells, a previously published R package called 
QDNAseq (Scheinin et al., 2014), version 1.8.0 was utilised. The bioinformatic analysis 
of the low-pass whole genome sequencing data for karyotyping was performed by Jasmin 
Zohren.  
2.9.5 RNAseq library preparation 
Blastocyst-stage embryos were collected (in accordance with 2.1.3 above) and washed 3 
times in FHM droplets, and once in dPBS and placed in individual low-bind RNase-free 
0.2ml PCR tubes in minimal volume. The cDNA synthesis, amplification and purification 
steps were performed according to manufacturer’s instructions, using the SMART-Seq® 
v4 Ultra® Low Input RNA Kit (Takara Bio USA Inc, USA). A QC step was performed 
by the ASF using the Agilent 2100 Bioanalyzer. Samples that passed QC were carried 
forwards for library preparation according to manufacturer’s instructions (Nextera XT 
DNA Library Preparation Kits, Illumina, USA). The Illumina library preparation was 
carried out by the ASF. The libraries were sequenced on the HiSeq 4000. The minimum 
number of reads returned per embryo was 12.5 million, 100bp paired-end reads. 
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2.9.6 RNAseq data analysis 
The quality of the sequencing for all samples was assessed by MultiQC. Failed samples 
were removed from the analysis. A total of 41 samples were carried forward for further 
analysis. The RNA sequencing FastQ reads were mapped using HISAT2 (Kim et al., 
2015). The default HISAT2 parameters were used, which allowed for soft-clipping of 
reads without trimming. The .sam files were converted into .bam files and indexed using 
SAMtools (Li et al., 2009). The RNAseq reads were counted and annotated using the 
RSubRead function “featureCounts” (Liao et al., 2014). For each sample I generated 
matrices containing each sample and gene feature information, including genes, exon-
exon boundaries, and promoters. I used the inbuilt annotation matrix for the mouse 
genome Mm10. I changed the default featureCounts parameters to account for paired-end 
reads:  
 
MyfeatureCounts <- featureCounts(vectorfile, annot.inbuilt = 
"mm10", isPairedEnd = TRUE) 
 
The annotation and count matrices generated by featureCounts were carried forward for 
differential gene expression (DESeq) analysis. Statistical analysis of differential gene 
expression was performed in RStudio Version 1.2.1335 using DESeq2 (Love et al., 2014). 
I performed DESeq analysis for individual genes of interest. I generated plots of 
individual differential gene expression using ggplot2. I adapted the default parameters for 
aesthetics, and to show the mean expression value (example shown for Uty expression): 
 
uty <- plotCounts(dds, gene = "22290", intgroup = "condition", 
returnData = TRUE) 
 
sp_uty <- ggplot(uty, aes(x = condition_sex, y = count, color = 
condition)) + geom_point(position=position_jitter(w = 0.1,h = 
0), size=6) + ggtitle("Uty") + theme(axis.title.x = 
element_text(size=12),axis.title.y = element_text(size=12)) 
 
sp_uty + stat_summary(fun.y=mean, aes(group="wt"), geom="point", 
colour="black", size=15, shape=95) 
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Chapter 3. Results 1: Female specific lethality by 
expression of Cre inducible Diphtheria Toxin A 
3.1 Introduction  
Generating single-sex litters could have a positive impact on many areas of biology, 
including health, agriculture and in biomedical or scientific research, as described in 
section 1.6. When harnessing a method that relies on embryonic non-viability of the non-
required sex,  there must be no negative effect on the development of the required sex.  
 
In this Chapter I generated a proof-of-principle experiment to determine whether sex-
specific embryonic non-viability could be genetically induced. Further, I examined 
whether the survival of the non-affected sex was compromised. I firstly used multiple 
pre-existing mouse models to investigate the possibility of generating single-sex litters. 
Secondly, I investigated the transcriptomic differences between surviving embryos from 
a mating where the non-required sex was embryonic lethal, compared to wildtype 
embryos.  
 
In order to generate embryonic non-viability, the mouse model Gt(ROSA)26Sortm1(DTA)Kio 
(Marques et al., 2009), hereafter referred to as “R26-DTA” was utilised. The R26-DTA 
transgene encodes an attenuated toxin; Diphtheria Toxin A (DTA) inserted into the 
permissive locus Rosa26 (Friedrich and Soriano, 1991). DTA expression is inhibited due 
to a LoxP-STOP-LoxP cassette preceding the DTA sequence (Sternberg and Hamilton, 
1981). Cre recombinase-excision of the floxed-STOP cassette induces DTA expression. 
Cre-induced DTA allows for precise spatiotemporal DTA expression. Previous studies 
have shown that expression of DTA in different tissue types results in cell death. For 
example, Marques et al crossed the R26-DTA mice with a Tnfrs4 promoter driving Cre 
recombinase to cause T-cell specific ablation (Marques et al., 2009).   
 
To induce DTA expression I wished to use a Cre recombinase that was expressed during 
early mouse gestation to maximise the length of time that DTA would be expressed. 
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Furthermore, for the Cre-induced DTA to be sex-specific, the Cre allele needed to be sex 
chromosome-linked. Therefore, I utilised the pre-existing mouse model Hprttm1(CAG-
Cre)Mnn, hereafter “X-Cre” (Tang et al., 2002), where a constitutively active Cre cassette 
was inserted into the X-linked Hprt locus. In humans, Hprt has an essential function, with 
abnormal reduction in protein levels resulting in error of purine metabolism and excessive 
uric acid. The clinical diagnosis of this disease is called Lesch-Nyhan disease (Lesch and 
Nyhan, 1964). The symptoms include severe neurological disorders, including cognitive 
and attention deficits (Torres and Puig, 2007). Hemizygous men are more commonly 
affected whereas women are usually heterozygous and carriers for the disease. 
Conversely, Hprt loss-of-function in the mouse has no known detrimental phenotypes in 
viability, fertility and behaviour (Kuehn et al., 1987, Hooper et al., 1987, Koller et al., 
1989, Jinnah et al., 1990). The lack of detrimental phenotype upon Hprt knock-out is seen 
in other species, such as male rats (Meek et al., 2016). 
 
 
Figure 6. Hemizygous X-Cre/Y male mating to a homozygous R26-DTA female 
(a) Female-specific co-inheritance of the X-linked Cre allele and R26-DTA allele results in Cre-
induced activation of the DTA. Activation of the DTA results in female-specific embryonic non-
viability. The males, which do not inherit the Cre allele, are unaffected.  
 
If the father is hemizygous X-Cre, the transgene will be uniquely inherited by daughters. 
Therefore, when an X-Cre father is crossed with a homozygous R26-DTA mother, only 
the daughters will co-inherit the transgenes (Figure 6). Furthermore, co-inheritance of X-
Cre and R26-DTA would induce DTA expression in a female-specific manner. I 
hypothesised that co-inheritance of X-Cre and R26-DTA would therefore result in 
female-specific lethality and all-male litters (Figure 6).  
  





3.2.1 Timing of Cre recombinase expression 
Although Hprt is an extremely useful safe-harbour locus, there is a caveat to generating 
X-linked transgenic lines. This major caveat is dosage compensation of the X 
chromosomes by XUR and XCI. In the mouse pre-implantation embryo, XCI is 
imprinted, and the paternally-inherited X chromosome is silenced. The Xp XCI is 
retained in the extra-embryonic lineages such as the placenta. The epiblast, which 
contributes to the embryo-proper, undergoes X-reactivation before random XCI ensues, 
where either the maternal or paternal X is silenced (Takagi and Sasaki, 1975, Okamoto 
et al., 2004, Okamoto et al., 2005, West et al., 1977, Marahrens et al., 1997). The process 
and mechanism of imprinted XCI is discussed further in 1.3.4. An X-Cre transgenic father 
passes the X-Cre allele to the XX daughters. Therefore, the X-Cre transgene will likely 
be subject to imprinted Xp XCI. If silenced, the X-Cre transgene will remain 
transcriptionally inactive in the extra-embryonic lineages.  
 
Therefore, I first aimed to determine the timing of expression of the Cre recombinase 
allele to indicate the expected timing of the floxed-STOP removal in the DTA mice. To 
answer this question, the pre-existing mouse line B6:129S6-Gt(ROSA)26Sortm14(CAG-
TdTomato)Hze/J (hereafter “LSL-tdTom”) was utilised. This mouse line is a Cre reporter that 
contains a LoxP-STOP-LoxP cassette upstream of a TdTomato fluorescent reporter 
(Madisen et al., 2010). The TdTomato reporter is expressed under a constitutive CAG 
promoter, however expression is inhibited by the presence of the floxed STOP cassette; 
thereby preventing TdTomato expression. Removal of the STOP cassette by expression 
of Cre recombinase induces TdTomato expression. In this strategy, TdTomato expression 
is controlled spatiotemporally by the Cre recombinase driver.   
 
Timed matings were set up between X-Cre males and homozygous LSL-tdTom females 
(Figure 7a). I harvested embryos at each day of pre-implantation development (E1.5, E2.5 
and E3.5; Figure 7b) to pinpoint the day of TdTomato activation by expression of Cre 
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recombinase. I hypothesised that approximately half of the offspring would be TdTomato 
positive. The TdTomato positive embryos would be female embryos, where inheritance 
of paternal X-encoded Cre removed the floxed-STOP cassette and induced TdTomato 
expression. Male embryos would be TdTomato negative. Fluorescence microscopy 
visualisation of the TdTomato reporter at E2.5 (8-cell stage) and E3.5 (blastocyst-stage) 
confirmed that Cre is expressed during pre-implantation development (Figure 7c). 
TdTomato expression was not detectable at E1.5 (2-cell stage; Figure 7c). Embryos 
collected at E1.5 and E2.5 were kept in KSOM culture at 37°C, 5% CO2 until E3.5-4.0. 
At E3.5-4.0, embryos were confirmed again for TdTomato expression prior to PCR 
genotyping for the Y-linked gene, Sly. Amplification of Sly indicated whether the 
embryos were male (XY) or female (XX). The extended ex vivo development in KSOM 
until the E3.5-4.0 stage allowed me to detect TdTomato expression from embryos that 
could not be successfully phenotyped at E1.5. All TdTomato positive embryos (as 
determined by fluorescence microscopy phenotyping) were female (n=10/10, 100%), and 








Figure 7. X-Cre induced TdTomato expression in female embryos 
(a) Timed matings of X-Cre/Y males with homozygous LSL-tdTom females. (b) Pre-implantation 
stages of embryo development were collected at three time points; E1.5 (2-cell), E2.5 (~8-cell), 
and E3.5 (early blastocyst). (c) Pre-implantation embryos were phenotyped by fluorescence 
microscopy for expression of the tdTomato reporter. Scale bars=20µm. 
 
Overall, this data confirmed that the Cre recombinase allele was inherited only by female 
offspring and expression of Cre-induced TdTomato was detectable by E2.5. Therefore, 
the X-Cre mouse line was appropriate to use for generating single-sex litters by Cre 
activation of a lethal toxin, DTA.  
 
3.2.2 Cre recombinase-induced female-specific embryonic lethality  
To determine if there was female-specific lethality resulting from Cre recombinase-
induced DTA expression, experimental and control matings were set up and the pups born 
were genotyped at post-natal day 14 (PN14) for the Cre and DTA alleles. The control 
mating was X-Cre/Y males mated to wildtype (+/+) females. The experimental matings 
were either X-Cre/Y males mated to hemizygous R26-DTA/+ females, or homozygous 
R26-DTA/R26-DTA females. Pups were genotyped from multiple mating pairs, to ensure 
that the results were not due to mating-pair specific effects.  




In the control matings, 10 litters were born, with a total of 56 pups (Figure 8a). Male and 
female pups were present (n=27, n=29 respectively), assessed by phenotypic 
examination. I expected only two possible genotypes; female X-Cre/X;+/+ and male 
X/Y;+/+ pups. The offspring were born at approximately the expected 1:1 sex ratio with 
females making up 52% of the total litters (Figure 8d). This data confirmed the Cre 
recombinase allele has no impact on the offspring sex ratio. 
 
I next used X-Cre/Y males mated to heterozygous R26-DTA/+ females (Figure 8b). 
Mendelian inheritance predicted that there were four possible offspring genotypes: 
female X-Cre/X;+/+ (Figure 8b pale green), female X-Cre/X;R26-DTA/+ (Figure 8b dark 
green), male X/Y;+/+ (Figure 8b pale blue), male X/Y;R26-DTA/+ (Figure 8b dark blue). 
I hypothesised that co-inheritance of the X-Cre and R26-DTA allele would result in 
activation of the DTA allele, inducing embryonic non-viability. Therefore, I predicted 
that one-quarter of the litter would be lost prior to birth. In total, 13 litters were born from 
the heterozygous matings with a total of 52 pups. The pups were sexed by phenotypic 
analysis and ear notch biopsies were PCR-genotyped. At PN14, 65% (n=34/52) were 
male and 35% (18/52) were female. The ratio of male:female offspring was 2:1. As 
expected, two male genotypes were present; X/Y;+/+ (n=15, 44%) and R26-DTA/Y 
(n=19, 56%). Of the 18 female pups born, all were X-Cre/X;+/+ (18/18, 100%; Figure 
8b). This showed that co-inheritance of the X-Cre and R26-DTA alleles induces 
embryonic lethality uniquely in females. The deviation from expected offspring genotype 
ratios was statistically-significant (Chi-squared test, p=4x10-4).  
 
Next, I investigated whether X-Cre males crossed with a homozygous R26-DTA female 
would induce a complete loss of female offspring, generating a single-sex litter (Figure 
8c). First, pups were sexed by phenotypic examination. From nine litters born, with a total 
of 34 pups, all of the pups were male (34/34, 100%; Figure 8c). The complete sex ratio 
skew to all-male litters was a statistically-significant deviation from expected offspring 
sex ratios (Chi-squared test, p=6x10-9; Figure 8d).  
 
 




Figure 8. X-Cre induced Diphtheria toxin A female-specific lethality 
(a) X-Cre/Y mating to C57BL/6J females (+/+). Deviation from expected offspring genotype 
ratios was not significant (p=1) (b) X-Cre/Y mating to heterozygous R26-DTA/+ females. 
Deviation from expected offspring genotype ratios was statistically-significant (p=4x10-4). (c) X-
Cre/Y matings with homozygous R26-DTA females. Deviation away from expected offspring 
genotype ratios was statistically-significant (p=6x10-9). All statistical analysis performed using 
Chi-squared tests. (d) The female:male sex ratio (%) of offspring in litters for each mating. (e) 
Mean litter size for each mating. There was no statistically-significant reduction in mean litter 
size compared to the control X-Cre/Y mating. Statistical analysis performed using a Mann-
Whitney test.  




3.2.3 Effect of female lethality on litter sizes 
Due to the loss of a quarter of the offspring in the heterozygous cross and half of the 
offspring in the homozygous cross, I wished to determine if there was an effect on litter 
sizes (Figure 8e). I hypothesised that in the heterozygous matings, the mean litter size 
would be reduced by approximately one-quarter compared to the control matings, whilst 
in the homozygous matings, I predicted the mean litter size should be reduced by half.  
 
The mean litter size of the control mating was 5.6. According to my hypothesis, I 
predicted a mean litter size of 4.2 in the heterozygous cross. Results showed a mean litter 
size of 4.0 in this heterozygous mating, aligning with the expected reduction in litter size. 
The predicted mean litter size in the homozygous mating was 2.8. Interestingly however, 
the mean litter size from the homozygous cross was 3.8, i.e. greater than expected. 
Despite the reduction in litter sizes in the heterozygous and homozygous cross, there was 
no statistically-significant difference between the experimental litter sizes compared to 
the control.  
 
3.2.4 Transcriptomic analysis of blastocysts 
PCR genotyping of offspring born from the heterozygous (Figure 8b) and homozygous 
(Figure 8c) matings showed that female offspring that co-inherit the X-Cre and R26-DTA 
transgenes did not survive. The X-Cre allele was active by E2.5, as shown by TdTomato 
reporter expression, therefore I predicted that the R26-DTA allele was also active by this 
stage, and embryonic non-viability may occur around this time. To determine if the in 
utero embryonic lethality of the X-Cre/X;R26-DTA/+ females affected the surviving 
male littermates at the transcriptome level, I performed RNA sequencing (RNAseq) of 
blastocyst-stage embryos. I used the heterozygous mating because there were four 
possible offspring genotypes, one of which is wildtype, male X/Y;+/+. This genotype acts 
as an internal control, and allows for direct comparison of the transcriptome to wildtype 
blastocyst embryos from control matings. Experimental embryos were collected from X-
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Cre/Y by R26-DTA/+ matings, while control embryos were from X-Cre/Y by C57BL/6J 
matings.  
 
After blastocyst collections, the embryos were lysed, RNA-extracted, cDNA synthesis 
performed and libraries prepared. The resulting libraries were sequenced on the HiSeq 
4000. The minimum number of paired-end reads per embryo was 12.5 million. The 
sequencing reads were mapped using HISAT2 (Kim et al., 2015) using default 
parameters, without trimming and allowing for soft-clipping of RNAseq reads. The 
resultant .sam files were converted into .bam files for downstream processes using 
SAMtools (Li et al., 2009). Next, the RNAseq reads were aligned to the mouse Mm10 
genome (Figure 9a). I used the Rsubread packaged with featureCounts function (Liao et 
al., 2014) to count the number of RNAseq reads and align to the target Mm10 genome to 
features such as genes, exons and promoters. RSubRead/featureCounts aligns paired-end, 
exon-containing and exon-exon reads, and performs soft-clipping for non-aligning 
nucleotides. To perform statistical analysis of differential gene expression, I used the 
featureCounts read count matrix and annotation matrix output for analysis using DESeq2 
(Love et al., 2014). A detailed description of the RNAseq analysis protocols can be found 
in section 2.9.6. 
 
To determine if it was possible to distinguish different embryo genotypes, I performed 
gene expression analysis for individual genes in DESeq2. The relative expression per 
gene was quantified by log2-fold change in normalised read counts for experimental 
samples versus control samples. Firstly, I genotyped blastocysts for expression of Y-
linked genes Uty and Eif2s3y. Blastocysts that expressed the Y-linked genes were 
considered male (Figure 9b,c). To confirm the sex-genotyping, I analysed expression of 
Xist, which occurs only in females. Xist expression was detected in the non-Y-gene 
expressing blastocysts (Figure 9d). I next investigated three known blastocyst-expressed 
genes; Pou5f1 (Chazaud and Yamanaka, 2016), Cdx2 (Strumpf et al., 2005, Ralston and 
Rossant, 2008, Niwa et al., 2005) and Gata6 (Chazaud et al., 2006), which are markers 
of the inner cell mass/epiblast, trophectoderm and primitive endoderm, respectively. All 
of the blastocysts expressed all three lineage specifiers (Figure 9e,f,g). Therefore, I 
concluded that the blastocysts analysed could be determined by the mating condition 
Chapter 3 Results 
 
 91 
(experimental versus control), genotyped by sex (male versus female), and expressed the 
expected embryonic lineage markers.  
 
 
Figure 9. Relative gene expression 
(a) Pipeline for generating gene expression analyses by DESeq2. (b-g) Relative gene expression 
between male and female blastocysts (b) Uty (c) Eif2s3y (d) Xist (e) Pou5f1 (f) Cdx2 (g) Gata6. 
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The library preparation and sequencing by HiSeq 4000 steps in the protocol were performed by 
the ASF STP.  
 
Once I had confirmed that the blastocysts could be genotyped by sex, I examined 
expression of Hprt and Rosa26, the endogenous loci disrupted by transgene integration 
of X-Cre and R26-DTA, respectively. Integration of the X-Cre transgene into Hprt results 
in loss-of-function of Hprt. However the X-Cre is a paternal X-linked transgene, therefore 
Cre expression would be silenced in all female embryos, resulting in single maternal X-
linked Hprt expression. Males carry one X chromosome and therefore only express Hprt 
from the single X. Therefore, I hypothesised that Hprt expression should be similar 
between different sexes and genotypes. Results of the relative gene expression analysis 
showed that Hprt expression was similar between experimental and control blastocysts, 
and within the experimental and control populations the relative expression did not differ 
between females and males (Figure 10a). These results aligned with what I expected for 
Hprt expression. 
 
Integration of the R26-DTA transgene resulted in loss-of-function of Rosa26 (personal 
communication, Kassiotis lab). Therefore, blastocysts from the experimental mating 
could either be Rosa26 heterozygous (R26-DTA/+) or Rosa26 homozygous (+/+), with 
potentially greater Rosa26 transcriptional output. DTA expression could not be used for 
distinguishing the R26-DTA and +/+ male embryos, as DTA expression was inactive 
without Cre recombinase floxed-STOP excision. Therefore, homozygous versus 
heterozygous Rosa26 expression was used a proxy for presence or absence of the DTA 
transgene. I predicted that all R26-DTA/+ embryos were male, as the female R26-DTA/+ 
population was embryonic lethal due to Cre-activated DTA. In the experimental +/+ 
blastocyst population, approximately half would be female and half male. For Rosa26 
expression in the control blastocysts, I predicted there was no grouping into females and 
males.  
 
Results showed that in the experimental samples, the most lowly-expressing samples 
were males, and the expression was below that of all wildtype samples (bracket, Figure 
10b). This population of lowly Rosa26-expressing males suggested that this group was 
the R26-DTA/+ group, with single copy expression of Rosa26. The lack of females in the 
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low R26-DTA/+ group further suggested that the R26-DTA/+ females have been lost 
prior to the blastocyst-stage, due to Cre-activated DTA expression.  
 
Figure 10. Hprt and Rosa26 relative gene expression 
Relative gene expression between experimental and control blastocysts (a) Hprt (b) Rosa26. 
 
Conversely, the more highly Rosa26-expressing blastocysts consisted of males and 
females, suggesting this group was the +/+ population. 
 
I next determined if there were global transcriptomic differences between the surviving 
blastocysts from the experimental matings and the controls. I performed a Principle 
Component Analysis (PCA), to determine the variance between samples. The PCA 
showed that there was a cluster of male samples (triangles), and a cluster of female 
samples (circles). There were two outliers from the two main clusters, that were both 
female samples (clustered in an oval outline, Figure 11a). Interestingly, these two samples 
corresponded to embryos collected from the same control litter and were phenotypically 
underdeveloped compared to the blastocyst littermates, with morphology more similar to 
Chapter 3 Results 
 
 94 
late-morula/early-blastocyst. Principle component 1 (PC1) accounted for 33% of the 
variance between samples, and therefore likely differentiated between developmental age 
(Figure 11a). Principle component 2 (PC2) accounted for 13% of the variance between 
samples, and likely differentiated between sex (Figure 11a). There was clearly no distinct 
clustering of experimental from control samples (Figure 11a).  
 
Next, I generated heatmaps clustering the samples on transcriptomic similarity based on 
the transformed log2-fold change. I analysed the top 20 most highly differentially 
expressed genes across all of the samples. The two genes that showed the most highly 
differential expression were Eif5a (Eukaryotic translation initiation factor 5A) and Hspa8 
(Heat shock protein 8). However the differential gene expression of these two genes was 
not attributable to the condition as the upregulation of Eif5a and Hspa8 was detected in 
experimental and control samples (Figure 11b, left first two columns). There was no 
hierarchical clustering of experimental or control samples based on differential gene 
expression.  
 
Next, I generated a heatmap of the top 20 most highly differentially expressed genes, 
when quantified as differential gene expression from the average gene expression across 
all samples. Clustering in this way takes into account variance across all the samples. The 
samples were hierarchically clustered on differential gene expression, however there was 
no distinct hierarchical clustering between experimental versus control samples. 
Interestingly, the samples instead clustered mostly by sex, with four distinct gene 
expression profiles that were upregulated in a group of samples compared to others. These 
four genes were Ddx3y, Eif2s3y, Uty and Xist. The upregulation of these genes was only 
in male samples for Ddx3y, Eif2s3y and Uty, whilst Xist was only upregulated in females 
(Figure 11c). Furthermore, the two underdeveloped control samples (red box, Figure 11c) 
again were more hierarchically similar and clustered together, with similar patterns of 
gene upregulation in these two samples.   
 
There was very little global transcriptomic differences between blastocysts from control 
matings, compared to blastocysts from experimental matings, based on differential gene 
expression analyses from RNAseq data. Therefore, I concluded that the in utero lethality 
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of X-Cre/X;R26-DTA/+ embryos had minimal effect on the unaffected littermates at the 
transcriptomic level.  
 
 
Figure 11. Differential gene expression analyses 
(a) Principle component analysis on experimental versus control blastocysts. (b) Heatmap and 
hierarchical clustering of experimental versus control blastocysts. The top 20 most highly 
differentially expressed genes (log2 transformed count) are shown. (c) Heatmap and hierarchical 
clustering of experimental versus control blastocysts. The top 20 most highly differentially 
expressed genes (log2 transformed count), as differential expression from the average gene 
expression of all samples.  
 
 




The data presented in this chapter shows that it is possible to generate single-sex litters. 
Producing all-male litters was performed genetically, by X-linked Cre-induced 
expression of a Diphtheria Toxin A allele. Initially I was concerned that the paternal X-
linked Cre allele would be transcriptionally silenced in female embryos, due to imprinted 
X-inactivation in the mouse pre-implantation embryo. Silencing of the Cre allele would 
prevent activation of the DTA allele and DTA-induced female-specific lethality. 
However, experiments using the Cre reporter TdTomato line showed that the X-linked 
Cre is active from at least E2.5, and was functional to induce Cre expression in utero. 
Although the paternal X is silenced from the 2-4 cell stage in the pre-implantation mouse 
embryo (Okamoto et al., 2005, Okamoto et al., 2004, Zuccotti et al., 2002), Xist spreads 
progressively in cis from the X inactivation centre (XIC). Therefore, given that the Hprt 
locus where the Cre transgene is integrated is not immediately adjacent to the XIC, there 
may have been a period of expression from X-Cre, prior to XCI.  
 
Using the X-linked Cre, inducing DTA expression resulted in female-specific lethality. I 
hypothesised that the complete sex skew to all-male litters would result in the mean 
experimental litter size of these matings being approximately half of the mean litter size 
of the control matings. Although there was some reduction in mean litter size, the mean 
litter size was not half. This partial compensation could be because the loss in utero of 
the female offspring may allow more male embryos to implant and survive gestation 
through to birth. The partial compensation of litter size was also seen in later experiments, 
and is discussed in greater depth in 5.3. 
 
Moreover, despite the embryonic lethality of female embryos, there appeared to be no 
transcriptomic detriment on the surviving embryos compared to wildtype embryos. I 
suspected that the X-Cre/X;R26-DTA/+ blastocysts were non-viable prior to the 
blastocyst-stage, and were therefore not harvested during blastocyst-stage collections. 
Therefore, the X-Cre/X;R26-DTA/+ embryos were not represented in the RNAseq 
dataset. The lack of X-Cre/X;R26-DTA/+ females was confirmed by an absence of lowly 
Rosa26-expressing female embryos. In humans, DTA functions by ribosylation of host 
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eEF-2 (elongation factor-2), disrupting eEF-2 function and inhibiting protein synthesis 
(Bell and Eisenberg, 1996). Therefore I predicted that if I had captured the X-Cre/X;R26-
DTA/+ female embryos, there may be dysregulation of genes involved in protein 
synthesis. Although the translation initiator gene Eif5a appears to be upregulated in some 
samples, the upregulation did not appear to be unique to the experimental samples. 
Therefore it is unlikely this upregulation is a result of embryonic littermate lethality. 
Furthermore, there was no differences in relative Eef-2 gene expression between 
experimental and control blastocysts in this dataset. It is likely that any transcriptomic 
differences seen at the individual level is due to in utero variability, for example 
differences in developmental time, and/or lysis, cDNA and library preparation procedure. 
The finding that the littermates are unaffected at the transcriptomic level is important if a 
similar strategy is to be undertaken in agricultural species, as the required litter-mates 
must develop similarly to wildtype.  
 
These experiments generated all-male litters. However, using an inducible DTA 
transgene to cause female lethality may not be immediately translatable to agriculture and 
livestock. Most commonly in agriculture it is the females that are required; for example 
in dairy cow or layer hen production. In the future it may be possible to reverse this 
technology by inserting a Cre recombinase allele onto the Y chromosome. In this strategy, 
the Cre recombinase would be uniquely inherited by the sons, resulting in a sex skew 
towards female offspring.  
 
The main caveat of the inducible DTA mating strategy is that the live offspring carry an 
allele encoding a toxin. Although theoretically DTA expression is only induced upon 
recombination by Cre (Marques et al., 2009), it is possible that DTA expression could be 
leaky. If this technology was to be translated to an agricultural application, the public 
may be apprehensive of livestock or farm-produce encoding a toxin. The problem of 
surviving offspring carry an allele encoding a toxin could be overcome by using a 
CRISPR-Cas9 bi-component system, where the Cas9 allele is lost with the unrequired 
sex. In this approach, a known housekeeping gene with essential embryonic function can 
be targeted for loss-of-function knock-out. Furthermore, the embryos could be collected 
at multiple developmental time points, to assess the CRISPR-Cas9 induced mutation 
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dynamics at the target locus. Furthermore, in the CRISPR-Cas9 approach, the Cas9 and 
sgRNA can be genetically segregated to control inheritance of both components. The 
sgRNA would be inherited by the surviving offspring. This sgRNA allele is not a protein-
coding gene, and therefore is clearly advantageous compared to a toxin protein-encoding 
gene. The development of the CRISPR-Cas9 approach will be discussed in the next three 
Chapters. 
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Chapter 4. Results 2: Screening highly mutagenic sgRNAs 
to generate an sgRNA expressing knock-in mouse line 
4.1 Introduction  
CRISPR-Cas9 genome editing requires two essential components; a Cas9 endonuclease 
and a single guide RNA (sgRNA). The sgRNA is made up of two regions. The first region 
is 20 nucleotides long and is complementary to a target site, adjacent to a PAM. The 
second region of the sgRNA guides the Cas9 to the target site to induce DNA DSBs. The 
DNA DSB is repaired either by non-homologous end joining (NHEJ) or homology 
directed repair (HDR), discussed in more detail in 1.5.1.1 and 1.5.1.2, respectively. NHEJ 
is error-prone, and results in indel mutations at the target site. Frame-shift mutations at 
the target site can disrupt the reading-frame of the gene, resulting in loss-of-function.  
 
To generate single-sex litters, the two components of the CRISPR-Cas9 system have to 
be genetically segregated in a “bi-component” system (Figure 12). In this strategy, a Cas9 
transgene, is integrated onto the X- or Y chromosome and carried by the father (similarly 
to the X-Cre transgene described in Chapter 3). The Cas9 transgene is uniquely inherited 
by daughters (X-Cas9) or sons (Y-Cas9) dependent on which sex chromosome the Cas9 
is integrated. The sgRNA targets a housekeeping gene with an essential role in early 
embryonic development. This “lethal sgRNA” is carried bi-allelically by the mother and 
therefore inherited by all offspring irrespective of sex. Only when both components of 
the CRISPR-Cas9 system are inherited would mutations at the target housekeeping gene 
occur, resulting in embryonic non-viability.  
 




Figure 12. CRISPR-Cas9 bi-component system for sex-specific lethality 
(a) Female-specific embryonic lethality, producing an all-male litter. An X-Cas9/Y male is 
crossed with a homozygous sgRNA-expressing female. Inheritance of both the X-Cas9 and 
sgRNA alleles in females induces mutations at an essential housekeeping gene, resulting in loss-
of-function and embryonic non-viability. (b) Male-specific embryonic lethality, producing an all-
female litter. An X/Y-Cas9 male is crossed with a homozygous sgRNA-expressing female. 
Inheritance of the Y-Cas9 and sgRNA allele in males induces mutations in an essential 
housekeeping gene, resulting in loss-of-function and embryonic non-viability.  
 
Inducing embryonic lethality during pre-implantation embryonic development would 
maximise the length of time possible to induce a sex ratio skew. Ideally, the Cas9 and 
sgRNA components would be under constitutive promoters, to ensure onset of expression 
soon after EGA in the mouse embryo. Targeting an essential housekeeping gene for 
knock-out requires a highly efficiency sgRNA to eliminate the protein-coding function 
of the gene. Ideally the CRISPR-Cas9 would induce a frame-shift mutation to disrupt the 
reading-frame of the gene, producing a loss-of-function phenotype.  
 
To translate the bi-component strategy in vivo, the final aim was to generate a transgenic 
mouse line expressing a highly efficient sgRNA expressed from an autosome. However 
standard Streptococcus pyogenes CRISPR-Cas9 HDR approaches could not be used to 
generate this sgRNA-knock in mouse model. Contemporaneous expression of the sgRNA 
transgene and residual Cas9 expression may induce mutations in the essential 
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housekeeping gene and embryonic lethality. Thereby, any positive knock-in embryos 
would be lost. I looked to using different modes of generating sgRNA transgenic mouse 
lines. One method of generating targeted knock-ins is by TARGATT technology (Zhu et 
al., 2014, Tasic et al., 2011, Chen-Tsai, 2019, Rossant et al., 2011). Tasic et al (2011), 
produced a transgenic mouse model containing a tandem of three attP sites (attPx3) 
inserted into the permissive autosomal Hipp11 locus (H11; Hippenmeyer et al., 2010) and 
the Rosa26 locus (R26; Friedrich and Soriano, 1991, Tasic et al., 2011). Repair templates 
containing attB sites, are integrated into the attPx3 locus by C31f integrase-mediated 
recombination. Due to the transgene insertion being generated using non-CRISPR based 
approaches, I hypothesised that expression of the lethal sgRNA, either transiently 
expressed or stably integrated as a transgene, would have no lethality effect on the 
developing embryo.  
  




4.2 Results  
4.2.1 Deriving Rosa26 Cas9 eGFP embryonic stem cells  
To test multiple sgRNAs in vitro whereby the Cas9 and sgRNA are genetically 
segregated, I required an in vitro culture of Cas9-expressing cells. I chose to derive 
embryonic stem cells (ESCs) from the Gt(ROSA)26Sortm1.1(CAG-Cas9*;eGFP)Fezh/J (hereafter 
referred to as “R26-Cas9”) pre-existing mouse line (Platt et al., 2014) for this purpose. 
This mouse strain constitutively expresses a SpCas9 (hereon referred to “Cas9”) 
endonuclease driven by a constitutively active CAG promoter. Furthermore, an eGFP 
fluorescent reporter is linked to the Cas9 via a 2A polypeptide. eGFP expression was used 
as a proxy for Cas9 expression in downstream experiments.  
 
To derive the ESC line, homozygous R26-Cas9 males were set up for timed mating with 
wildtype (MF1) females (+/+). I collected E3.5 embryos and derived three ESC lines (#1, 
2 and 3) in 2i+LIF conditions (see 2.1.3 and 2.6.2, Figure 13a). ESCs derived in 2i+LIF 
conditions are able to retain euploidy and they express the pluripotent markers of the 
epiblast (Mulas et al., 2019a). Female (XX) 2i+LIF derived ESCs are more susceptible 
to hypomethylation (Zvetkova et al., 2005, Choi et al., 2017), and loss of an X 
chromosome (Zvetkova et al., 2005) compared with male ESCs, reducing their ability to 
germline transmit in chimeras. Although I was not aiming to generate chimeras from these 
ESCs, I nevertheless aimed to do all downstream experiments with male (XY) ESCs. I 
determined the sex of each of the ESC lines by PCR amplification of the Sly gene, a Y 
chromosome-linked gene (Figure 13b). In two of the three derived ESC lines (#2 and #3) 
I could amplify Sly, indicating the presence of a Y chromosome. An autosomal gene 
Myogenin was also amplified as a PCR control (Figure 13b). One male ESC line (#2) was 
carried forwards for future experiments.  
 
Next, I confirmed eGFP and Cas9 expression from the R26-Cas9 ESCs. Theoretically, all 
derived ESC lines should have been R26-Cas9 hemizygous, due to using a homozygous 
father for timed matings. I performed reverse transcriptase PCR (RT-PCR) with minus-
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RT controls for gDNA contamination, and a b-actin housekeeping gene control. R26-
Cas9 and XY wildtype ESC lines were positive for b-actin expression whilst the R26-
Cas9 ESCs expressed eGFP and Cas9 (Figure 13c). Furthermore, I confirmed that eGFP 
expression could be visualised by fluorescence microscopy in male ESC line #2 (Figure 
13d).  
 
I also performed quantitative-PCR (qPCR) to confirm expression of Y chromosome genes 
Uty and Eif2s3y to ensure the R26-Cas9 #2 ESCs were male (Figure 13e). In all qPCR 
experiments, R26-Cas9 XY and XX gene expression was normalised to wildtype Gapdh 
expression. Results showed that the R26-Cas9 ESCs expressed the Y chromosome genes. 
I compared expression with R26-Cas9 line #1, which was female, and did not express 
Uty/Eif2s3y. I also assessed expression of Pou5f1, a highly-expressed ESC pluripotency 
marker (Nichols et al., 1998) as a qPCR control. Pou5f1 was expressed in all samples. 
Lastly, I confirmed that eGFP was expressed in the R26-Cas9 male #2 and female #1 
ESCs but not in the wildtype control (Figure 13e).  
 
 




Figure 13. Derivation of R26-Cas9 embryonic stem cells 
(a) A male homozygous R26-Cas9 (“Cas9”) was mated with wildtype MF1 females (+/+) and 
embryos collected at E3.5. Embryos were plated in 2i+LIF ESC medium until expanded. The 
outgrowth was dissociated into ESCs, plated and maintained in 2i+LIF. (b) Three ESC lines (#1-
3) were genotyped by PCR for Sly (Y chromosome) and for Myogenin (autosome) including a 
water no template control (ntc). (c) RT-PCR to confirm expression of Cas9/eGFP in male R26-
Cas9 ESCs (#2) plus minus-RT and ntc controls. (d) Fluorescence microscopy of ESC line #2 
Scale bar=50µm (e) qPCR analysis to confirm expression of Y chromosome genes Uty and 
Eif2s3y, ESC marker Pou5f1 and the eGFP transgene.  
 
Overall, these results showed successful derivation of male R26-Cas9 ESCs with 
detectable Cas9 and eGFP expression. Male ESC line #2 was carried forward to facilitate 
low-throughput screening of multiple sgRNAs. In all future experiments using this line 
#2, the ESCs are referred to as “R26-Cas9”.  
 
4.2.2 Candidate embryonic lethal gene: Topoisomerase 1 
I assessed candidate genes that when knocked-out, would induce embryonic non-viability 
at pre-implantation (http://www.informatics.jax.org/mp/annotations/MP:0011094). I 
focused on genes that showed a complete penetrance of lethality, and had a role in DNA 
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repair and replication, as knock-out of this gene is likely to have a function across many 
cell types during embryonic development.  
 
I chose to target the essential housekeeping gene Topoisomerase 1 (Top1), a protein-
coding gene present on mouse chromosome 2. Mouse Top1 has 21 exons, encoding a 
protein with four domains. The C-terminal exons 13 to 20 encode the essential DNA-
binding domain and catalytic site. Exons 11 and 12 encode the coiled-coil linker domain. 
Top1 also encodes two poorly conserved N-terminal low-complexity domains, exons 3-
4 and 7-8 (Figure 14a; Wright et al., 2015). 
 
TOP1 is a monomeric protein that functions by encircling the dsDNA helix to form a 
complex. Once the complex is formed, a single tyrosine within an active site functions to 
induce a 3’-phosphotyrosyl intermediate in a nicked single strand of DNA, allowing the 
supercoils to relax when the DNA rotates, and eventually re-ligating the nicked DNA 
strand (Pommier et al., 2010). TOP1 protein is highly conserved, particularly at the C-
terminal domain. The amino-acid alignment between four species, mouse, cow, chicken 
and rat is shown in Figure 14b with the DNA-binding domain and catalytic site shown by 
the positioning of the grey box below the alignment (Figure 14b). 
 
Studies have taken advantage of a LoxP-Cre system, generating conditional knock-outs, 
driven by a cell type specific reporter to investigate the precise function of Top1. Mabb 
et al, generated a conditional knock-out mouse line by inserting two LoxP sites flanking 
exon 3 (Mabb et al., 2016). Previous studies have also taken advantage of the highly 
conserved C-terminal region of the Top1 gene, generating Top1 null mutant mouse ESCs 
by replacement of exon 15 with a neomycin cassette (Morham et al., 1996) or by inserting 
two LoxP sites flanking exon 15 to generate a conditional knock-out (Kobayashi et al., 
2011). In the mouse, homozygous knock-out of Top1 results in embryonic non-viability, 
occurring around the 4-16 cell stage of pre-implantation development (Morham et al., 
1996). In cultured mammalian cells, homozygous Top1 knock-out is lethal (Morham et 
al., 1996) and TOP1 reduction causes genetic instability (Kobayashi et al., 2011), 
chromosome breaks and translocations (Tuduri et al., 2009). Therefore, it is essential 
Top1 expression is tightly controlled, to ensure genomic stability (Wang, 2002). 




Figure 14. Top1/TOP1 
(a) The mouse Top1 gene with exons in yellow. (b) TOP1 is highly conserved among multiple 
species. The amino acid level alignment between cow, chicken, mouse and rat. The grey box 
indicates the amino acid sequence coding for the essential DNA binding and catalytic domain. 




The pre-implantation embryonic lethal phenotype of Top1 suggested that this gene would 
be appropriate to target in the bi-component system. I aimed to develop a method to low-
throughput screen a number of sgRNAs targeting different exons of the Top1 locus, and 
determine the mutation efficiency of each of the sgRNAs.  
 
4.2.3 Generating the lethal sgRNA plasmid to screen sgRNAs 
For proof-of-principle experiments generating single-sex litters by CRISPR-Cas9 
induced knock-out, Top1 was selected as the candidate gene. Top1 exons 13 to 20 encode 
the highly-conserved catalytic core and DNA-binding domain (Wright et al., 2015, 
Morham et al., 1996, Kobayashi et al., 2011). Therefore, I designed one sgRNA targeting 
exon 15 and one sgRNA targeting exon 16 (Figure 15a). Previous CRISPR-Cas9 knock-
out strategies have designed sgRNAs targeting proximally to the ATG start codon, to 
disrupt the reading frame early (Doench et al., 2016).  I designed a third sgRNA targeting 
close to the ATG codon, in exon 2 (Figure 15a).  
 
I utilised the pX333 plasmid vector (Maddalo et al., 2014) as a backbone for sgRNA 
cloning. I exchanged the Cas9 cassette for an mCherry reporter driven by a constitutive 
Cbh promoter (Figure 15b). Expression of the sgRNA and mCherry reporter could not be 
driven by the same promoter and cleaved via a 2A polypeptide, because the sgRNA does 
not encode a protein. Therefore sgRNA expression is driven separately by a human U6 
promoter. The pX333 plasmid was advantageous because it contains a tandem of sgRNA 
cassettes under separate U6 promoters The two sgRNA scaffolds contain different 
restriction enzyme directional cloning sites (BbsI and BsaI). Therefore, two sgRNAs can 
be expressed from the same plasmid. The BbsI restriction enzyme site was also contained 
within the mCherry gene sequence, and this BbsI site was edited to contain a silent 
mutation (GAAGAC to GAAAAC) to prevent sgRNA cloning disrupting the mCherry 
coding sequence. The final sgRNA plasmid (annotated as “pLethal”, Figure 15b) 
contained the Cbh-mCherry reporter and two U6-sgRNA scaffolds, and was transfected 
in HEK293T cells. The mCherry expression was detectable by fluorescence microscopy 
(Figure 15c).  





Figure 15. Generating the "pLethal" plasmid for screening sgRNAs 
(a) The Topoisomerase 1 (Top1) locus highlighting the target regions of each sgRNA; sgRNA1 
(exon 15) , 2 (exon 16) and 3 (exon 2) (b) Generation of the pLethal plasmid by modification of 
pX333; replacement of the Cas9 cassette with the mCherry reporter. The plasmid also contains 
two tandem U6 promoters for separate sgRNA expression. A silent mutation was introduced into 
a BbsI restriction enzyme site within the mCherry sequence (c) Confirmation of mCherry 
expression by transient transfection in HEK293T cells. Scale bars=100µm. 
 
 
The individual Top1 sgRNAs (1, 2 and 3) were cloned into separate pLethal plasmids, to 
be driven by the first U6 promoter, and confirmed by Sanger sequencing. I also cloned 
an sgRNA targeting the Y chromosome gene Sry (targeting the single exon 1) into a 
pLethal plasmid. This Sry sgRNA could be used as a non-lethal control sgRNA. This 
sgRNA has been used previously in the Turner lab, to generate Sry mutations at high 
efficiency (unpublished). After generating the pLethal plasmids containing Top1 and Sry 
sgRNAs, I next aimed to evaluate the mutation efficiency of the lethal Top1 sgRNAs in 
vitro.  
 
4.2.4 Generating mutations at Top1 and evaluating mutation efficiency  
In order to assess mutagenic efficiency of the three Top1 sgRNAs in vitro, I designed a 
strategy whereby the pLethal plasmids could be individually transfected into R26-Cas9 
ESCs and the transfected and un-transfected ESCs sorted into separate populations by 
fluorescence activated cell sorting (FACS). The ESCs already express eGFP and Cas9, 
and pLethal-transfected ESCs would also transiently express mCherry and the sgRNA.  
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Therefore, two populations would be sorted; mCherry+eGFP+ and eGFP+ only. This 
‘traffic-light’ system of mCherry and eGFP reporter expression allowed me to use the 
fluorescence as a read-out for presence of sgRNA and Cas9, respectively. The “single-
positive” eGFP+ ESCs, which express Cas9 in isolation, functioned as an internal control 
to determine the basal variability at a target locus. Whilst in the mCherry+eGFP+ 
“double-positive” cell populations, both components of the CRISPR-Cas9 system are 
present, allowing mutations at the target exon.  
 
My first aim was to determine the optimum time point post-transfection in which to 
perform FACS. Knock-out of Top1 in ESCs is lethal (Morham et al., 1996) therefore the 
ESCs would need to be sorted by FACS before ESC death, but after sufficient pLethal-
transfection and expression to capture mCherry+ ESCs. To assess the transfection 
efficiency, I transiently transfected R26-Cas9 ESCs with the pLethal plasmid containing 
the non-lethal Sry sgRNA. In four separate plates, 1x106 R26-Cas9 ESCs were transfected 
and FACS performed 4, 24, 48 and 72 hours post-transfection. There was an increase in 
mCherry+eGFP+ ESCs with increasing time post transfection (Figure 16a). This was 
quantified as a percentage of mCherry+eGFP+ ESCs from the total amount of sorted 
ESCs. I decided on a 48 hour post-transfection time point for FACS for all future Top1 
sgRNA experiments, a compromise between high rate of transfection, and minimum time 
post-transfection to minimalize ESC death.   
 
My next aim was to sort ESCs post-transfection with the Top1 sgRNAs, to assess the 
mutation efficiency of each sgRNA. Each sgRNA-containing pLethal plasmid was 
transfected into a separate plate of R26-Cas9 ESCs (1x106 ESCs per transfection). After 
48 hours the transfected cells were sorted by FACS (representative FACS plots shown in 
Figure 16c). The FACS was performed on DAPI negative ESCs, i.e. live ESCs, for both 
the mCherry+eGFP+ and eGFP+ populations. The mCherry+eGFP+ ESCs were gated 
above 103 fluorescence units  for mCherry (Figure 16c). The eGFP+ ESCs was gated at 
approximately 103.5  to 104.5  fluorescence units for GFP (Figure 16c). I kept the mCherry 
and GFP gates discrete, as not to capture contaminating ESCs between populations. The 
two populations, mCherry+eGFP+ or GFP+ were sorted into separate tubes and the ESCs 
lysed (Figure 16b). After lysis, the ESC extract was PCR amplified at the target exon 
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regions for each sgRNA. The PCR amplicons were then deep-sequenced by MiSeq and 
analysed by bioinformatic analysis to evaluate the range of reads at the target site (Figure 
16b) using a previously published R package, CrispRVariants (Lindsay et al., 2016), (see 
2.9.2). A bioinformatic approach to analyse the spectrum of reads ensured that I could 
capture all variability of mutations at each of the target loci. The mutation efficiency 
output of the R package was calculated by evaluating the number of reads containing an 
insertion or deletion (indel) mutation, as a percentage of the total number of reads. The 
sgRNAs were tested in triplicate, and the mean mutation efficiency was calculated. Single 
nucleotide variants (SNVs) were not counted as mutations. 
 
The results showed that transfection of sgRNA1, targeting Top1 exon 15, produced the 
highest mutation efficiency (Figure 16d). The mean mutation efficiency in 
mCherry+eGFP+ ESCs post-transfection with sgRNA1 was 52.2%. The mutation rate 
was comparably greater than the mean mutation efficiency of 22.0% and 28.9% after 
transfection of sgRNA2 or 3, respectively (Figure 16d). In the eGFP+ populations, the 
mean mutation efficiency was 1.15% (sgRNA1), 0.43% (sgRNA2) and 1.18% (sgRNA3; 
Figure 16d). I attribute the low but detectable non-Cas9-induced mutation rate in the 
eGFP+ population to PCR error, endogenous variability at Top1, and/or contamination of 
mCherry+eGFP+ ESCs in the eGFP+ population. These explanations will be elaborated 
on further in 4.3. 
 
I then determined if there was a reduction in TOP1 protein after transfection with each of 
the single sgRNAs. The pLethal plasmids were transfected as previously, and the 
mCherry+eGFP+ and eGFP+ ESC populations sorted by FACS 48 hours post-
transfection. After sorting, bulk protein was extracted and western blot performed for 
TOP1 using either an N-terminal or C-terminal antibody. In the eGFP+ non-transfected 
ESCs TOP1 was expressed, when using either the N- or C-terminal antibody (Figure 16e). 
Conversely in the mCherry+eGFP+ ESCs there was a complete loss of TOP1 expression, 
whether using either the N- or C-terminal antibody (Figure 16e).  
 
Successful transfection of a single sgRNA into R26-Cas9 ESCs induced mutations at the 
target exons in vitro. However, using multiple sgRNAs targeting a gene of interest may 
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increase the probability of generating a null mutation. Therefore, given the highly 
mutagenic activity of Top1 sgRNA1, I cloned a second Top1 sgRNA into the sgRNA1 
plasmid, driven by the second U6 promoter. Two new pLethal plasmids were generated: 
sgRNA1+2, targeting exon 15 and 16, and sgRNA1+3, targeting exon 15 and 2. After 
generating the ‘double sgRNA’ pLethal plasmids, I aimed to determine whether the 
second U6 promoter would work equivalently to the first to drive sgRNA expression. The 
single sgRNA1 plasmid, and two double sgRNA plasmids (1+2 and 1+3) were transfected 
into individual plates of R26-Cas9 ESCs, as earlier described. The mCherry+eGFP+ and 
eGFP+ ESCs were sorted by FACS into separate populations. When the double sgRNA 
plasmids were transfected, two separate PCR MiSeq products were amplified for each of 
the individual target sites for each sgRNA. The two target exons for the double sgRNA 
plasmids could then be analysed separately to assess mutation efficiency.  
 
After amplification of the expected target sites and sequencing by MiSeq, the mutation 
efficiency was determined using the CrispRVariants pipeline. The mean mutation 
efficiency of the single sgRNA1 was 63.9% in mCherry+eGFP+ ESCs, compared with 
1.1% in eGFP+ ESCs (Figure 16f). Post-transfection with sgRNA1+2, the mean mutation 
efficiency for mCherry+eGFP+ ESCs at exon 15 (sgRNA1) was 64.5%. At this exon, the 
eGFP+ only ESCs had a mean mutation efficiency of 1.5%. When the second sgRNA 
was sgRNA2, the induced mutations are at exon 16, with a mean mutation efficiency of 
50.8%, compared with 0.3% in the eGFP+ population (Figure 16f). After transfection 
with plasmid sgRNA1+3, in the mCherry+eGFP+ population, sgRNA1 generated a mean 
mutation efficiency of 59.1%. The sgRNA3 generated a mean mutation efficiency of 
61.3% at exon 2. In the eGFP+ only population, exon 15 (sgRNA1) showed a mutation 
efficiency of 1.3%, whilst at exon 2 (sgRNA3) the mutation efficiency was 0.7% (Figure 
16f). This data indicated that in a double sgRNA plasmid, the second sgRNA induces 
mutations at the target exon and that the tandem U6 promoter can drive sgRNA 
expression. However having additional sgRNAs expressed from a single plasmid, does 
not increase the efficiency of indel mutations generated at individual exons.  
 
Introducing two sgRNAs (and Cas9) with close target proximity can result in complex 
genomic rearrangements between the two sgRNA sites (Kosicki et al., 2018, Allen et al., 
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2018); Figure 16h). I amplified a PCR product from mCherry+eGFP ESCs, using primers 
aligning up- and downstream of sgRNAs 1 and 2, which are approximately 940bp apart  
(Figure 16g). Two products were amplified, the expected 1.1kb product and one at 
approximately 230bp (Figure 16g, arrow heads). I cloned the PCR products into a cloning 
vector plasmid and Sanger sequenced the clones. I firstly investigated the mutation 
efficiency at each of the two DSB sites individually. Results showed that in 28% colonies 
sequenced, there was a single mutation in exon 15 (sgRNA1). In 6% of colonies 
sequenced, there was a single mutation at exon 16 (sgRNA2). In 50% of colonies, there 
was a mutation at both exons. Only 16% products presented wildtype sequence at both 
sgRNA1 and sgRNA2 cut sites (Figure 16g). This data shows that Cas9-induced DSBs at 
two loci do not always result in indels simultaneously at one dsDNA molecule.  
 
Secondly, I investigated if there was a large deletion between the sgRNA1 and 2 target 
sites. Two clones contained a ~250bp product that aligned to Top1 DNA sequence 5’ to 
sgRNA1 and 3’ to sgRNA2, with none of the intervening DNA sequence (Figure 16h). 
This chimeric PCR product confirmed that transfection with a double sgRNA plasmid 
can induce large deletions of the intervening sequence between two sgRNA target sites. 
Unfortunately, between exon 2 (sgRNA3) and exon 15 (sgRNA1), there is over 44kb of 
sequence, preventing any PCR amplification flanking these two cut sites.  
 
Given the known mutagenic potential of the single sgRNA1 plasmid, and the two double 
sgRNA plasmids; sgRNA 1+2 and sgRNA 1+3, I then lastly aimed to investigate the 
mutagenic efficiency of these three sgRNA plasmids over time. For each sgRNA-
containing plasmid, four separate plates of R26-Cas9 ESCs were transfected. The ESCs 
were sorted into mCherry+eGFP+ and eGFP+ only populations by FACS at 4, 24, 48 and 
72 hours post-transfection, in duplicate, as earlier described. The populations of 
mCherry+eGFP+ and eGFP+ only ESCs could be sorted by FACS as early as 4 hours 
post-transfection by reporter expression. In all three transfections with each pLethal 
plasmid, mutations occurred 4 hours post-transfection. The highest mutation efficiency 
(46.2%) was present at exon 16, induced by sgRNA2 in the double sgRNA plasmid 
(sgRNA1+2). At 24 hours, the most highly efficient sgRNAs were sgRNA1 (single 
sgRNA, 65.9%) and sgRNA3 (71.2%) expressed from the sgRNA1+3 plasmid (Figure 
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16i). At 48 hours post-transfection, the time point used for all earlier experiments, the 
most efficient sgRNA was sgRNA2 (in sgRNA1+2, 69.9%) and sgRNA1 alone (60.7%). 
This result is echoed at 72 hours (Figure 16i).   
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Figure 16. Low-throughput sgRNA screen 
(a) Assessment of the percentage (transfection efficiency by FACS) of mCherry+eGFP+ ESCs 
using a non-lethal sgRNA targeting Y chromosome gene Sry. (b) Strategy for transfection of R26-
Cas9 ESCs with different sgRNAs (with mCherry reporter), followed by FACS of ESCs 48 hours 
post-transfection and MiSeq analysis to assess mutation efficiency in different ESC populations. 
The sorting by FACS was performed by the Flow Cytometry STP. (c) Representative FACS plots 
of Top1 sgRNA1, 2 and 3, 48 hours post-transfection. (d) Mutation efficiency of sgRNA1, 2 and 
3 at the expected target exon in Top1. The mutation efficiency is quantified by MiSeq of a PCR 
amplicon of the target region, followed by analyses using the CrispRVariants R package pipeline 
(Lindsay et al, 2016). (e) Western blot of TOP1 using an N-terminal and C-terminal antibody in 
mCherry+eGFP+ ESCs (+sgRNA) and eGFP+ only (-sgRNA) ESCs for each sgRNA. The 
western blot was performed by Valdone Maciulyte (Turner lab). (f) Mutation efficiency when 
two sgRNAs are inserted into the sgRNA1 pLethal plasmid for each of the target exons. (g) 
Assessment of occurrence of two separate indel mutations at exon 15 and exon 16 by sgRNA1 
and 2 by cloning and Sanger sequencing. (h) Deletion of the intervening DNA sequence when 
using a double sgRNA approach; sgRNA1+2 and production of a chimeric PCR product. (i) Time 
course experiment quantifying the mutation efficiency at Top1 for sgRNA1, 2 and 3 after FACS; 
4, 24, 48 and 72 hours post-transfection. All of the MiSeq library preparations were performed 
by the GeMS STP. All of the MiSeq sequencing was performed by the ASF STP. The 
CrispRVariants R package pipeline was performed by Jasmin Zohren (Turner lab).  
 
 
Overall, this data highlighted the potential of inducing mutations at the Top1 locus using 
a bi-component CRISPR-Cas9 system in vitro. Results showed that sgRNA1 gave the 
highest efficiency of mutation when expressed as a single sgRNA, and induced mutations 
as rapidly as 4 hours post-transfection. Although sgRNA2 and 3 gave considerable 
mutation efficiency, particularly in combination with sgRNA1 in the double sgRNA 
plasmids, there was a complexity in analysing the mutation types when large intervening 
sequence deletions arose. Therefore, given this highly mutagenic potential of sgRNA1 as 
a single sgRNA, combined with the simplicity of screening for single mutations at a single 
target locus, I next wished to investigate the dynamics and spectrum of mutations induced 
by sgRNA1.  
 
4.2.5 Dynamics of sgRNA 1 CRISPR-Cas9 induced mutations  
Top1 loss-of-function is more likely if the mutation is a frame-shift. Therefore, I aimed 
to assess the spectrum of Top1 exon 15 mutations in mCherry+eGFP+ ESCs, after 
transfection with sgRNA1, the sgRNA that created the highest mutation efficiency.   
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Firstly I performed an in silico prediction of the mutational outcome of sgRNA1, using a 
published tool, “CRISPOR”(crispor.tefor.net, (Concordet and Haeussler, 2018, Haeussler 
et al., 2016). This tool produces an “out-of-frame” score, based on a prediction of the 
number of clones that would contain frame-shift indel mutations at the target site, scored 
out of 100 (Bae et al., 2014). The out-of-frame score for sgRNA1 was 72, a high 
probability of generating a frame-shift mutation. The CRISPOR analysis projected that 
the most likely mutation type is a 14bp deletion, based on sequence microhomology 
flanking the DNA target site.  
 
I next compared the results of the CRISPOR analysis with the results from the MiSeq and 
CrispRVariants pipeline. The output of CrispRVariants provides the number of different 
reads generated by MiSeq and quantifies the occurrence of each read type. I manually 
evaluated the occurrence and types of reads occurring at Top1 exon 15. I considered the 
position between nucleotide -3 and -4 at the sgRNA target as position “0”, with the 
coordinates of the insertions or deletions of individual nucleotides 5’ (“minus”) or 3’ 
(“plus”) to this location (Figure 17a). In all three replicates, the three most commonly 
occurring mutations at Top1 exon 15 were; -1:1bp insertion, -1:2bp deletion, and +1:1bp 
deletion, suggesting that CRISPR-Cas9 mutagenesis is stereotypic at this locus. In all 
three of these mutation types, a frame-shift is predicted in Top1. Interestingly, in all three 
replicates, the mononucleotide insertion in the -1:1I mutation was an adenine (A) 
nucleotide. 
 
I evaluated the occurrence of these top three mutations as a percentage of the total number 
of MiSeq reads aligning to Top1 exon 15. For each replicate, these three mutations 
collectively contribute 20.6%, 11.2% and 18.9% (mean 16.9%) of the total number of 
reads (Figure 17b). I also evaluated the occurrence of these three mutations as a 
percentage of total indel-containing reads. The percentage occurrence increases to 26.6%, 
35.8% and 39.2% for each replicate (mean 33.9%, Figure 17c). Therefore, on average, 
over one third of the range of indel mutations can be pinpointed to just three precise 
frame-shift mutations occurring at the expected dsDNA target position.  
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Lastly, I assessed the occurrence of the in silico predicted mutation (14bp deletion) within 
these replicates. The most commonly occurring 14bp deletion was at nucleotide position 
-6, occurring with frequency of 3.6%, 4.3% and 6.0% (mean 4.6%) for each replicate 
(Figure 17d). This was quantified as a percentage occurrence of all reads containing indel 
mutations.  
 
Overall, the high mutational efficiency of inducing mutations at Top1 exon 15 by 
sgRNA1 CRISPR-Cas9 genome editing, enhanced by the stereotypic frame-shift 




Figure 17. Dynamics of sgRNA1 mutations 
(a) Schematic of CRISPR-Cas9 targeting at Top1 exon 15, guided by sgRNA1, showing the 
sgRNA (blue) and PAM (pink) sequence. The Cas9 induces a DNA DSB at the -4 nucleotide 
position (red X), proximal to an A nucleotide. (b) The complete spectrum of read categories 
(wildtype, SNV, types of indel mutations). The dominant mutations (1:1D, -1:2D, -1:1I) are 
highlighted as a percentage of the total sequence reads. (c) The dominant mutations (1:1D, -1:2D, 
-1:1I) are shown as a percentage of the total reads containing indel mutations (d) The occurrence 
of a 14bp deletion at the -6 position as a percentage of indel mutations, a predicted highly 
dominant mutation by in silico tools; CRISPOR, crispor.tefor.net (Concordet and Haeussler, 
2018, Haeussler et al., 2016). 
 




4.2.6 Generating the sgRNA 1 knock-in mouse model 
Given the highly mutagenic capacity of sgRNA1 with a prevalence of stereotypic frame-
shift mutations, I next aimed to generate a transgenic mouse line that expresses sgRNA1. 
I was unable to use CRISPR-Cas9 genome editing to generate this knock-in, as any 
successful integrations of the transgene could have resulted in contemporaneous 
expression of residual Cas9 and the sgRNA transgene. The presence of both CRISPR-
Cas9 components would target Top1 for mutation, potentially resulting in non-viability 
of the successfully targeted pups. I therefore used a previously published knock-in 
approach called “TARGATT” (target-attP; Tasic et al., 2011) which utilises fC31 
integrase-mediated recombination between attP and attB sequences. Recombination at 
the attP/B sites produces an attL/R sequence which is inhibitory to continued fC31 
integrase action and prevents any further locus recombination. A mouse line containing 
three attP sequences inserted into the permissive H11 locus was previously generated 
(“H11-attPx3”; Tasic et al., 2011, Hippenmeyer et al., 2010). An attB-flanked transgene 
can be integrated into this transgenic H11 locus by microinjection of fC31 integrase and 
the targeting vector into H11-attPx3 embryos. The authors also published another mouse 
line where three attP sequences were integrated into Rosa26 (R26-attPx3; Tasic et al., 
2011). However for my sgRNA1 transgene targeting experiments, I decided to target the 
H11-attPx3 locus, as this provides future flexibility for transgenic mice to be mated with 
the R26-Cas9 mouse line (Platt et al., 2014). 
 
I edited the Top1 sgRNA1 pLethal plasmid (U6-sgRNA1:Cbh-mCherry) to contain attB 
sequences flanking the transgene (Figure 18a). The second, empty U6-sgRNA scaffold 
was retained, to ensure consistency within the structure of the construct if a future double 
sgRNA transgenic mouse line was made. The Cbh-mCherry cassette was kept for 
transgenic fluorescent reporter read-out.  
 
To generate the stable transgenic mouse line, zygote stage hemizygous H11-attPx3 (Tasic 
et al., 2011) embryos were microinjected by the GeMS STP, with the knock-in 
Chapter 4 Results 
 
 119 
components; the attB-flanked targeting vector, and fC31 integrase mRNA, facilitating 
integrase-mediated recombination in the pronuclear DNA (Figure 18b).   
 
All microinjected embryos that successfully cleaved to the two-cell stage were surgically 
transferred into the uteri of pseudopregnant females (n=5) by GeMS. Three of five 
females littered, giving a total of 25 pups born. I assessed the pups for presence of the 
transgene by in vivo imaging at 3 days post birth, which detected the expression of the 
mCherry reporter. Of 25 pups born, 1 male was positive, giving an knock-in efficiency 
rate of 4%. The one positive male was not confirmed to have a targeted integration at the 
H11 locus. 
 
The male founder was set up in matings with wildtype C57BL/6J females and offspring 
were assessed by in vivo imaging to identify the mCherry positive pups. In the first two 
litters produced, five pups were born that were mCherry positive (n=5/10, 50%). 
Therefore the founder successfully germline transmitted the transgene to the F1 
generation (two F1 pups shown in Figure 18c).  
 
To confirm mCherry expression at the RNA level, I performed a qPCR using a TaqMan 
probe. mCherry expression was assessed in four different tissues (brain, liver, kidney, 
spleen) dissected from an F1 generation sgRNA mouse, normalised to wildtype liver 
Gapdh expression. Results showed the mCherry was expressed in all four tissues, and not 
in the wildtype control (Figure 18d). The stable transgenic mouse line was annotated as 
“H11:U6-Top1sgRNA1:Cbh-mCherry”, and is hereon referred to as “sgRNA”.  
 




Figure 18. Generating an sgRNA expressing mouse line by TARGATT knock-in 
(a) Schematic of the targeting strategy to generate a U6-sgRNA1:Cbh-mCherry knock-in at the 
permissive Hipp11 locus on autosomal chromosome 11 (H11). The pLethal plasmid described 
previously, containing a U6 promoter followed by sgRNA 1 (targeting Top1 exon 15) with a 
second tandem empty U6 promoter and sgRNA scaffold, followed by a Cbh promoter and 
mCherry reporter, was modified to contain attB sequences flanking the knock-in region of 
interest. (b) The attB-pLethal plasmid was co-injected with f C31 integrase into TARGATT H11-
attPx3 heterozygote embryos. Successfully cleaved embryos were surgically transferred into 
pseudopregnant females to litter (c). A single male founder was generated and germline 
transmitted to the F1 generated, assessed by in vivo imaging. (d) The H11:U6-sgRNA:Cbh-
mCherry (“sgRNA”) mouse expressed mCherry in multiple tissues, quantified by qPCR, 
normalised to wildtype Gapdh expression. The embryo microinjections and surgical transfers 
were performed by the GeMS STP.  
 
Once I determined that the sgRNA mouse line was stably transmitting the transgene and 
expressing the mCherry reporter, I assessed efficiency of sgRNA expression by mating 
with the R26-Cas9 mouse line, to model the bi-component CRISPR-Cas9 system in vivo. 
The in vivo bi-component system will be discussed in Chapter 5. 
 




In this chapter I derived a Cas9-expressing ESC line to routinely and easily evaluate the 
efficiency of sgRNAs in vitro, when the Cas9 and sgRNA are genetically segregated 
thereby modelling the bi-component system in vitro. I confirmed that the ESCs expressed 
Cas9 and eGFP, providing a useful fluorescent reporter system as a proxy for Cas9 
expression. Three different sgRNAs targeting Top1 were cloned into the pLethal plasmid 
vector, also expressing a mCherry reporter. This allowed me to perform a ‘traffic light’ 
system to sort and evaluate double positive (sgRNA+Cas9+) versus single positive 
(Cas9+ only) cell populations. Using ESCs provided an easily transfected in vitro model, 
with high numbers of cells in each sorted population for mutation and expression 
analyses.  
 
I decided on a time point of 48 hours post-transfection for Top1 sgRNA FACS, based on 
transfections with a non-lethal sgRNA, targeting Sry. Although the number of mCherry+ 
ESCs increased over time in the Sry transfection, the Top1 sgRNAs may have a lethal 
phenotype in ESCs. Therefore, I chose 48 hours as a good compromise between high 
levels of transfected cells, and a reasonable time post-transfection to attempt to minimise 
ESC death. ESCs are usually passaged every 2-3 days, so 48 hours post-transfection also 
appeared a reasonable time according to standard ESC maintenance. When performing 
FACS, only the DAPI negative, alive ESCs, were collected for both mCherry+eGFP+ 
and eGFP+ only populations. The caveat of this approach is that any non-viable ESCs 
may be lost from the analysis. These ESCs may have large indel mutations that have 
resulted in an efficient loss-of-function phenotype and ESC lethality. This may be 
particularly relevant in the double sgRNA experiments, where sgRNA1 efficiency was 
lower post-transfection with double sgRNAs than with a single sgRNA1. Double sgRNAs 
may result in more complex mutations, or a “double hit” of indel mutations at two exons, 
resulting in loss-of-function of Top1 more quickly. This caveat could be overcome by 
also collecting the DAPI positive population of ESCs. However since the reporter 
expression cannot be detected in this population, the cohort may have contributions of 
mCherry+eGFP+ ESCs and eGFP+ only cells. This would result in a highly inaccurate 
mutation efficiency calculation.  




The mutation efficiency of sgRNA1 was higher than sgRNA2 and 3. In-depth analyses 
of the mutation dynamics of sgRNA1 showed a high likelihood of generating frame-shift 
mutations, increasing the probability of generating loss-of-function of Top1. Using ESCs 
to perform a low-throughput analyses to test multiple sgRNAs provided a simple and 
tractable method to assess mutation efficiency and make like-wise comparisons of each 
sgRNA, irrespective of transfection efficiency. One caveat to using ESCs to assess 
mutation efficiency is the number and variability of mutations present when transfecting 
large numbers of cells. In order to circumvent the manual process of individually aligning 
collapsed MiSeq reads to evaluate mutations at the target locus, I utilised the 
CrispRVariants R package (Lindsay et al., 2016). This allowed me to take into account 
every read aligning to the target site and accurately evaluate all of the variability in 
mutations in the target region. This also has the advantage of bioinformatically removing 
any non-specific or primer-dimer amplicons from the analysis, making analyses more 
streamlined.  
 
I chose to evaluate the spectrum of mutations at a range of 20 nucleotides 5’ and 3’ from 
the 20bp sgRNA target. Any deletions up to 60bp long will be captured by this approach. 
Any mutations longer than 60bp are lost from the mutation efficiency quantification. To 
quality control check for large deletions, the data can be manually checked for large 
deletions greater than 60bp, and parameters of mutation efficiency quantification 
adjusted, if necessary. The maximum sequence length of the MiSeq amplicon is 500bp. 
Any mutations generating a product larger than 500bp would never be captured by PCR 
amplification, as the primer binding sites would be lost. This could be circumvented by 
using PCR primers that are complementary to sequence significantly further from the 
expected DSB site, and sequencing products smaller than 500bp.  
 
Furthermore, there is a rising concern about large deletions and complex mutations 
arising using CRISPR-Cas9. Studies published in 2017 suggested that single sgRNAs 
induced deletions up to 600bp in mouse zygotes (Shin et al., 2017) and up to 1500bp in 
cancer cell lines (Gasperini et al., 2017). Kosicki et al showed that a single sgRNA 
targeting the X-linked gene PigA (Phosphatidylinositol glycan anchor biosynthesis class 
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A) in XY ESCs generated deletions up to 9.5kb (Kosicki et al., 2018, Allen et al., 2018). 
The potential for huge complexity in large deletions, inversions and rearrangements is 
not caught in this single sgRNA analysis.  
 
To compare with the results of MiSeq/CrispRVariants, published in silico tools also give 
an indication of likely frame-shift mutational outcomes at the target site. The results 
shown by MiSeq/CrispRVariants at Top1 exon 15 did not fully recapitulate the expected 
most commonly occurring mutation from these in silico tools. Single nucleotide variants 
were not considered to be ‘true’ mutations if they are not contained within the sgRNA 
target sequence. These may be naturally occurring single nucleotide variants. For 
example, a R26-Cas9 male was mated to MF1 females to collect embryos for ESC 
derivations. Given the different mouse genetic backgrounds, the ESCs could be variant 
rich. However, the occurrence of SNV-containing reads can be determined by this 
analysis and taken into account if required. In this analysis, I chose to keep SNVs as a 
separate category to indel mutations. In terms of variants, there may also be some PCR 
error or inefficiency, particularly towards the 5’ and 3’ edges of the amplicon during PCR 
amplification or sequencing. This can be circumvented by reducing the area flanking the 
sgRNA nucleotide sequence to investigate mutated reads, however this may lose large 
deletions in the region. The PCR amplicon generated for MiSeq sequencing may have 
some preferential bias, meaning that some sequences are amplified more readily than 
others. This would lead to an over-representation of some read types in the analysis. In 
order to try and reduce this amplification-bias, I kept the number of PCR cycles low, in 
order to amplify the region sufficiently for sequencing, but without over-amplification of 
few read types.  
 
Importantly, with all of these described caveats, the eGFP+ only population was also 
included in the pipeline. This population undergoes the same PCR amplification, MiSeq 
sequencing and analysis by CrispRVariants and/or CRISPOR. Therefore this population 
highlights the basal variability around this locus, and after the analysis pipeline. In all of 
these analyses, I decided not to normalise to this population, to give a true indication of 
the variability at each Top1 locus. As earlier described, there was a low non-Cas9-induced 
rate of mutations at the locus in these eGFP+ only ESCs. As well as the endogenous 
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variability at Top1, it is also possible that the pseudo-mutation rate is attributable to PCR 
error, during the amplification and library preparation steps. This PCR error would also 
occur in the mCherry+eGFP+ ESC populations in each experiment. Furthermore, the two 
populations are sorted by FACS on fluorescence reporter expression. It is possible that 
there was some contamination between population types during the collection, PCR 
amplification and library preparation steps. Contamination between samples would 
falsely increase the mutation efficiency in eGFP+ populations, and decrease the 
efficiency in mCherry+eGFP+ populations.  
 
The data presented in this chapter showed that only when both CRISPR-Cas9 components 
are present, in the double positive ESCs, a high efficiency of mutations at the target site 
was introduced. I tested for TOP1 expression in transfected and non-transfected ESCs, at 
both the N-terminus and C-terminus of TOP1. This was because sgRNA1 and 2 target 
Top1 at exons in the middle of the reading frame. Therefore, mutations in exon 15 or 16 
may have generated a truncated protein which may have some function. Targeting by 
sgRNA3 at exon 2 near the expected start codon (ATG) may have induced a mutation 
resulting in alternative start codons being used. This means that a functional TOP1 protein 
may still be generated. In the single positive, Cas9+ only, populations TOP1 was 
expressed in all three samples, when using antibodies to both the N-terminus and C-
terminus. Post-transfection with all three sgRNAs, in the Cas9+sgRNA+ ESCs, there was 
a loss of TOP1 protein, compared with the Cas9+ population. 
 
Overall, this data highlights that a bi-component system efficiently drives mutations at 
Top1 in a target-specific manner. The mutations induced at the target exon sites occurred 
after transient transfection with a plasmid in vitro. Therefore I speculate that the mutation 
efficiency may be greater in an in vivo environment due to constitutive expression of the 
sgRNA construct (when crossed with a constitutively expressing Cas9 mouse line). In the 
in vitro experimental strategy, three sgRNAs were tested that target the Top1 locus. 
However this strategy is not limited to investigating mutational efficiency at this gene. 
This pipeline could be expanded to testing many sgRNAs targeting multiple genes, or the 
same gene in multiple loci. Furthermore, it is not limited to a single sgRNA but also 
multiple sgRNAs being expressed from a single plasmid, allowing for increased 
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flexibility in evaluating different knock-out designs. I hypothesized that a highly efficient 
sgRNA at the in vitro level, would translate to an in vivo approach and therefore generated 
the sgRNA expressing mouse line to test this hypothesis. I also aimed to investigate 
whether the most dominant mutational outcome at the in vitro level, would also be 
recapitulated in vivo.  
 
Initially in the low-throughput sgRNA screen, I investigated efficiency of single sgRNAs 
and evaluated the mutations occurring at each target locus. This was a simple method of 
analysing the efficiency, spectrum and dynamics of the mutations for each sgRNA target. 
However given that there is also a high rate of mutagenesis when two sgRNAs are 
expressed in tandem, it may also be possible to generate knock-in mouse models 
expressing multiple sgRNAs. This may have a greater efficiency of generating a null 
mutation at the sgRNA target gene. Hypothetically, expression of the Cas9 and sgRNA 
in the early embryo could induce a mutation at the target locus that is a silent mutation. 
The presence of the silent mutation in the sgRNA target will prevent future DNA DSBs 
but not inhibit the protein function. Generating a mouse line that expresses multiple 
sgRNAs means multiple exons are targeted to induce frame-shift mutations, resulting in 
a greater likelihood of producing target gene loss-of-function.  
 
A single sgRNA was shown to induce a high rate of mutations at the target locus in this 
data. Furthermore, single sgRNAs have been shown previously to have catastrophic 
deletion and rearrangements events in target genes (Kosicki et al., 2018).  Using a double 
sgRNA system could further increase the possibility of a range of mutations or complex 
mutations in the intervening sequence between the two sgRNAs (Kraft et al., 2015, 
Boroviak et al., 2016, Boroviak et al., 2017). Complex mutations introduced by 
two/multiple sgRNAs are more challenging to accurately assess. This was shown in this 
results chapter when transfecting ESCs using the double sgRNA plasmids. Cas9-induced 
indels didn’t always occur in the same DNA molecule. This data suggested that the two 
sgRNA/Cas9 complexes were not always cutting simultaneously at the same DNA 
molecule. There were also PCR products generated from large deletions of the 
intervening sequence in the double sgRNA transfections. These very large Top1 deletions 
may contribute to an increased rate of ESC death. These non-viable, DAPI positive ESCs 
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would not have been sorted during FACS and therefore lost from the analysis. This may 
explain the underrepresentation of ‘large deletion’ clones found during the Sanger 
sequencing analysis. The 44kb distance between sgRNA1 and 3 could not be amplified 
by PCR and therefore the types of mutations occurring at each of the two sgRNAs in a 
single DNA molecule could not be evaluated.  
 
Given the simplicity of screening for single sgRNA mutations, with in silico and 
bioinformatically predicted frame-shift mutations, the first priority was to generate a 
single sgRNA expressing mouse line. The sgRNA1 20 nucleotide Top1 target site was 
sequenced conserved between mouse, cow, chicken and rat, and others.  The bi-
component in vitro system in mouse ESCs could be utilised for testing sgRNA mutation 
efficiency targeting genes of non-mouse species, provided they are sequence conserved.  
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Chapter 5. Results 3: In vivo bi-component CRISPR-Cas9 
induced mutations at Top1 
5.1 Introduction 
The in vitro system described in Chapter 4 showed that expression of Cas9 and a Top1 
sgRNA in ESCs induced mutations at Top1. To become applicable to other species, for 
example agricultural animals, the bi-component system must be functional in vivo. There 
are two previously published studies of in vivo bi-component systems, one in the 
silkworm (Zhang et al., 2018), and one in the mouse (Yosef et al., 2019). The silkworm 
bi-component system used heterogametic females to induce female-specific lethality 
(Zhang et al., 2018). However, in the mouse, the males are the heterogametic sex. The 
Yosef et al (2019) mouse study used a Y-linked sgRNA transgene crossed with an 
autosome-linked Cas9. Both transgenes were inherited uniquely by males, and generated 
mutations in essential genes Atp5b, Casp8 and Cdc20 to induce male-specific lethality. 
The limitation of this study was the incomplete sex skew: 9 of 113 (8%) newborns were 
male. Although this skew was a statistically-significant deviation from the usual 1:1 ratio 
of males:females, it did not show completely all-female litters.  
 
In this chapter I investigated the penetrance of lethality when the Top1 sgRNA and Cas9 
transgenes are co-inherited. I firstly examined whether mutations were detectable at the 
Top1 locus in pre-implantation embryos and whether the mutations recapitulated the 
mutation spectrum seen in vitro. Secondly, I investigated whether co-inheritance of the 
transgenes resulted in embryonic lethality, and whether loss of Cas9/sgRNA embryos 
impacted the mean litter size.   
 




5.2.1 Assessing mutations at the Top1 locus in pre-implantation embryos in the bi-
component CRISPR-Cas9 system  
In Chapter 4 I generated an sgRNA-expressing mouse line, H11:U6-Top1sgRNA1:Cbh-
mCherry, hereon referred to as “sgRNA”, targeting Top1 exon 15. I hypothesised that 
inheritance of both the sgRNA and a Cas9 transgene in vivo would result in mutations in 
Top1, inducing embryonic lethality, whereas inheritance of either transgene in isolation 
would have no effect.  
 
A traffic light system for detecting the sgRNA (mCherry) and Cas9 (eGFP) transgenes 
was utilised in vitro to sort the ESCs by genotype. Therefore, I first assessed whether the 
reporters were expressed in embryos. To pinpoint the time of transgene expression, I 
collected pre-implantation embryos at three stages: E1.5 (2-cell, n=9), E2.5 (8-cell, n=22) 
and E3.5 (early blastocyst, n=51) from timed mating between hemizygous sgRNA fathers 
(sgRNA/+), and homozygous R26-Cas9 mothers (Cas9, Platt et al., 2014; Figure 19a,b). 
There were two possible embryo genotypes; Cas9/sgRNA or Cas9/+. The Cas9/sgRNA 
expressed eGFP and mCherry, whilst Cas9/+ embryos only expressed eGFP. eGFP 
expression was detectable at E1.5, E2.5 and E3.5 in every embryo analysed. mCherry 
expression was absent from E1.5 embryos, but expressed at E2.5 and E3.5 (Figure 19c). 
Therefore, I confirmed that pre-implantation embryo genotypes could be assessed by 
reporter expression at E2.5 and E3.5. The early expression of eGFP but not mCherry in 
the E1.5 embryos was likely due to maternally deposited mRNA in the oocyte from the 
R26-Cas9 mother.  
 
After sorting the embryos by reporter expression, the E2.5 and E3.5 embryos were lysed, 
PCR amplified for Top1 exon 15 and sequenced by MiSeq. E1.5 embryos were not 
sequenced because they could not be genotyped by reporter expression and therefore any 
mutations at Top1 could not be ascribed to genotype. For each embryo, the percentage 
mutation efficiency was calculated as the total number of reads containing an insertion or 
deletion mutation, divided by the total number of reads. Single nucleotide variant-
containing reads were not counted as mutations. E2.5 Cas9/sgRNA embryos (n=14) had 
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a mean mutation efficiency at Top1 exon 15 of 54.2%, whilst Cas9/+ embryos (n=8) had 
a mean mutation efficiency of 5.7%. The difference in mutation efficiency between 
Cas9/sgRNA and Cas9/+ embryos was statistically-significant (p=3x10-3, Mann-Whitney 
test; Figure 19d). E3.5 Cas9/sgRNA embryos (n=16), had a mean mutation efficiency of 
60.5% while in the Cas9/+ embryos (n=35) it was 7.4%. The difference in mutation 
efficiency between the Cas9/sgRNA and Cas9/+ embryos at E3.5 was statistically-
significant (p=1x10-10, Mann-Whitney test; Figure 19d). Similarly to in Chapter 4, there 
was a non-Cas9-induced rate of mutation in the Cas9/+ embryos, despite the supposed 
lack of sgRNA transgene. This mutation rate was most likely produced by PCR error 
during amplification and library preparation. Furthermore, the error may have also 
occurred by incorrect sorting of Cas9/sgRNA and Cas9/+ embryos, resulting in 
contamination of the ‘incorrect’ genotype contributing to the mean mutation efficiency. 
In the Cas9/sgRNA population, the presence of Cas9/+ embryos would falsely reduce the 
mean mutation efficiency, whilst in the Cas9/+ population, presence of Cas9/sgRNA 
embryos may false increase the mutation efficiency. Explanations for the mutation 
efficiency seen in the Cas9/+ population is described further in 5.3. 
 
The mean mutation efficiency of Cas9/sgRNA embryos increased by 6.3% from E2.5 to 
E3.5, however this difference was not statistically-significant (p=5x10-1, Mann-Whitney 
test). Overall, these results showed that co-inheritance of the Cas9 and sgRNA transgenes 
in pre-implantation embryos, generates CRISPR-Cas9 induced mutations at Top1. 
 




Figure 19. Evaluation of mutations at the Top1 locus in pre-implantation embryos 
(a) sgRNA/+ hemizygous male and R26-Cas9 homozygous female mice timed matings. (b) 
Embryos were collected at three pre-implantation stages; E1.5 (2-cell), E2.5 (8-cell) and E3.5 
(blastocyst). (c) Embryos were imaged by fluorescence microscopy for mCherry and eGFP. Scale 
bars=20µm. (d) Genotype-sorted embryos were lysed, MiSeq sequenced and reads analysed by 
CrispRVariants. Statistical analysis was performed using Mann-Whitney tests. The MiSeq library 
preparations were performed by the GeMS STP. The MiSeq sequencing was performed by the 
ASF. The CrispRVariants R pipeline was performed by Jasmin Zohren (Turner lab).  
 
 
5.2.2 Evaluating the spectrum of mutations  
Co-inheritance of the Cas9 and sgRNA transgenes induced mutations at Top1, similarly 
to mCherry+eGFP+ ESCs in vitro. The most commonly occurring mutation in the in vitro 
screen was a 1bp insertion at the -1 position (-1:1I); which was consistently an A 
nucleotide. The A mononucleotide insertion was replicated in all three repeats of the in 
vitro experiments. Therefore, I assessed the occurrence of the -1:1I mutation in E2.5 and 
E3.5 Cas9/sgRNA embryos (E2.5, n=14; E3.5, n=16).  
 
MiSeq sequencing of E3.5 embryos produced 61580 total mapped reads, on average, 
whilst E2.5 embryos produced an average of 42860 total mapped reads. Reads containing 
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the -1:1I mutation were present in 100% (n=30/30) of analysed embryos. In all 30 
embryos (100%) the inserted mononucleotide in the -1:1I mutation, was also an A 
nucleotide. This accurately recapitulated the in vitro analysis. Next, I quantified the 
number of reads containing a -1:1I mutation as a percentage of the total reads for each 
embryo (Figure 20a). The prevalence of this -1:1I read type was varied. In E2.5 embryo 
#17 only 0.005% of reads contained the -1:1I insertion (4/73536 total reads, Figure 20a). 
Conversely, in E3.5 embryo #13, 76.3% of reads contained the -1:1I mutation 
(169264/221869 total reads, Figure 20a).  
 
Next, I evaluated the number of reads containing the -1:1I mutation as a percentage of 
the total number of reads containing any indel mutation (Figure 20b). This quantification 
gives an indication of how frequent the -1:1I mutation is within the indel-containing read 
population. In E2.5 embryo #17, the -1:1I only occurred in 0.008% of reads (4/47342, 
Figure 20b). Conversely, E3.5 embryo #13 had 94.9% of -1:1I reads within the population 
of the indel-containing reads (169264/178378, Figure 20b). In 43.3% embryos (n=13/30; 
asterisk, Figure 20b), the -1:1I mutation was the most commonly occurring indel 
mutation. 
 




Figure 20. Occurrence of a -1:1bp insertion mutation in individual embryos 
(a) The occurrence of a -1:1bp insertion read as a percentage of all MiSeq reads in each 
Cas9/sgRNA embryo at E2.5 (n=14) and E3.5 (n=16). (b) The occurrence of the -1:1bp insertion 
read as a percentage of all reads containing any insertion or deletion for the Cas9/sgRNA E2.5 
and E3.5 embryos, as in (a). Asterisk indicates the individual embryo sample where the -1:1bp 
insertion read is the most commonly occurring/most dominant mutation (13/30).   
 
I hypothesised that if the -1:1I mutation was the dominant mutational outcome, then the 
occurrence of the read would correlate with the total number of reads. I calculated the 
Pearson’s correlation coefficient between the total number of reads, and the number of -
1:1I reads per embryo. The correlation equalled 0.77, p=5.9e-07, a moderately high 
correlation. The correlation suggested that the -1:1I mutation was a likely outcome at 
Top1 exon 15 induced by CRISPR-Cas9 mutagenesis. The raw read data per embryo is 
summarised in Table 1, highlighting the number of reads for the -1:1I mutation, the 
specific mononucleotide insertion, the total number of reads containing an insertion or 
deletion, and the total number of mapped reads generated by MiSeq sequencing.  
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1 53793 A 59724 84305 
2 32054 A 81603 92490 
3 53 A 76488 90443 
4 24578 A 121966 142352 
5 896 A 3269 8504 
6 880 A 2054 6251 
7 22 A 3019 6727 
8 1895 A 5560 11646 
9 538 A 965 4595 
10 321 A 1450 7217 
11 30 A 344 4168 
12 43975 A 78155 92822 
13 169264 A 178378 221869 
14 521 A 66209 79283 
15 24082 A 44176 49460 




17 4 A 47342 73536 
18 6954 A 53918 106973 
19 317 A 13498 31328 
20 1757 A 16757 38933 
21 291 A 3173 49498 
22 429 A 45978 52416 
23 362 A 24451 38317 
24 2081 A 4065 5652 
25 1485 A 63981 64091 
26 3063 A 12965 18859 
27 11924 A 23950 28009 
28 6205 A 19765 30210 
29 523 A 1505 35218 
30 383 A 1204 27000 
Table 1. Occurrence of reads in Cas9/sgRNA embryos at E2.5 and E3.5 
The raw number of reads for each Cas9/sgRNA embryo at E2.5 (n=14) and E3.5 (n=16). The 
table lists read occurrence for: -1:1bp insertion, the nucleotide inserted, total number of mutation 
reads, total number of all reads. 




In conclusion, this data shows that a large percentage of Cas9/sgRNA embryos presented 
a stereotypic mononucleotide insertion mutation at the -1 position, as in the in vitro 
results. A mononucleotide insertion will induce a frame-shift mutation resulting in Top1 
reading-frame disruption. I therefore predicted that loss-of-function of Top1 in pre-
implantation embryos will induce non-viability, and loss of Cas9/sgRNA live births.   
 
5.2.3 Cas9/sgRNA embryos are non-viable 
To determine if CRISPR-Cas9 induced Top1 mutations induced embryonic lethality, I 
assessed the frequency of genotypes born from the experimental matings. I set up matings 
between hemizygous sgRNA/+ fathers and homozygous R26-Cas9 mothers and 
genotyped their pups. Multiple breeding pairs were used to ensure there were no mating-
pair specific effects. The experimental matings produced two possible offspring 
genotypes; Cas9/sgRNA and Cas9/+ (Figure 21ai). I hypothesised that the Cas9/sgRNA 
pups would not be born, due to in utero Top1 loss-of-function induced lethality.   
 
To assess the offspring genotypes, transgene-genotyping was performed on ear-biopsies 
from post-natal day 14 (PN14) pups. Results showed that there were no Cas9/sgRNA 
pups present from a total of 42 pups, from 7 litters (n=0/42, 0%; Figure 21b). This 
deviation from expected Mendelian ratios was found to be highly statistically-significant 
(p=9x10-11, Chi-squared test). 
 
Once I had confirmed that Cas9/sgRNA pups were not born, I compared the genotype 
ratios at PN14 to E2.5 and E3.5. At E2.5, 63% (n=14/22) of embryos were Cas9/sgRNA, 
whilst 37% (n=8/22) were Cas9/+. The genotype ratio was not a statistically-significant 
deviation from Mendelian frequency (p=2x10-1, Chi-squared test; Figure 21b). At E3.5, 
33% (n=16/48) embryos were Cas9/sgRNA, whilst 67% (n=32/48) were Cas9/+. The 
genotype ratio was a statistically-significant deviation from Mendelian frequency 
(p=2x10-2, Chi-squared test, Figure 21b). This data showed that Cas9/sgRNA embryos 
were detected at E2.5 and E3.5 but not at PN14.   
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To confirm that Cas9/sgRNA embryos are non-viable, I switched the parental genotypes. 
Homozygous sgRNA females were set up in matings with hemizygous R26-Cas9/+ males 
(Figure 21aii). I genotyped pups from two litters at PN14 and results showed there were 
no sgRNA/Cas9 pups present (n=0/16, 0%; Figure 21c). This data confirmed that 
Cas9/sgRNA embryos are non-viable and this was a statistically-significant deviation 
from Mendelian frequency (p=5x10-5, Chi-squared test). 
 
To confirm that the sgRNA transgene in isolation was not causing the embryonic lethality, 
I set up heterozygous sgRNA/+ male mice in matings with wildtype C57BL/6J females 
(+/+, Figure 21d). In this mating there were two expected offspring genotypes; 
hemizygous sgRNA/+ or non-transgenic wildtype (+/+). Multiple breeding pairs were 
used to ensure there was no mating-pair specific effects . First, E3.5 embryos were 
collected and genotyped by reporter expression. Results showed that 56% (n=5/9) 
embryos were hemizygous sgRNA/+ embryos, whilst 44% (n=4/9) were wildtype (Figure 
21e). At PN14, 33 pups were genotyped, 15 were sgRNA/+ (46%), whilst 18 were 
wildtype (54%,  Figure 21e). This data confirmed that the sgRNA transgene in isolation 
is not inducing embryonic lethality as sgRNA/+ and +/+ offspring were present in 
approximately equal ratio.  
 
5.2.4 Effect of Cas9/sgRNA lethality on litter size 
The Cas9 and sgRNA transgenes induced embryonic lethality by Top1 knock-out when 
co-inherited, whilst the Cas9/+ siblings were unaffected. I hypothesised that the loss of 
Cas9/sgRNA embryos would reduce the mean litter size by half relative to control 
matings. In these experiments, experimental matings were hemizygous sgRNA/+ males 
mated with homozygous R26-Cas9 females (Figure 21ai). The control matings were 
hemizygous sgRNA/+ males crossed with wildtype females (Figure 21d). Multiple 
breeding pairs were assessed to ensure litter size was not a mating-pair specific effect.  
 
To determine the mean litter size for experimental and control matings, the number of 
pups per litter was counted at PN14. In the control mating, the mean litter size was 5.5 
(n=33 pups from 6 litters, Figure 21f). In the experimental mating, the mean litter size 
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was 4.3 (n=26 pups from 6 litters, Figure 21f) Therefore, the experimental mating litter 
size was reduced by 22% relative to the controls. This reduction was not statistically-
significant (p=5x10-1, Mann-Whitney test). These results disproved my hypothesis and 
showed that lethality of Cas9/sgRNA embryos did not reduce the mean litter size by half.  
 
5.2.5 Effect on sex ratios 
Next, I investigated if there was an effect on offspring sex ratios in experimental matings 
compared to controls. I hypothesised that because both the Cas9 and sgRNA transgenes 
are autosome-linked, there would be no effect on offspring sex ratios. Hemizygous 
sgRNA/+ males were set up in mating with wildtype females as controls (Figure 21d), 
and homozygous R26-Cas9 females for experimental matings (Figure 21ai). I also set up 
homozygous sgRNA females with hemizygous R26-Cas9 males (Figure 21aii). The pups 
were phenotypically assessed at PN14.  
 
In the control mating, 33 pups were phenotypically examined. Of the pups present, 22 
were male (n=22/33, 67%), and 11 were female (n=11/33, 33%). The occurrence of each 
sex was not a statistically-significant deviation from the expected frequency (p=6x10-2, 
Chi-squared test, Figure 21g). When hemizygous sgRNA/+ males were mated to R26-
Cas9 homozygous females, 42 pups were examined. Of the pups present, 16 were male 
(n=16/42, 38%) and 26 were female (n=26/42, 62%, Figure 21g). The sex ratio in the 
experimental mating was a non-significant deviation from expected Mendelian frequency 
(p=1x10-1, Chi-squared test). When hemizygous R26-Cas9/+ males were mated with 
sgRNA homozygous females, 7 of 16 pups were male (44%), whilst 9 of 16 were female 
(56%). This was a non-significant deviation from Mendelian frequency (p=6x10-1, Chi-
squared test, Figure 21g). 
 
Overall, this data shows that the CRISPR-Cas9 bi-component system is able to induce 
embryonic lethality in embryos that have inherited both transgenes, but not when the 
sgRNA transgene is inherited in isolation. Although Mendelian inheritance frequency 
would predict the litter size to be halved, this was not the case. 
 




Figure 21. Developmental potential of transgenic sgRNA and Cas9 lines 
(ai) Experimental mating strategy, crossing a heterozygous sgRNA/+ male with homozygous 
R26-Cas9 females. (aii) The reversed experimental mating strategy, crossing a homozygous 
sgRNA male with heterozygous Cas9/+ females. (b) The penetrance of each offspring genotype 
at E2.5 (8-cell), E3.5 (blastocyst) and post-natal day 14 (PN14) from mating (ai). (c) The 
penetrance of each offspring genotype at PN14 from mating (aii). (d) A control mating to assess 
sgRNA allele induced lethality; crossing a heterozygous sgRNA/+ male with C57BL/6J wildtype 
females. (e) Assessing genotype ratio from mating (d). (f) Mean litter size from control matings 
(d) and experimental mating (ai). Statistical analysis with Mann-Whitney test. (g) The sex ratio 
of offspring from three different mating strategies; sgRNA/+ by wildtype (c), sgRNA/+ by R26-
Cas9 (ai) and sgRNA by R26-Cas9/+ (aii). Deviation from expected ratios measured using Chi-
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5.2.6 Post-implantation (E11.5) assessment of Cas9/sgRNA embryos 
Previous studies have shown that Top1 knock-out is embryonic lethal in the mouse at the 
4-16 cell stage (Morham et al., 1996). Although Cas9/sgRNA embryos were not born, I 
was able to harvest Cas9/sgRNA blastocyst-stage embryos. Therefore, I determined 
whether the Cas9/sgRNA embryos could also be detected post-implantation. I therefore 
collected and genotyped embryos from hemizygous sgRNA/+ by homozygous R26-Cas9 
matings at E11.5 (Figure 22a).  
 
At E11.5, I collected 33 embryos from 4 matings. Of these, 23 were easily dissected from 
the uterus. Ten of the embryos (n=10/33, 30%) had been reabsorbed and could not be 
genotyped (Figure 22b). All 23 developing embryos (n=23/23, 100%) expressed eGFP, 
but did not express mCherry (representative image in Figure 22d). The 23 surviving 
embryos were genotyped for the Cas9 and sgRNA transgenes. Results confirmed that all 
of the embryos were Cas9/+ (Figure 22c). This data suggests that Cas9/sgRNA embryos 
have been lost by E11.5, and some of the reabsorbed embryos may have been 
Cas9/sgRNA.   
 
In conclusion, the sgRNA transgene targets Top1 in vivo and commonly produces a single 
mononucleotide A insertion at the minus 1 position resulting in a frame-shift mutation. 
Co-inheritance of the Cas9 and sgRNA alleles induces embryonic lethality due to Top1 
loss-of-function, as highlighted by a complete loss of Cas9/sgRNA embryos by E11.5. 
To generate sex-specific lethality, I looked to generate a sex chromosome-linked Cas9 
transgene, described in the next Chapter.  
 




Figure 22. Assessment of E11.5 embryos 
(a) Hemizygous sgRNA/+ males were crossed with homozygous R26-Cas9 females (“Cas9”) and 
embryos collected at E11.5. (b) Assessment of phenotype by fluorescence microscopy by reporter 
expression, eGFP or RFP. (c) Genotyping for Cas9-eGFP or sgRNA-mCherry. Statistically-
significant deviation from expected offspring genotypes (Chi-squared test, p=2x10-6). (d) Upper 
panel: representative E11.5 embryo fluorescence microscopy and brightfield images. Lower 
panel: a sgRNA/+ heterozygous embryo was included as a positive control for mCherry 
fluorescence. Scale bar=1mm.  
 
 




The data presented in this chapter highlighted the capacity for the CRISPR-Cas9 bi-
component system to induce mutations in vivo. The mutation rate was significantly higher 
in Cas9/sgRNA embryos compared to Cas9/+ at both E2.5 and E3.5. Moreover, the 
Cas9/sgRNA embryos were non-viable, and could not be recovered by E11.5.  
 
To determine the different genotypes, embryos were phenotyped by the expression of 
eGFP and mCherry reporters. The eGFP was detectable by fluorescence microscopy as 
early as E1.5, the 2-cell stage. This is unsurprising because the R26-Cas9 allele is 
maternally-inherited. Maternal transcripts are deposited in the oocyte for early embryonic 
development post-fertilisation, prior to EGA (Clegg and Piko, 1983, De Leon et al., 1983, 
Wassarman and Kinloch, 1992). Cas9 transcripts are also deposited in the early embryo, 
when the mother encodes a Cas9 transgene (Cebrian-Serrano et al., 2017). Therefore, it 
is likely that eGFP expression would be detected in the 2-cell stage before the onset of 
EGA (Flach et al., 1982, Bernstein and Mukherjee, 1972). To confirm if eGFP is 
maternally loaded, oocytes and zygote stage embryos should be checked for eGFP 
expression. The eGFP reporter remained expressed at all assessed pre-implantation stages 
of development and at E11.5. Expression of mCherry was not visible at E1.5, but 
expressed at E2.5, suggesting transgene activation occurs at EGA. By the early 
blastocyst-stage, mCherry was clearly expressed, and the expression remained at E11.5 
and after birth.  
 
Once the embryos were sorted by genotype, I assessed the mutation efficiency at the Top1 
locus. Top1 knock-out in the mouse induces embryonic lethality at the 4-16 cell stage 
(Kobayashi et al., 2011, Morham et al., 1996, Wright et al., 2015). In these previously 
published studies the knock-outs were generated by mating two heterozygous knock-out 
parents. In my experiments, Cas9/sgRNA embryos developed to E3.5. There are a 
number of possible explanations for this extended survival. The CRISPR-Cas9 system 
takes longer to become active and generate mutations at the Top1 locus to induce non-
viability, compared to inherited homozygous knock-out alleles. Although Cas9 mRNA 
was likely maternally-loaded, the sgRNA-transgene was not activated until post-EGA, 
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therefore formation of CRISPR-Cas9 induced mutations may be delayed. The embryo 
may have undergone the first cleavage divisions during the period of inactive CRISPR-
Cas9, utilising Top1 maternal mRNA (Clegg and Piko, 1983, De Leon et al., 1983, 
Wassarman and Kinloch, 1992). By E2.5, the CRISPR-Cas9 system was active, and the 
mean mutation efficiency was 54.2%, suggesting that approximately half of the Top1 
alleles contained a potentially loss-of-function mutation. By E3.5, the mean mutation 
efficiency increased to 60.5%, suggesting that the majority of alleles contained a 
potentially disruptive mutation. 
 
The mutation rate for E2.5 and E3.5 embryos is calculated as the percentage of indel-
containing MiSeq reads from the total number of reads. The mean mutation rate for both 
E2.5 and E3.5 suggests that the majority of reads contain a potentially loss-of-function 
mutation. The indel-containing reads contributing to the mutation efficiency calculation 
are not sorted into in-frame and frame-shift mutations. Therefore, it is possible that indel-
mutations that are in-frame and would not induce loss-of-function. The ‘loss-of-function 
mutation rate’ could be calculated from the percentage of frame-shift indel-containing 
mutations, as a percentage of the total number of reads. Although Cas9/sgRNA embryos 
were present at E3.5, they were increasingly lost from the population at each stage. At 
E2.5, Cas9/sgRNA embryos made up 63% of the litters. By E3.5, this was reduced to 
33%, and was 0% by E11.5. The loss of Cas9/sgRNA embryos over developmental time 
suggested there was some lethality at each stage. The Cas9/sgRNA embryos being lost at 
each stage may have had a greater mutation efficiency than the average mutation capture 
by MiSeq analysis, and were degraded before harvesting and therefore were not included 
in the analysis.  
 
Once the mutations have been made, any remaining TOP1 protein previously translated 
has to be degraded from the developing embryo, before a complete loss-of-function has 
been generated. The predicted TOP1 half-life varies between different cell types. 
Kobayashi et al (2009) estimated TOP1 half-life is approximately 3.7 hours in limb bud 
cells (Kobayashi et al., 2009), whilst Desai et al (1997) estimated 10-16 hours in FM3A 
and ts85 mouse mammary carcinoma cells (Desai et al., 1997). All of these factors may 
contribute to the delay in non-viability compared to previous knock-out experiments.  




Similarly to the in vitro analysis in Chapter 4, the Cas9/+ embryos show a small mutation 
rate at the Top1 locus. The non-Cas9-induced pseudo-mutations seen are most likely due 
to PCR or sequencing errors during the MiSeq PCR amplification and sequencing 
pipeline. The Cas9/+ mutation efficiency is an internal control for basal variability at the 
Top1 locus and therefore I did not normalise to this value. The E2.5 and E3.5 embryos 
were segregated into Cas9/sgRNA or Cas9/+ genotype by the expression of mCherry and 
eGFP reporters. Sorting at E2.5 by reporter expression was more challenging, because 
mCherry was lowly detected by fluorescence microscopy. Therefore, it is possible that 
there was some ‘contamination’ by incorrect embryo sorting (i.e. an mCherry+eGFP+ 
embryo may have been considered to be eGFP+ and vice versa). To overcome these 
genotyping challenges associated with early reporter expression, reporters could be 
driven by earlier pre-implantation gene promoters.  
 
The small number of cells in E2.5 and E3.5 embryos meant that it was not possible to 
perform genotyping PCRs prior to MiSeq PCRs for more accurate segregation of 
genotypes. Despite this caveat, the difference in Top1 mutation efficiency between 
Cas9/+ and Cas9/sgRNA embryos was highly statistically-significant, both at E2.5 and 
E3.5. 
 
The Cas9/sgRNA embryos were non-viable from E11.5, whilst their sgRNA/+ littermates 
were viable. I predicted that the mean litter size of the experimental matings would be 
half of the control matings. However the experimental mating only showed a 22% 
reduction in mean litter size compared to the control. These results recapitulate the litter 
size results seen in Chapter 3, using the Cre-inducible DTA. The X-Cre male mating to 
DTA homozygous females induced a complete sex skew, generating all-male litters. 
Therefore, I predicted that the mean litter size would be halved. On the contrary, the mean 
litter size was reduced by a non-significant value of 32%, compared with the control. 
Curiously, the non-significant reductions seen in both the Cre/DTA and CRISPR-Cas9 
approaches conflicts with the results in the Yosef et al study, the only other mouse bi-
component study published thus far. Yosef et al reported a control mean litter size of 6.57 
and an experimental mean litter size of 3.71 (Yosef et al., 2019). Although the 
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discrepancies in mean litter size can be partially due to different mouse genetic 
backgrounds, the non-viability effect appears to be stronger in the Yosef et al study.  
 
I speculated that there may be multiple factors or events that are contributing to the 
reduction but not halving of the mean litter sizes seen in my experimental matings. In the 
control matings, e.g. sgRNA/+ by +/+, there could be some embryos that do not develop 
at a synchronous rate to siblings, and/or are unable to implant. These embryos may be 
normally non-viable. Furthermore, it is possible that in these control matings, there is an 
optimised number of embryos that have enough space to develop in utero successfully. 
In the experimental matings, some loss of the embryonic lethal genotype prior to 
implantation may allow embryos that usually cannot implant, to implant successfully. 
The reduction in Cas9/sgRNA embryos from E2.5 to E3.5 suggests that some are being 
lost between these two embryonic stages. The loss of E2.5 embryos may allow embryos 
that were not destined to implant, to do so. It is likely that both embryos types could 
‘attempt’ to grow and implant but given that Cas9/sgRNA is embryonic lethal, only the 
single-positive embryos would survive. Therefore, the litter size is slightly, but not 
entirely, compensated. This partial compensation would result in a reduction, but not 
halved litter size of the experimental compared to the control.  
 
The partial compensation by further embryo implantations may only be possible if the 
non-lethality effect is induced during pre-implantation, as in my experiments. In the 
Yosef et al study they targeted genes Atp5b, Casp8 and Cdc20. Atp5b and Casp8 knock-
out embryos are embryonic-lethal at E9.5 and E10.5, respectively. However Cdc20 
knock-out is embryonic lethal prior to E3.5. If Cdc20 was not disrupted, and loss-of-
function mutations were induced only at Atp5b and/or Casp8, knock-out embryos would 
be non-viable post-implantation. Therefore it is unlikely any partial compensation pre-
implantation mechanisms would be functioning to replace lost embryos.  
 
The partially compensated litter size may be because the pregnant females induced 
diapause during gestation. Diapause is a process of embryonic ‘suspension’ at the 
blastocyst-stage, where the embryo is held in a period of non-development. Embryonic 
diapause in the mouse can occur from one day to several weeks (Weichert, 1940, 
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Weichert, 1942, Renfree and Fenelon, 2017, Pritchett-Corning et al., 2013). It is possible 
that mating of the CRISPR-Cas9 lines and resultant non-viability in some offspring may 
have induced an in utero stress. The massive embryonic lethality may be sufficient to 
induce the female into diapause. Holding the viable embryos in diapause may allow for 
some compensation of delayed embryos to also implant and develop. It is again possible 
that both delayed Cas9/sgRNA and viable genotype embryos may attempt to implant, but 
only viable embryo genotypes will survive. Therefore, there will be partial compensation 
but not complete compensation. However, diapause is usually induced in response to the 
presence of suckling pups, preventing the oestrogen surge and thereby causing the 
blastocysts to enter diapause (Renfree and Fenelon, 2017). In 5/6 (83%) litters measured 
for litter size quantification, the female did not have suckling pups during the pregnancy.  
 
A further possible explanation to the partial compensation of litter size is the non-random 
fertilisation of gametes. A study in 2017 reported that mutations in 12 different genes 
resulted in a significantly lower or greater number of heterozygotic offspring than 
expected, and was entirely deficient in homozygotes. However, in each of the 12 genes 
studied, there was no reduction in litter size. Similar evidence was shown for mutations 
in genes affecting neural tube development, such as Apob (Nakouzi and Nadeau, 2014, 
Nadeau, 2017). Mice deficient for the genes were embryonic lethal, and genotype ratios 
were non-Mendelian. Upon addition of folic acid to the diet, the loss-of-function 
phenotype was rescued, and knock-out pups were born at Mendelian frequency. In each 
case, the mean litter size was similar (Nadeau, 2017). These studies suggested that there 
is a mechanism of non-random fertilisation of the gametes by transmission ratio distortion 
(TRD). Lyon described TRD as a departure from expected 1:1 offspring genotype ratio 
(Lyon, 2003). It is thought that TRD in females occurs by preferential entry of one allele 
into the polar body at meiosis, whilst in males, likely through sperm dysfunction. An 
example of TRD that affects sperm function is expression of the t-complex, described in 
1.6.3.2 (Lyon, 2003). The litter size experiments in this thesis used a homozygous R26-
Cas9 female, therefore all of the gametes would be equal. However the male was a 
hemizygous sgRNA/+ mouse. Therefore, it is possible that the + sperm carry a 
preferential fertility advantage over sgRNA-carrying sperm. This explanation for 
compensated litter sizes is unlikely, because in the control matings, both + and sgRNA-
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carrying sperm were fertilised + oocytes to generate sgRNA/+ and +/+ offspring at 
approximately equal ratios. Therefore, the + sperm do not appear to carry a fertility 
advantage.   
 
The generation of a litter that is embryonic lethal for the unrequired genotype but does 
not reduce the litter size by half is extremely advantageous for translation of the 
technology. Although in the dairy cow industry the number of offspring per litter is 
usually one, other agricultural species such as chickens and pigs usually have larger 
litters. A partial compensation of the litter size using this CRISPR-Cas9 bi-component 
technology would be extremely economically advantageous as a greater number of the 
required sex would be produced, compared to non-sex selected breeding. Furthermore, 
this would also be advantageous in the research laboratory setting, where a greater 
number of the required sex can be produced in a single litter. This could reduce the 
number of overall breeding pairs that would need to be set up in matings to generate the 
required offspring, thereby aligning with the Home Office 3Rs.  
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Chapter 6. Results 4: Generating sex chromosome-linked 
Cas9 knock-ins 
6.1 Introduction 
Generating a knock-in on the mouse X or Y chromosome ensures sex-specific inheritance 
of the transgene. If carried by the heterogametic male in a mouse mating, a transgene 
integrated on the X chromosome will be uniquely inherited by the daughters, and a Y-
linked transgene, by the sons. When an X- or Y-linked Cas9 transgenic male is crossed 
with a homozygous sgRNA-expressing female, the inheritance of both CRISPR-Cas9 
components is sex-specific. Co-inheritance of a Cas9 and sgRNA allele induces 
mutations at Top1, resulting in Top1 loss-of-function and embryonic non-viability.  
 
In this Chapter I aimed to generate an X- and Y-linked Cas9 transgene by in vitro 
targeting of ESCs. Successfully targeted ESCs could be used to generate stable transgenic 
mouse lines. In Chapter 4 and Chapter 5 I utilised mCherry and eGFP reporters for read-
out of the sgRNA and Cas9 transgene expression, respectively. Therefore, I aimed to 
recapitulate this strategy by using a Cas9-eGFP transgene targeting the X or Y 
chromosome, where eGFP could be used as a read-out for Cas9 expression.  
 
In Chapter 3 I used an X-linked Cre transgene (Tang et al., 2002) to induce DTA 
expression in female embryos. I was initially concerned that the paternally-inherited X-
Cre allele would be transcriptionally silenced in female pre-implantation embryos due to 
imprinted X-chromosome inactivation in the mouse. However using a Cre reporter 
TdTomato line, I showed that the X-Cre is active by at least E2.5. Therefore, I aimed to 
recapitulate the targeting strategy of X-Cre to generate the X-Cas9 transgenic mouse line. 
I targeted the X-linked locus permissive loci, Hprt, as Hprt knock-out has no known 
detrimental phenotype in the mouse (Kuehn et al., 1987, Hooper et al., 1987, Koller et 
al., 1989, Jinnah et al., 1990). 
 
Conversely to the X-linked Hprt gene, the Y chromosome does not contain any known 
permissive loci. Therefore, finding a locus to integrate the Cas9 transgene was 
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significantly more challenging. Many of the Y-genes have essential functions in 
endogenous cell mechanisms, for example DNA replication and repair (Lahn and Page, 
1997, Bellott et al., 2014, Cortez et al., 2014, Bachtrog, 2014) or in sex determination and 
spermatogenesis, for example Sry (Gubbay et al., 1990, Koopman et al., 1991) and 
Eif2s3y (Yamauchi et al., 2014, Mazeyrat et al., 2001).  
 
Although these Y-linked genes cannot be used as permissive loci to integrate transgenes 
into, some Y-gene promoters have been utilised to drive transgene expression. For 
example, studies have generated transgenic Sry reporter mouse lines, with Sry-promoter 
driven eGFP, such as the C57BL/6-Tg(Sry-GFP)92Ei Chr YAKR/J /EiJ (“Sry-GFP”) 
mouse line (Dewing et al., 2006, Albrecht and Eicher, 2001). In 2013, Wang et al 
generated knock-ins on the Y chromosome, utilising a method of genome editing called 
TALENs (Transcription activator-like effector nucleases; Wang et al., 2013a). They 
successfully targeted Sry for knock-out using two pairs of TALENs, specifically targeted 
to the high mobility group (HMG) DNA binding domain of the gene sequence. The XY 
offspring were sex-reversed (Wang et al., 2013a).  They also used TALENs to generate 
an eGFP knock-in at the Sry locus in mouse ESCs. Targeted ESCs were injected into 
embryos and the injected embryos were left to develop in utero, before assessment at 
E12.0. Transgenic eGFP expression was visible in the gonad and brain (Wang et al., 
2013a). Imaimatsu et al generated a flag-tag knock-in at the C-terminal end of the Sry 
gene using CRISPR-Cas9 and reported normal testis differentiation and spermatogenesis 
(Imaimatsu et al., 2018). The disadvantage of Sry-promoter driven transgenic lines is that 
Sry expression in the mouse is very tightly controlled from E10.5 to E12.5 during 
embryonic development (Koopman et al., 1990, Kashimada and Koopman, 2010) 
resulting in limited expression of the transgene. 
 
Wang et al (2013) also generated a Uty-linked eGFP reporter line. Uty is ubiquitously 
expressed in the embryo, and Uty knock-out appears to have no detrimental effect on 
viability or fertility (Shpargel et al., 2012). Uty is expressed in ESCs, allowing for 
characterisation of reporter integration and expression in vitro. A Uty-eGFP ESC line was 
successfully generated and expressed eGFP. However the study did not comment on the 
effect on Uty expression after integration of eGFP (Wang et al., 2013a). This study 
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highlighted the possibility of generating expression constructs on the Y chromosome and 
Uty may be a useful target for integrating a Cas9-GFP transgene, given the ESC 
expression. 
 
To generate single-sex litters, the components of the genetically segregated CRISPR-
Cas9 system must be expressed during pre-implantation development. Pre-implantation 
expression maximises the length of developmental time the Cas9 and sgRNA transgenes 
are expressed to generate null mutations at the target locus, for example at Top1. Driving 
Cas9 expression by a male-determining gene promoter such as Sry means that the Cas9 
expression window is short, and may be insufficient for Cas9 activity. Therefore a 
constitutive CAG promoter was utilised for both the X- and Y-Cas9 targeted lines.  
  





6.2.1 CRISPR-Cas9 HDR components for X-Cas9 HDR 
The first aim of this Chapter was to generate a constitutively expressing Cas9-eGFP 
knock-in to the X chromosome Hprt locus, hereafter called “X-Cas9” (Figure 23a). I 
generated an X-Cas9 targeting vector (TV) encoding Cas9 and eGFP linked via a T2A 
sequence. The pX458 plasmid (Ran et al, 2013) was used as the dsDNA plasmid 
backbone. Hprt homology arms were amplified using gDNA extracted from C57BL/6J 
ESCs. The 5’ homology arm (3.2kb; HAL) was inserted into pX458 using unique 
restriction sites XbaI and KpnI. The 3’ homology arm (1.1kb; HAR) was inserted into the 
pX458 plasmid using unique restriction sites NotI and NarI. Both homology arms were 
confirmed by Sanger sequencing, as any mismatches reduce the efficiency of homologous 
recombination. Successful integration of the X-Cas9 TV by HDR deletes 173bp of Hprt, 
resulting in Hprt loss-of-function. A PGK promoter driving a neomycin resistance 
cassette, flanked by LoxP sites, was inserted into the X-Cas9 TV by Gibson Assembly 
cloning (Figure 23a). The neomycin gene allowed for selection of transgenic ESC clones.  
 
Once I generated the X-Cas9 TV, I evaluated if eGFP was expressed from the TV in vitro. 
Wildtype ESCs were transiently transfected with either the X-Cas9 TV, the pX458 
backbone plasmid, or were left non-transfected. Two days post-transfection, the ESCs 
were examined by fluorescence microscopy for eGFP expression. In the untransfected 
ESCs there were no cells expressing eGFP, however in the X-Cas9 TV-transfected ESCs, 
eGFP was expressed in some cells (Figure 23b). To confirm the X-Cas9 TV expressed 
Cas9, the essential component of the transgene, protein was extracted from bulk ESCs 
and analysed by western blot. Transfection of ESCs with pX458 or the X-Cas9 TV 
showed that Cas9 was expressed from the plasmids (Figure 23c). There was no Cas9 
expression in the untransfected control ESCs. These results show that the X-Cas9 TV 
expresses Cas9 and eGFP and therefore could be used as the Hprt knock-in vector.  
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To maximise the efficiency of generating an X-Cas9 knock-in at Hprt, I generated a 
CRISPR-Cas9 sgRNA-expressing plasmid which induces a DNA DSB at Hprt exon 2 
(Figure 23a). The sgRNA targeted the 173bp intervening DNA sequence between the two 
homology arms. The 20 nucleotide sgRNA oligonucleotide was cloned into pX458, using 
unique restriction site BbsI and was confirmed by Sanger sequencing. To confirm that 
the sgRNA induces DNA DSBs at Hprt, the sgRNA-pX458 plasmid was transiently 
transfected into wildtype ESCs. pX458-encoded eGFP expression was used to sort 
transfected ESCs from non-transfected ESCs by FACS. The populations of eGFP+ and 
eGFP- ESCs were lysed, the Hprt region amplified by PCR and sequenced by MiSeq. 
The MiSeq reads were analysed by the CrispRVariants pipeline to determine the mutation 
efficiency at the Hprt locus, which measured 66.0% (Figure 23d). I concluded that the 
sgRNA induces DNA DSBs at Hprt.  
 
 
Figure 23. Generating the components for X-Cas9 HDR 
(a) Targeting strategy for generating a X-Cas9 transgene by HDR. The TV encodes a Cas9-eGFP 
cassette driven by a CAG promoter and PGK promoter driven neomycin resistance cassette, 
flanked by LoxP sites. The TV contains two homology arms; 5’ (HA left) and 3’ (HA right) for 
HDR into Hprt exon 2. (b) The X-Cas9 TV or pX458 plasmid was transiently transfected in 
C57BL/6N ESCs to confirm eGFP expression by fluorescence microscopy. Scale bars=100µm 
(c) Western blots were carried out to assess Cas9 expression from protein extracted from 
transiently transfected ESCs. The western blot was performed by Valdone Maciulyte (Turner lab). 
(d) A CRISPR-Cas9 (pX458) plasmid containing a sgRNA targeting Hprt was transfected in 
C57BL/6N ESCs and mutation efficiency evaluated by the MiSeq and CrispRVariants analysis 
pipeline. The MiSeq library preparations were performed by the GeMS STP. The MiSeq 
sequencing was performed by the ASF. The CrispRVariants R pipeline was performed by Jasmin 
Zohren (Turner lab).  





In conclusion, I generated the X-Cas9 TV encoding Cas9 and eGFP, for X-linked Hprt 
targeting by HDR. Co-transfection of the X-Cas9 TV and a Hprt sgRNA increases the 
efficiency of knock-in. Therefore, an sgRNA was confirmed to induce DNA DSBs at 
Hprt by the presence of CRISPR-Cas9 induced indel mutations. 
 
6.2.2 Generating and characterising X-Cas9 embryonic stem cells  
After confirming that the X-Cas9 TV expressed Cas9 and eGFP, I generated a stable X-
Cas9 knock-in ESC line by HDR. Serum+LIF-maintained wildtype C57BL/6N ESCs 
were co-transfected with the X-Cas9 TV and Hprt-sgRNA plasmid. Two days post-
transfection, neomycin was added to the medium to select for ESC clones that expressed 
the X-Cas9 plasmid. Neomycin selection was performed for eight days, followed by ESC 
colony picking and plating clones into individual wells of a 96-well plate (Figure 24a).  
 
Individual colonies (n=48) were expanded and PCR-genotyped with a forward primer 
aligning to the endogenous Hprt locus and a reverse primer aligning to the CAG promoter 
in the transgene (“boundary PCR”, Figure 23a pink arrow heads). Amplification of the 
3.5kb product would only occur in ESCs with a targeted knock-in. The PCR product was 
amplified in nine ESC clones (n=9/48, 18.8%, Figure 24b). These ESC clones were 
called; a1, b6, c5, d3, d6, e6, f1, f5 and h5. The boundary PCR was also performed at the 
3’end of the transgene for the nine positive ESC lines. I confirmed that in all nine clones 
there was successful amplification of the 3’ boundary PCR product (4.1kb, Figure 24b). 
I therefore confirmed that the transgene was integrated at Hprt in nine ESC clones.  
 
Boundary PCRs are extremely useful for assessing targeted integrations but do not 
determine whether the transgene has also integrated randomly elsewhere in the genome. 
Therefore, I next determined the transgene copy number in all nine X-Cas9 clones. Copy 
number greater than one inferred further transgene integrations. I performed copy number 
qPCR for eGFP and neomycin. Copy number was normalised to a reference gene Tfrc 
and a control homozygous R26-Cas9 sample, that has two copies of eGFP and neomycin. 
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In 78% of clones (n=7/9) there was less than two copies of eGFP and neomycin (a1, c5, 
d3, d6, e6, f1, h5, Figure 24c). Clone d3 appeared to have two copies of eGFP, but one 
copy of neomycin. Clone b6 had two copies of eGFP and neomycin (Figure 24c). Clone 
f5 had greater than six copies of eGFP and neomycin (Figure 24c). As a control, I also 
performed copy number qPCR for the X-linked gene, Hprt. I used a TaqMan probe to 
exons downstream of the HDR integration site, and therefore these exons should have 
been preserved. In all clones (n=9/9, 100%), Hprt was present in a single copy, as 
expected for XY ESCs (Figure 24c).  
 
To confirm the copy number qPCR results, I also performed a digital droplet PCR 
(ddPCR). The eGFP copy number was normalised to Tfrc, a R26-Cas9 homozygous 
sample and a water control. The ddPCR results recapitulated the qPCR results. In the 
ddPCR, seven ESC lines (n=7/9, 78%) had one eGFP copy. These seven samples are the 
same samples that showed a single copy in the qPCR (a1, c5, d3, d6, e6, f1, f5). ESC line 
b6 again showed two copies. ESC line f5 again showed a significantly greater number of 
copies, exhibiting approximately five copies of the transgene (Figure 24d).  
 




Figure 24. Characterising X-Cas9/Y ESCs 
(a) Targeting strategy to integrate the Cas9-eGFP transgene onto the X chromosome in 
C57BL/6N ESCs. (c) PCR genotyping of surviving ESC clones. (d) Copy number qPCR for 
eGFP, neomycin and X-linked gene Hprt. Samples were normalised to the reference gene Tfrc in 
the R26-Cas9 (XX) homozygous control sample. (d) Copy number ddPCR for eGFP. Samples 
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were again normalised to the reference gene Tfrc in the R26-Cas9 (XX) homozygous control 
sample.   
 
Next, I investigated if there were chromosomal aneuploidies in the X-Cas9 ESCs 
resulting from ESC culture. ESC aneuploidies may result in failure of the ESCs to 
contribute to the chimera and germline transmit. Genomic DNA was extracted from each 
ESC line, libraries prepared, followed by whole genome sequencing on the HiSeq 4000 
at 0.1X coverage (“low-pass WGS”). The reads were aligned to the mouse genome 
(Mm10). Reads were binned into 500 kb regions, and log2 coverage from two autosomes 
was considered 0.  The majority of samples showed consistent read average of 0 for all 
18 autosomes, suggesting autosomal diploidy (Figure 25). In d3 and f5, some ESCs 
carried a duplication of chromosome 8, shown by a log2 of between 0 and 1 (arrows, 
Figure 25). The X chromosome was present at -1, suggesting a single X for all ESC lines 
(Figure 25). Although the Y chromosome reads are not in sufficient number to be visible 
on the plots, presence of a Y chromosome was confirmed by assessment of the raw reads, 
where Y-mapped reads are abundant (Table 2).  Therefore, I confirmed that the majority 
of lines were diploid, and all lines were XY.  
 




A1 16753566 534529 284071 
B6 15003107 480932 253836 
C5 15104788 477282 233640 
D3 19060549 588769 316450 
D6 21581887 688095 296232 
E6 29019503 918110 485219 
F1 26691797 854912 453075 
F5 20747772 632858 338743 
H5 24672453 787401 24404 
Table 2. Sequencing reads (low-pass WGS) for X-Cas9 ESC clones 
 




Figure 25. Low-pass whole genome sequencing of X-Cas9 clones for karyotyping 
(a) HiSeq whole genome sequencing, 0.1X coverage, of X-Cas9 samples. Reads were binned into 
500kbp regions and aligned to the mouse genome (mm10). The two autosomes for each mouse 
chromosome are considered as 0. The library preparations and sequencing were performed by the 
ASF. The R pipeline for analysis and to generate the plots was performed by Jasmin Zohren 
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6.2.3 Assessing expression of X-Cas9 
The majority of ESC clones were XY with a single copy of the X-linked Cas9 transgene 
by PCR-genotyping, copy analysis and low-pass WGS. I next determined if the ESCs 
expressed eGFP and Cas9. In all nine ESC lines, eGFP was expression was visible by 
fluorescence microscopy (Figure 26a).  
 
Next, I performed qPCR for eGFP and Hprt. Gene expression was normalised to a 
housekeeping gene Gapdh, from wildtype C57BL/6J ESCs. I hypothesised that the X-
Cas9/Y ESCs would express eGFP but have lost Hprt expression due to X-Cas9 transgene 
integration. In all nine X-Cas9/Y clones, eGFP was expressed while there was no eGFP 
expression in wildtype ESCs (Figure 26b). The strongest eGFP expression was from 
clone b6, and the weakest was from f1 (Figure 26b). The presence of multiple transgene 
copies in clones b6 and f5 did not significantly increase eGFP expression, compared with 
single copy clones. Confirming my hypothesis, there was a complete loss of Hprt 
expression in the X-Cas9/Y clones, compared with an XY wildtype sample and an XX 
R26-Cas9 sample (Figure 26b). The qPCR result therefore confirmed that the transgene 
had been successfully integrated into the Hprt locus, resulting in loss of Hprt expression. 
 
I determined whether Cas9 expression was detectable at the protein level by performing 
a western blot for Cas9. The R26-Cas9 ESC line was used as a positive control, and ESCs 
and liver tissue from C57BL/6J mice were used as a negative control. Cas9 was expressed 
in all nine X-Cas9/Y ESC clones (n=9/9, 100%, Figure 26c), but expression was weaker 
than R26-Cas9 encoded Cas9. In summary, the X-Cas9/Y ESC clones express eGFP and 
Cas9. 
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Figure 26. X-Cas9 expression analysis 
(a) Fluorescence microscopy images of X-Cas9 ESCs. (b) qPCR analysis of cDNA using TaqMan 
probes to quantify eGFP and Hprt expression, normalised to Gapdh in C57BL/6J. (c) Western 
blot of X-Cas9 ESCs using antibodies for CAS9 and TUBULIN. Comparing to R26-Cas9 ESCs 
and two C57BL/6J negative control samples; liver tissue and ESCs. The western blot was 
performed by Valdone Maciulyte (Turner lab).  
 
 
6.2.4 Assessing the bi-component system in vitro using X-Cas9 ESCs 
The X-Cas9/Y ESCs expressed eGFP and Cas9, therefore I investigated whether they 
would be functional in an in vitro bi-component system. I utilised the traffic light system 
of sorting transfected versus non-transfected ESCs by FACS, on reporter expression. I 
transfected the nine X-Cas9/Y ESC lines separately with the Sry-sgRNA pLethal plasmid. 
Transfected ESCs were mCherry+eGFP+, whilst non-transfected ESCs were eGFP+. The 
mCherry+eGFP+ ESCs were gated on mCherry fluorescence units greater than 103. The 
eGFP+ ESCs were gated on eGFP fluorescence units 103.5 to 104.5 (Figure 27). Post-
sorting by FACS, the two populations of ESCs were lysed, Sry was PCR amplified for 
MiSeq sequencing and the reads analysed by the CrispRVariants pipeline (Lindsay et al, 
2016).  
 
In seven ESC lines (a1, b6, c5, d6, e6, f1, f5, h5) the mutation efficiency at Sry in 
mCherry+eGFP+ ESCs was greater than in the eGFP+ ESCs. The mean mutation 
efficiency in the mCherry+eGFP ESCs for these seven clones was 23.1%, whilst in the 
eGFP+ ESCs it was 1.7%. In the mCherry+eGFP+ ESCs from transfection of clone h5, 
the mutation efficiency was 10.7%, however in the eGFP+ ESCs, it was only slightly 
reduced, at 7.6% (Figure 27). In clone d3, a surprising converse result was seen, with the 
mutation efficiency in mCherry+eGFP+ ESCs at 9.6%, while in the eGFP+ ESCs it was 
14.5% (Figure 27). Therefore, in seven ESC lines, the X-Cas9/Y ESCs are functional in 
a bi-component system, with the mutation at Sry being significantly higher when both 
CRISPR-Cas9 components are present, compared to Cas9 alone.  
 
Considering the seven lines where the mutation efficiency was greater in the 
mCherry+eGFP+ ESCs, the non-Cas9-induced mutations in the eGFP+ ESCs averaged 
1.7%. This pseudo-mutation efficiency is most likely attributable to PCR error during 
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amplification and library preparation, as in previous experiments using the bi-component 
system. The value of 1.7% is comparable to that seen in in Chapter 4 in the R26-Cas9 
eGFP+ ESCs. Furthermore, this value may be attributable to the basal endogenous 
variability at the Top1 locus. As in Chapter 4 and 5, the 1.7% mutation efficiency may 
also be attributable to contamination of mCherry+eGFP+ ESCs within the eGFP+ 
population, which will falsely increase the mutation efficiency of this population.  
 
Curiously, in the bi-component experiment for clones h5 and d3, there is very little 
difference between the mutation efficiency in the mCherry+eGFP+ ESCs and the eGFP+ 
ESCs. I suspect that there was contamination between mCherry+eGFP+ and eGFP+ ESCs 
during the FACS, lysis and/or PCR amplification procedures, therefore these two 
populations are indistinguishable at the mutation efficiency level.  




Figure 27. Sry sgRNA transfection and FACS/MiSeq in X-Cas9/Y ESCs 
(a) FACS plots showing the gating for the mCherry+eGFP+ population (upper box in each plot) 
and the eGFP+ only population (lower box in each plot). The FACS was performed by the Flow 
Cytometry STP. (b) The ESC populations were lysed, PCR amplified, sequenced by MiSeq, and 
mutation efficiency quantified by CrispRVariants (Lindsay et al, 2016). The MiSeq library 
preparations were performed by the GeMS STP. The MiSeq sequencing was performed by the 
ASF. The CrispRVariants R pipeline was performed by Jasmin Zohren (Turner lab).  




6.2.5 Generating X-Cas9 chimeras and assessing germline transmission 
All of the X-Cas9/Y ESC clones expressed eGFP/Cas9 and the majority were functional 
in the bi-component system when the ESCs were transfected with a non-lethal sgRNA. I 
then used multiple X-Cas9/Y ESC lines to generate chimeras. The X-Cas9/Y ESCs were 
generated on a C57BL/6N genetic background and were therefore injected into albino 
C57BL/6J blastocysts, before surgical transfer into pseudopregnant females. When the 
pups were born I assessed the X-Cas9/Y ESC contribution by the percentage black coat 
colour.  
 
The following lines were injected by the GeMS STP; a1, c5, d3, d6, e6, f5 and h5 (Figure 
28a, Table 3). The surgical transfer was also performed by GeMS. Three clones did not 
produce any male chimeras. Of these three, clone c5 produced pups however they were 
all albino, showing no X-Cas9/Y ESC contribution (n=4/4 pups born, 100%). Clone d3 
produced no pups. The lack of pups born was unsurprising given that this ESC line 
appeared to be trisomic for chromosome 8. Clone e6 produced one chimera with 50% 
black coat colour, but the chimera was female and was therefore unlikely to germline 
transmit the male XY ESC line. The remaining e6-produced pups were albino. The other 
four injected clones produced chimeras with varied percentage black coat colour. Clones 
a1, d6 and f5 all produced chimeras with a mean black coat colour above 50%. Clone h5 
produced two male chimeras, but with low percentage contribution (20%, 25%, Figure 
28a,b, Table 3). One high contribution male from injection of clone f5 had to be culled 
(red box around the data point, Figure 28a), and therefore could not be used to assess 
germline transmission. Representative images of some X-Cas9/Y chimeras produced by 
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pups born (%) 
A1 41 4 2 10/13 (77%) 
C5 30 2 1 0/4 (0%) 
D3 59 4 0 - 
D6 75 5 2 5/8 (63%) 
E6 60 5 2 1/9 (11%) 
F5 30 2 1 2/2 (100%) 
H5 25 2 1 2/3 (67%) 
Table 3. Generating X-Cas9/Y chimeras 
 
Male chimeras with high contribution from X-Cas9/Y ESCs were set up in matings with 
either albino C57BL/6J females, or autosomal constitutive Cre-expressing homozygous 
females Tg(Pgk1-Cre)1Lni, “PGK-Cre” (Lallemand et al., 1998). Chimeras generated 
from clones d6 and f5 were old enough to be set up in matings. One f5 male with a black 
coat contribution of 60% was set up in matings with albino C57BL/6J females. Two d6 
chimeras with percentage black coat colour 95 and 92% were set up in matings with 
albino C57BL/6J females. One d6 chimera (95%) was set up in matings with PGK-Cre 
females. All four males were fertile, as assessed by successful pregnancies of females and 
live pups born (Figure 28c,d).  
 
The F1 pups born from the d6 or f5 clone X-Cas9/Y chimeric males mated with albino 
C57BL/6J females were genotyped by coat colour and for the eGFP-containing transgene. 
Only one mating gave rise to black pups, male #3 (clone d6). This mating produced five 
pups born, four were male and were eGFP negative. There was one female pup who was 
eGFP positive (Figure 28e). In the X-Cas9/Y chimera mating to PGK-Cre females, there 
was a single litter born, with a total of four pups. None of the pups inherited the eGFP 
transgene (Figure 28e). 
 




Figure 28. Generating X-Cas9/Y chimeras and germline transmission 
(a) Percentage black coat colour contribution from X-Cas9/Y ESCs, on a C57BL/6N genetic 
background. Seven putative X-Cas9/Y ESC clones were injected. The ESC microinjection into 
embryos, and embryo surgical transfer was performed by the GeMS STP.  (b) Images of X-
Cas9/Y chimeras generated from clones d6, a1 and h5. (c) The number of litters produced from 
X-Cas9/Y chimeric males generated from clones f5 and d6, in matings with albino C57BL/6 
females. (d) The number of litters produced from a single X-Cas9/Y male generated from clone 
d6 in matings with a PGK-Cre homozygous female. (e) Assessment of germline transmission of 
the X-Cas9 transgene by eGFP-genotyping.  
 
 
In summary, there was a one female eGFP-positive pup born from a d6 X-Cas9/Y chimera 
mating with albino C57BL/6J females (Figure 28e, Figure 29a). To determine if the X-
linked Cas9 transgene is expressed in this female, I performed a low-input western blot 
from an ear notch biopsy. Cas9 expression was also analysed from biopsies taken from 
the X-Cas9/Y chimeric father and an F1 male sibling that was eGFP negative.   




In the X-Cas9/X F1 female and X-Cas9/Y chimeric father there was Cas9 expression, 
whilst there was no Cas9 expression in eGFP-negative male sibling (Figure 29b).  
 
 
Figure 29. Cas9 expression in a X-Cas9/X F1 generation female 
(a) Female X-Cas9/X F1 generation female with black coat colour from matings of X-Cas9/Y 
chimera to albino C57BL/6J females. (b) Western blot for Cas9 expression. The western blot was 
performed by Valdone Maciulyte (Turner lab).  
 
I generated an X-Cas9 stable transgenic mouse line that germline transmitted successfully 
to the F1 generation. The Cas9 transgene was inherited uniquely by female offspring from 
the chimeric father generated from clone d6, confirming that the transgene was X-linked. 
Cas9 expression was detected both in ESCs and in low-input ear biopsy tissue. However 
unfortunately due to time constraints, the X-Cas9 mouse line could not be tested in the in 
vivo bi-component system by mating to the sgRNA mouse line. 
 
6.2.6 CRISPR-Cas9 HDR components for Y-Cas9 HDR 
In the complementary strategy, where the Cas9 transgene is only inherited by sons, the 
transgene is Y chromosome-linked. I generated a Y-Cas9 TV and sgRNA targeting an 
intergenic Y chromosome region. The Y-Cas9 TV also encoded eGFP, where Cas9 and 
eGFP were driven by a CAG promoter.  
 
I generated a TV that targeted an intergenic Y chromosome region downstream of Uty 
and Eif2s3y, two highly expressed, constitutively active genes. The constitutive 
expression of Uty and Eif2s3y suggested this was a euchromatic region. The homology 
arms were amplified from C57BL/6J gDNA, aligning to the intergenic Y chromosome 
region. The 5’ homology arm (0.6kb; HAL) was inserted into pX458 using unique 
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restriction sites XbaI and KpnI. The 3’ homology arm (0.6kb; HAR) was inserted into 
unique restriction site NarI via Gibson Assembly cloning methods (Figure 30a). There 
was 52bp of intergenic sequence between the two homology arms. A PGK promoter-
driven neomycin cassette, flanked by LoxP sites, was inserted into the TV by Gibson 
Assembly cloning.  
 
Alongside earlier described experiments assessing expression of Cas9 and eGFP from the 
X-Cas9 TV by transient ESC transfection, contemporaneously I confirmed expression of 
Cas9 and eGFP from the Y-Cas9 TV.  Wildtype ESCs were transfected with either the 
backbone pX458 plasmid, the Y-Cas9 TV or were left as an untransfected control. In the 
ESCs transfected with the Y-Cas9 TV, eGFP was expressed in some cells (Figure 30b), 
similarly to the X-Cas9 TV and pX458 plasmid. To confirm that the Y-Cas9 TV 
expressed Cas9, I extracted bulk protein from the ESCs and western blots for Cas9 were 
performed. Results showed that the ESCs transfected with the Y-Cas9 TV expressed 
Cas9, similarly to pX458 (Figure 30c). There was no Cas9 expression in the untransfected 
controls, as expected. Therefore, I confirmed that the Y-Cas9 TV expressed eGFP and 
Cas9. 
 
I also generated a plasmid expressing an sgRNA targeting the Y-chromosome intergenic 
region within the 52bp intervening sequence between the two homology arms. The 20 
nucleotide oligonucleotides were cloned into pX458 and confirmed by Sanger 
sequencing. I transfected the Y-chromosome sgRNA pX458 plasmid into wildtype 
C57BL/6N ESCs. The transfected and non-transfected ESCs were sorted by FACS on 
eGFP reporter expression. The eGFP+ and eGFP- ESCs were lysed and the Y-intergenic 
target region amplified by PCR, sequenced by MiSeq and analysed by the CrispRVariants 
pipeline (Lindsay et al, 2016). The mean mutation efficiency at the Y-chromosome 
intergenic position was 17.9% in the eGFP+ ESCs (Figure 30d), highlighting the ability 
of the sgRNA to produce a DNA DSBs at the target region.  
 




Figure 30. Generating the components for Y-Cas9 HDR 
(a) Targeting strategy for HDR at the Y chromosome intergenic region. The transgene to be 
inserted contains Cas9-eGFP under a constitutive CAG promoter and neomycin under a 
constitutive PGK promoter, flanked by LoxP sites. The transgene is bordered by two homology 
arms; 5’ (HA left) and 3’ (HA right) for homology directed recombination at the target locus. (b) 
The plasmid targeting vector was transiently transfected in wildtype C57BL/6N embryonic stem 
cells to confirm eGFP expression by fluorescence microscopy. Scale bars=100µm (c) The 
transiently transfected embryonic stem cells were collected and bulk protein extracted for western 
blot. Antibodies against Cas9 and Tubulin were used for detecting gene expression at the protein 
level. The western blot was performed by Valdone Maciulyte (Turner lab). (d) A CRISPR-Cas9 
plasmid (pX330) containing an sgRNA targeting the Y chromosome was tested to ensure cleavage 
at the target position. Mutation efficiency was evaluated by PCR amplification of the target 
region, sequencing by MiSeq and evaluation by CrispRVariants. The MiSeq library preparations 
were performed by the GeMS STP. The MiSeq sequencing was performed by the ASF. The 
CrispRVariants R pipeline was performed by Jasmin Zohren (Turner lab).   
 
Overall, this data shows that DNA DSBs were generated by CRISPR-Cas9 at the 
intergenic Y chromosome region, downstream of Uty and Eif2s3y. I theorised that 
induction of the DNA DSB increases HDR efficiency at the Y chromosome for Y-Cas9 
HDR.  
 
6.2.7 Generating and characterising Y Cas9 embryonic stem cells  
Next, I generated the Y-Cas9 knock-in via CRISPR/Cas9 induced HDR in C57BL/6N 
ESCs. Serum+LIF-maintained ESCs were co-transfected with the Y-Cas9 TV and 
sgRNA plasmid. Two days post-transfection, neomycin was added to the cell culture 
medium for eight days. A total of 384 colonies were picked into individual wells of a 96-
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well plate, DNA extracted and PCR-genotyped (Figure 31a). To PCR-genotype, I 
performed a 5’ boundary PCR (primers shown by arrowheads, Figure 30a). Of 384 
colonies, one clone was boundary PCR positive, “1b5” (Figure 31b). The PCR product 
was Sanger sequenced and results confirmed an integration at the target site, by the 
presence of endogenous Y-sequence adjacent to homology arm sequence, immediately 
followed by transgene sequence. There were no indels around the 5’ integration site. 
Conversely however, the 3’ boundary PCR consistently failed, despite extensive trouble 
shooting. 
 
To determine whether there were other random transgene integrations elsewhere in the 
genome in ESC line 1b5, a copy number qPCR was performed. The eGFP and neomycin 
copy number was normalised to a reference gene Tfrc in R26-Cas9 homozygous sample 
(eGFP and neomycin present in two copies). In 1b5, the copy number of eGFP and 
neomycin was one, suggesting they are present in a single copy (Figure 31c). To confirm 
the qPCR copy number analysis, a Southern blot was performed using a neomycin probe 
and the R26-Cas9 ESC line as a positive control for probe hybridisation. In 1b5 there was 
a single band at the expected height when probing from both the 5’ (8.5kb) and 3’ 
(14.5kb) direction (Figure 31d). Overall, these data confirmed that there was a single 
integration of the Cas9-eGFP transgene at the Y-intergenic region.  
 
To determine if there were any chromosomal aneuploidies in the Y-Cas9 ESC line, low-
pass WGS was performed. The results showed that the autosomes were diploid. The X 
chromosome was present in a single copy, and reads aligned to the Y chromosome (not 
visible in the plot, read number listed in Table 4), confirming that 1b5 was XY (Figure 
31e).  
 




Figure 31. Generating a Y-Cas9 knock-in embryonic stem cell line 
(a) Strategy for generating a knock-in by HDR in C57BL/6N embryonic stem cells. Cells were 
transfected with CRISPR-Cas9 components and a Y-Cas9 plasmid targeting vector containing a 
neomycin resistance cassette. After 2 days post-transfection cells were selected by addition of 
neomycin antibiotic into the 2i+LIF medium. After 8 days selection, surviving colonies were 
picked into individual wells of a 96-well plate and expanded for genotyping. (b) PCR genotyping 
of Y-Cas9 clones using boundary PCR. (c) Copy number qPCR for eGFP and neomycin, 
normalised to Tfrc in R26-Cas9 homozygous sample. (d) Southern blot (5’ and 3’) of clone 1b5 
to determine the number of integrations of the transgene, probing for neomycin. The Southern 
blots were performed by Valdone Maciulyte (Turner lab). (e) Assessing chromosomal aneuploidy 
by DNA extraction from clone 1b5, low-pass WGS and bioinformatic analysis. The library 
preparations and sequencing were performed by the ASF. The R pipeline for analysis and to 
generate the plots was performed by Jasmin Zohren (Turner lab). 
 








1b5 2828894 89030 49025 
Table 4. Sequencing reads (low-pass WGS) for the Y-Cas9 ESC clone. 
 
Overall, these results showed that X/Y-Cas9 clone 1b5 contained a single integration of 
the Cas9-eGFP transgene at the target Y chromosome intergenic region, and was 
therefore suitable for blastocyst injection to generate chimeras.  
6.2.8 Producing Y Cas9 chimeras and assessing germline transmission 
After determining that the Cas9-eGFP transgene was a single copy integration at the 
expected position on the Y chromosome, the GeMS STP generated chimeras by 
blastocyst injection of 1b5. Passage 3 serum+LIF-maintained 1b5 ESCs were injected 
into albino C57BL/6J blastocysts and GeMS surgically transferred the injected embryos 
into pseudopregnant females. I assessed the pups born for black coat colour chimerism. 
A total of 27 pups were born and 18 (67%) had black coat colour contribution (Table 5, 
Figure 32a). Of the pups that showed any X/Y-Cas9 contribution, the mean black coat 
colour percentage was 45%. The methylation status of 2i+LIF-maintained ESCs is 
considered to be more representative of the epiblast and therefore 2i+LIF ESCs may 
contribute more highly to chimeras (Mulas et al., 2019b). Therefore, passage four 1b5 
X/Y-Cas9 ESCs were transferred into 2i+LIF for three passages (Figure 31a). After 
2i+LIF culture, the ESCs were injected into albino C57BL/6J blastocysts by the GeMS 
STP. Of 28 pups born, 71% (n=20/28) had black coat colour contribution from X/Y-Cas9 
ESCs. The mean black coat colour contribution was 62% (Table 5, Figure 32a,b) and one 
pup had 100% black coat (can be seen in Figure 32b). These results suggested that short 
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pups born (%) 
1b5 
(serum+LIF) 
80 4 3 18/27 (67%) 
1b5 
(2i+LIF) 
96 8 4 20/28 (71%) 
Table 5. Generating the X/Y-Cas9 chimeras 
 
Next, I assessed Y-Cas9 germline transmission from the chimeras. The Y-Cas9 transgene 
was integrated 40kb and 10kb downstream of Uty and Eif2s3y, respectively. Eif2s3y 
knock-out results in male infertility (Matsubara et al., 2015) and therefore disruption to 
Eif2s3y from transgene insertion may have the same phenotype. Therefore, I first 
determined if the high contribution chimeras were fertile by successful mating with 
wildtype females. Four chimeric males were set up in matings with wildtype females. 
Two of the males were produced from serum+LIF 1b5 ESCs (male #1 and #2), and two 
were produced from 2i+LIF-transferred ESCs (male #3 and #4). Males #1 and #2 were 
both 75% black. Male #3 was 90% black, and male #4 was 100%. Three of the males 
produced multiple litters by wildtype females; #2, #3 and #4. Therefore, the fertility of 
these three males was not impaired by insertion of the transgene (Figure 32c).  
 
Once I had confirmed the chimeric males were fertile, I ear biopsy-genotyped the 
offspring to determine if the transgene was germline transmitted. The male offspring 
should uniquely inherit the transgene; however all pups were genotyped to confirm this. 
Of the three fertile males, all germline transmitted the Cas9-eGFP transgene to offspring 
(Figure 32d). From male #2 (75% chimeric, serum+LIF), only 11% male pups born was 
X/Y-Cas9 (n=1/9). From male #3 (90% chimeric, 2i+LIF), 58% male pups were X/Y-
Cas9 (n=7/12), while from male #4, (100% chimeric, 2i+LIF), 90% male pups were X/Y-
Cas9 (n=9/10; Figure 32d). I also confirmed there were no eGFP positive female 
offspring born (n=0/31 total females born, 0%; Figure 32d).  
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The Y-Cas9 F1 males were assessed for fertility by testis weight measurement. Both 
testes were removed by dissection from culled males, weighed and the two values 
averaged. The mean testis weight was calculated from seven X/Y-Cas9 males and five 
wildtype C57BL/6J males (+/+). The mean testis weight for wildtype males was 98mg, 
while for the X/Y-Cas9 it was 103mg (Figure 32e). 
 
To confirm Y-linked gene expression from F1 generation males, I performed qPCR for 
Uty and Eif2s3y. Y-linked gene expression was normalised to Gapdh from a wildtype 
male. In the X/Y-Cas9 male, expression levels of Uty and Eif2s3y were similar to that of 
a C57BL/6J wildtype male. There was no expression of Uty and Eif2s3y in control female 
tissue (Figure 32f). Expression of the X-linked gene Hprt was also analysed as a 
housekeeping gene control. Hprt was expressed in wildtype male and female, and X/Y-
Cas9 tissue (Figure 32f). Overall, this data shows that expression of Y-linked genes Uty 
and Eif2s3y were unimpaired in the X/Y-Cas9 male F1 generation.  




Figure 32. Generating Y-Cas9 chimeras, germline transmission and assessing fertility 
(a) Coat colour contribution from black X/Y-Cas9 ESCs after culture in serum+LIF or 2i+LIF 
conditions. (b) Example chimeras generated from injection with clone 1b5. The ESC 
microinjection into embryos, and embryo surgical transfer was performed by the GeMS STP.  (c) 
Litters produced after mating with wildtype females. (d) Assessment of germline transmission of 
the Y-Cas9 transgene. (e) Testis weights of C57BL/6J wildtype males (+/+) versus X/Y-Cas9 
males. (f) qPCR analysis of Y chromosome linked genes, Uty and Eif2s3y and X-linked gene 
Hprt.  




6.2.9 Investigating Cas9 expression by Cre recombinase removal of neomycin 
The Y-Cas9 transgene was stably integrated into the Y-chromosome intergenic region 
and was successfully germline transmitted. I next assessed Cas9 and eGFP expression. 
The PGK promoter driving neomycin expression could have local silencing effect on the 
transgene. Therefore, I assessed Cas9 and eGFP expression from the Y-Cas9 transgene 
both with PGK-neo and post-Cre excision.   
 
Protein from an X/Y-Cas9 male, wildtype male and R26-Cas9 male was extracted and 
western blots performed to assess Cas9 expression. In the R26-Cas9 positive control, 
Cas9 was expressed. Conversely, in the wildtype and X/Y-Cas9 samples, there was no 
Cas9 expression (Figure 33a). To determine if the Cas9 deficiency was in vivo specific, 
the X/Y-Cas9 1b5 ESCs were also tested by western blot. Similarly to the X/Y-Cas9 
tissue, there was no Cas9 expression (Figure 33b). The western blot results show that the 
X/Y-Cas9 transgene is not expressed in vivo or in vitro.  
 
To excise the floxed PGK-neomycin cassette in vivo, X/Y-Cas9 males were set up in 
matings with X-Cre hemizygous females (X-Cre/X). Pups were genotyped for Cre and 
the transgene. Two X-Cre/Y-Cas9 males, 3.1a and 3.1c, were used for future experiments. 
To confirm that the floxed-PGK cassette was excised I PCR-genotyped the two X-Cre/Y-
Cas9 males. I utilised PCR primers that align to the transgene, 5’ of the PGK-neomycin 
cassette, and to the homology arm, 3’ of the cassette (orange arrows, Figure 33c). If the 
PGK-neomycin is present, the amplicon is 2.2kb. If the PGK-neomycin has been lost, the 
amplicon had a size shift to 0.85kb (orange arrows, Figure 33c). The two X-Cre/Y-Cas9 
males showed the amplicon size shift compared to X/Y-Cas9 males (Figure 33d), 
confirming the floxed-neomycin had been excised.   
 
I tested Cas9 and eGFP expression post-Cre recombinase excision of the floxed-PGK-
neomycin at the RNA and protein level, by performing qPCR and western blot. In the 
western blot I included the positive control R26-Cas9, negative control C57BL/6J and 
parental X/Y-Cas9 tissue. Results showed that there was no Cas9 expression in either X-
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Cre/Y-Cas9 males, similar to the X/Y-Cas9 father (Figure 33e). In the qPCR, expression 
of Y-linked genes Uty/Eif2s3y and transgenic eGFP was normalised to Gapdh in wildtype 
tissue. In the X-Cre/Y-Cas9 males, there was expression of Uty and Eif2s3y, however 








Figure 33. Transgene expression in X/Y-Cas9 and X-Cre/Y-Cas9 males 
(a) Western blot to assess expression of Cas9 in the Y-Cas9 mouse. (b) Western blot to assess 
expression of Cas9 in the 1b5 Y-Cas9 ESC line. All western blots were performed by Valdone 
Maciulyte (Turner lab). (c) Cre recombinase removal of the floxed-PGK-neomycin cassette in 
vivo by crossing a Y-Cas9 male with a X-Cre female mouse. (d) PCR genotyping highlighting 
removal of the floxed-PGK-neomycin cassette in vivo. (e) Western blot to assess expression of 
Cas9 in X-Cre/Y-Cas9 male mice after removal of the floxed-PGK-neomycin cassette. (f) qPCR 
analysis of Y chromosome genes Uty and Eif2s3y, and transgene eGFP, in X-Cre/Y-Cas9 males.  
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It was possible that the lack of transgene expression in the X-Cre/Y-Cas9 males was due 
to mosaicism of floxed-neomycin excision. To assure that this was not the case, I set up 
X-Cre/Y-Cas9 males in matings with wildtype females (Figure 34a). Male pups born 
were genotyped for the Y-Cas9 and X-Cre alleles. All female offspring were X-Cre/X 
(n=7) while all males were X/Y-Cas9 (-neo; n=8, Figure 34b). Two X/Y-Cas9(-neo) 
males, 6.1a and 6.1b, were carried forward for future experiments. I confirmed that there 
was a complete loss of the floxed-neomycin cassette by PCR genotyping, determined by 
the presence of the size-shifted amplicon. In both X/Y-Cas9(-neo) males (hereafter “X/Y-
Cas9”), the neomycin cassette had been excised (Figure 34c). I also confirmed that the 
eGFP had remained in a single copy by performing copy number ddPCR, normalising to 
R26-Cas9 homozygous Tfrc. The ddPCR results showed that the eGFP was single copy 
in the X/Y-Cas9 males (Figure 34d).  
 
I determined whether complete removal of the PGK-neomycin induced eGFP expression 
by qPCR. Expression of transgenic eGFP and X-linked gene Hprt was normalised to 
Gapdh expression in wildtype tissue. Two different tissues were tested for each X/Y-
Cas9 male. The qPCR results showed that there was low, but detectable eGFP expression 
in both tissue types in the X/Y-Cas9 males (Figure 34e). The expression of X-linked gene 
Hprt was comparable between control samples and X/Y-Cas9 samples (Figure 34f). 
 




Figure 34. eGFP expression in X/Y-Cas9 males from X-Cre/Y-Cas9 parents 
(a) X-Cre/Y-Cas9 males were set up for matings with wildtype C57BL/6J females (+/+) to ensure 
all Y-Cas9 offspring were non-mosaic for removal of the neomycin cassette. (b) Offspring 
genotypes (n=15 pups): X-Cre/X females (n=7) and X/Y-Cas9 males (n=8). (c) Two X/Y-Cas9 
males were genotyped for loss of the neomycin cassette. (d) Confirmation that the eGFP cassette 
had remained intact and was present in a single copy in both males. (e) Detection of eGFP and 
Hprt expression by qPCR compared to +/+ control. For both X/Y-Cas9 samples two different 
tissue samples were used, liver and kidney.  
 
To determine whether the males encoded a functional Cas9, I set up two X/Y-Cas9 males 
in matings with hemizygous sgRNA/+ females (Figure 35a). There are four possible 
offspring genotypes: female mCherry+eGFP- (X/X;sgRNA/+), female mCherry-eGFP- 
(X/X;+/+), male mCherry+eGFP+ (X/Y-Cas9;sgRNA/+) male mCherry-eGFP+ (X/Y-
Cas9;+/+). If co-inheritance of the Y-Cas9 transgene and the sgRNA transgene was 
embryonic lethal due to CRISPR-Cas9 induced mutations at Top1, then I would expect 
no male mCherry+eGFP+ offspring to be born.  
 
The pups born from the matings were phenotyped for sex and assayed by in vivo imaging 
for mCherry expression at PN4. A total of 24 pups were born from three litters, and all 
four genotypes were present. Of the 24 pups born, nine (37%) were female sgRNA/+ 
heterozygous, and six (25%) were female mCherry negative (Figure 35b). All females 
were eGFP negative. Six males (25%) were X/Y-Cas9 and mCherry negative. However 
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three males (13%) were X/Y-Cas9;sgRNA/+ (Figure 35b). The occurring ratio of 
genotypes was not a statistically-significant deviation from Mendelian frequency. Overall 
this data suggests that the Y-linked Cas9-eGFP allele does not express Cas9, despite the 





Figure 35. X/Y-Cas9 (-neo) matings to sgRNA/+ heterozygous females 
(a) Mating strategy to assess if mCherry+eGFP+ offspring are embryonic lethal. X/Y-Cas9 males 
were set up for matings with sgRNA/+ heterozygous females. Four offspring genotypes were 
possible: female mCherry+eGFP- (X/X;sgRNA/+), female mCherry-eGFP- (X/X;+/+), male 
mCherry+eGFP+ (X/Y-Cas9;sgRNA/+) male mCherry-eGFP+ (X/Y-Cas9;+/+). (b) Offspring 
genotype ratios, assessed by phenotypic sex, in vivo imaging, and standard genotyping. 
 
  





The data presented in this chapter showed that transgenes can be successfully integrated 
into the X chromosome Hprt locus.  In the mouse, targeting Hprt is extremely convenient 
as loss-of-function of Hprt has no detrimental phenotype (Kuehn et al., 1987, Hooper et 
al., 1987, Koller et al., 1989, Jinnah et al., 1990). I used a PGK-neomycin cassette for 
positive selection of transgenic clones, instead of 6-tg selection. Therefore, the neomycin 
was used as a target for copy number analysis and could be later excised by Cre 
recombination. Only two of the nine X-Cas9 clones appeared to have multiple or off-
target integrations of the transgene. To determine if the multiple integrations were random 
integrations or transgene concatemers on the X chromosome, Southern blots could be 
performed. In ESCs and in a F1 generation X-Cas9/X female, the Cas9 transgene was 
expressed. In this X-Cas9/X female, the Cas9 transgene was hemizygous and therefore 
single-copy. Furthermore, the single-copy transgene may have been susceptible to X 
chromosome inactivation, silencing the transgene in some cells. Therefore, looking 
forward, I predict that male F2 generation X-Cas9 offspring may show a greater level of 
transgene expression, than the X-Cas9/X F1 mother.  
 
The use of Hprt for knock-in of transgenes is extremely useful for generating female-
specific mutations in the mouse, when the transgene, such as Cas9 or sgRNA, is carried 
by the father. Generating single-sex litters by sex-selective non-viability is immediately 
translatable for reducing mouse culling of the unrequired sex, in line with the Home 
Office 3Rs. Furthermore, the CRISPR-Cas9 bi-component system is translatable to other 
research groups that wish to use this system to induce sex-specific mutations at a gene of 
interest. However when translating the bi-component system to other species, it may be 
more challenging, if loss-of-function targeting of Hprt is not possible. In rabbits, 
heterozygous females are viable and fertile, however hemizygous knock-out males are 
embryonic lethal (Yin et al., 2015). Therefore, in the rabbit, male-carrying Hprt knock-
in transgenes could not be generated. Conversely, loss-of-function Hprt in the male rat 
appears to have no detrimental phenotype on viability or fertility. However Hprt null male 
rats do show dysfunction of purine and nucleotide metabolism (Meek et al., 2016). In 
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cows, it is known that Hprt is expressed during pre-implantation development (Kita and 
Imai, 1993) however there have been no studies to date investigating the loss-of-function 
phenotype.  
 
Although Hprt is an extremely useful docking-site in the mouse, direct translation of the 
technology to other species does not have to follow the exact-same strategy of knock-in. 
For example in cows, Hprt is expressed in the pre-implantation embryo (Kita and Imai, 
1993). Therefore, the Hprt promoter could be utilised to drive transgene expression and 
there would be no loss-of-function of Hprt. Furthermore, transgenes could also be 
targeted to an intronic region of Hprt, thereby leaving the coding-sequence of Hprt intact. 
These strategies are not limited to Hprt, but other pre-implantation expressed gene 
promoters could be harnessed to drive transgene expression.   
 
The data presented in this chapter showed that transgenes can be successfully integrated 
into the Y chromosome, at an intergenic region downstream of Uty and Eif2s3y. However, 
the efficiency of targeting at this location was extremely poor, with a single clone from 
384 containing the targeted insertion. The poor efficiency of knock-in could be for two 
reasons. Firstly, the homology arms (HAs) in the Y-Cas9 TV were smaller than for the 
X-Cas9 targeting. The left HA was approximately 800bp, whilst the right HA was 
approximately 600bp. In the X-Cas9 targeting, both HAs were greater than 1kb. The 
reason for the smaller HAs in the Y-targeting was due to the highly repeat-rich nature of 
the Uty-Eif2s3y intergenic region. I generated HAs that not did contain highly repetitive 
regions, to reduce the potential risk of insert concatermerisation. The second reason is 
that although the HAs did not contain repeats, the intergenic region is highly complex 
and may be inhibitory to HDR. Therefore, irrespective of HA length, the rate of HDR 
may have been poor at this region. Nevertheless, the Y-chromosome targeting was 
successful, and injection of the Y-Cas9 ESC clone into blastocysts generated a stable 
transgenic mouse line.  
 
The initial rationale for targeting downstream of Y-linked genes Uty and Eif2s3y was 
because these two genes are highly expressed in the developing embryo. Therefore, I 
predicted that successful integration of a transgene at this transcriptionally permissive 
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region of the Y chromosome would increase the likelihood of Cas9 expression. However 
no Cas9 expression was detected. One explanation for the lack of Cas9 expression from 
the Y-intergenic region, could be transgene silencing. The dsDNA plasmid vector used 
to generate the knock-in by HDR is bacterial DNA. Integration of bacterial DNA plasmid 
backbone at the target site, adjacent to the construct, may induce endogenous mechanisms 
to silence the entire transgene. Support for this theory comes in the form of boundary 
PCR genotyping. In the results of this chapter, I was able to successfully amplify the 5’ 
boundary PCR product. However amplification of the 3’ boundary PCR product 
consistently failed. This suggests that there could be some further backbone integration 
of the TV after the 3’ HA. The reverse primer binding sites in the endogenous locus may 
have been lost, or are significantly further away from the transgene forward than predicted 
by in silico expected knock-in sequence. To investigate the sequence surrounding the 
integration site further, whole genome sequence or targeted high-throughput sequencing 
should be performed. If the sequencing results show that there is plasmid backbone 
present adjacent to the X-Cas9 cassette, it can be removed by CRISPR-Cas9 genome 
editing. 
 
Anecdotal evidence also suggested that the presence of a PGK-neomycin cassette may 
induce local transgene silencing (personal communication, Lovell-Badge lab). To 
circumvent this risk, I used a constitutive X-Cre to excise the floxed-neomycin cassette. 
Prior to the neomycin excision, there was no transgene expression. Post-neomycin 
excision, there appeared to be eGFP expression by qPCR. However Cas9 expression was 
not able to fully induce a male-specific lethality effect in vivo, suggesting that the 
transgene expression is negligible.  
 
Given the lack or negligible expression of the Y-Cas9 transgene in ESCs and in the 
mouse, future directions will be to repeat the Y-Cas9 targeting. One possibility for this 
repeat targeting is to the Uty locus. Uty is a constitutively expressed gene, both in ESCs 
and during embryo development. Loss-of-function of Uty is thought to be non-
detrimental to the mouse (Shpargel et al., 2012). Previous studies have successfully 
targeted Uty for eGFP reporter tagging, in-frame with the ATG start codon of the Uty 
reading frame (Wang et al., 2013a). Targeting the Uty locus was also shown in the 2019 
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study by Yosef et al who generated a Y-linked sgRNA transgenic mouse line. In this 
study, Yosef et al targeted Uty introns to integrate the transgene (Yosef et al., 2019). 
Intronic or in-frame Uty targeting by HDR with the Cas9-eGFP transgene could keep Uty 
expression intact whilst allowing Cas9-eGFP expression.  
 
 
Chapter 7. Discussion 
 
 183 
Chapter 7. Summary 
In conclusion, in this thesis I utilised and generated genetic tools to produce single-sex 
litters. Generating single-sex litters may have advantageous applications in agriculture, 
pest control, and in a laboratory research setting. In agriculture and in research, currently 
the unrequired sex is being culled needlessly after birth, generating a widespread animal 
welfare problem. I have described the potential of two different technologies to generate 
single-sex litters in order to reduce post-natal animal culling.  
 
In Chapter 3, I described a method of generating single-sex litters using pre-existing 
mouse lines, as a proof-of-principle. The mouse lines encoded an autosome-linked 
inducible diphtheria toxin A, and an X-linked Cre recombinase. Inheritance of both the 
Cre recombinase, and the toxin resulted in female-specific lethality and all-male litters. 
Importantly, these results showed that it was possible to generate single-sex litters without 
impacting the viability of all the required-sex siblings.   
 
In Chapters 4 and 5, I described the development of CRISPR-Cas9 tools, where the Cas9 
and sgRNA components are genetically segregated. I showed that the bi-component 
system, targeting essential gene Top1, was sufficient to generate indel mutations in vitro. 
Furthermore, the mutations at Top1 were stereotypic and generated frame-shift mutations, 
resulting in loss-of-function of Top1. The method of screening sgRNA mutation 
efficiency in vitro could be used for evaluating the efficiency of any sgRNA. The success 
of the in vitro bi-component system was recapitulated in vivo. Co-inheritance of the Cas9 
and sgRNA transgenes induced mutations at Top1 at a significantly higher rate to Cas9-
only littermates. Importantly, the Cas9/sgRNA embryos were non-viable, although 
curiously, the litter size was largely unaffected. Therefore, I concluded that the CRISPR-
Cas9 bi-component system was sufficient to introduce mutations at the sgRNA-target 
gene in vitro and in vivo and induce embryonic lethality. The CRISPR-Cas9 component 
is not limited to essential housekeeping genes, and could be used to target any gene of 
interest and therefore may be of interest to many research groups. 
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In Chapter 6, I generated sex chromosome-encoding Cas9 transgenic ESC lines, and used 
the targeted ESCs to generate transgenic mice. Generating X- and Y-linked Cas9 
transgenes would allow for sex-specificity of the bi-component system. Generation of the 
X-Cas9 was successful, with Cas9 expression in ESCs. Furthermore, X-Cas9 chimeras 
successfully germline transmitted the X-Cas9 transgene to female offspring that also 
expressed Cas9. Unfortunately, although correctly targeted at the 5’ end, the Y-linked 
Cas9 did not express either in ESCs or in mouse tissues. Nonetheless, this is the first 
example of generating X-linked Cas9-encoding lines, and the first example of generating 
autosome-linked sgRNA-expressing lines. These new transgenic mouse lines may be 
immediately useful for research laboratories.  
 
The technology is not limited to targeting genes with essential housekeeping function, 
but any gene of interest in the genome could be targeted. The sgRNA-expressing mouse 
line was generated by targeting the transgene to the permissive locus Hipp11 on mouse 
chromosome 11. The same targeting strategy could be used to generate a sgRNA 
transgene knock-in targeting any gene. This is highly translatable to other species, as the 
sgRNA transgene is autosome linked. As well as H11 and Rosa26 in the mouse, similar 
autosome-linked permissive-loci have been detected in other species, for example Rosa26 
is conserved in rats (Kobayashi et al., 2012), pigs (Kong et al., 2014, Li et al., 2014b, Li 
et al., 2014c), rabbits (Yang et al., 2016), and cows (Wang et al., 2018).  
 
Looking forward, there are multiple other methods of generating single-sex litters by 
modifying the bi-component system. One possible future strategy to generate single-sex 
litters would be to produce X- or Y-linked sgRNA transgenes. In this scenario, the sgRNA 
would be uniquely inherited by daughters or sons, respectively. The sex chromosome-
linked sgRNA mouse line would be crossed with the autosomal homozygous R26-Cas9 
(Platt et al., 2014) mouse line. If the sgRNA is X-linked, there are two possible genotype 
outcomes: X-sgRNA/X;R26-Cas9/+ (female) or X/Y;R26-Cas9/+ (male). Only the 
female offspring inherit both transgenes, and therefore contain both CRISPR-Cas9 
components (Table 6).  
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If the sgRNA is Y-linked, there are two possible genotype outcomes: X/X;R26-Cas9/+ 
(female), or X/Y-sgRNA;R26-Cas9/+ (male). In this scenario, only male offspring inherit 































Table 7. Hemizygous X/Y-sgRNA male mating to homozygous R26-Cas9 female 
 
The sgRNA targeting Top1 exon 15 has been shown in Chapters 4 and 5 to be highly 
efficient, generating loss-of-function mutations and embryonic non-viability. A construct 
expressing the Top1 sgRNA and mCherry reporter can be used for targeting to the X- and 
Y chromosome. I would predict that co-inheritance of the X- or Y-linked sgRNA 
transgene with autosomal Cas9 would result in embryonic lethality.  
 
Single-sex litters could also be generated by targeting genes necessary for male- or 
female-specific sex determination.  In Chapter 2, I utilised a non-lethal sgRNA targeting 
the male TDF/sex-determination gene Sry. The same sgRNA could be used for generating 
sgRNA-transgene knock ins. The X-sgRNA(Sry) transgene would be biallelically carried 
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by the mother and therefore would be inherited by all offspring (Table 8). The X-linked 
sgRNA(Sry) transgenic females would be mated to R26-Cas9 homozygous males.  
 
Conversely to earlier described strategies where inheritance of both the sgRNA and Cas9 
transgenes is sex-specific, in this strategy, all offspring inherit both the sgRNA(Sry) and 
Cas9 transgenes. The Sry gene is uniquely carried by male offspring on the male-specific 
Y chromosome, therefore the Sry gene can only be targeted for knock-out in males (Table 
8). Co-inheritance of the CRISPR-Cas9 components results in loss-of-function of Sry  and 
male-to-female sex reversal. This strategy would give rise to all-female litters however 
approximately half of the litter would be genetically XY. The same result could also be 
produced by utilising autosomal sgRNA transgenes crossed with autosomal Cas9 
transgenic lines, as only the Y-carrying males will be affected (Table 9). Although 
generating all-female litters by Sry knock-out may be a useful strategy for agriculture or 
pest control applications, researchers may be apprehensive to utilise this strategy in the 
laboratory. Although the litters will be all-female, the underlying genetic complement 
differs to the phenotypic sex, therefore the influence of the Y chromosome in 
phenotypically-female offspring could be a confounding factor in interpreting biological 
results. 
 
In each of the strategies presented here, the Cas9/sgRNA offspring are transgenic and are 
embryonic lethal, or carry mutations in the target locus. The single-component 













 (Sry knock-out) 
X-sgRNA(Sry)/Y;R26-Cas9/+ 
(Sry knock-out) 
Table 8. X-sgRNA(Sry) homozygous female mating with R26-Cas9 homozygous males 
 













 (Sry knock-out) 
X-sgRNA(Sry)/Y;R26-Cas9/+ 
(Sry knock-out) 
Table 9. Autosomal H11-sgRNA(Sry) homozygous female mating with R26-Cas9 
homozygous males 
 
The fact that surviving animals are transgenic holds concerns for agricultural translation, 
regarding the safety of genetically modified animals and animal products. One method to 
circumvent the issue of transgenic animal products is by taking advantage of maternally 
deposited mRNAs in the early embryo. In this strategy, an autosomal Cas9, e.g. R26-Cas9 
(Platt et al., 2014) would be carried by the mother, mono-allelically. Therefore, 
approximately half of the offspring inherit the Cas9 transgene. The other half of the 
offspring are not transgenic for Cas9; however all zygotes are pre-loaded with Cas9 
mRNA from the oocyte. Previous studies have shown that zygotic maternal-Cas9 mRNA 
generates higher rates of genome edits at target loci, compared to when Cas9 is supplied 
by mRNA or protein microinjection (Cebrian-Serrano et al., 2017).  
 
The mono-allelic Cas9/+ mother would be crossed with a sex chromosome-linked sgRNA 
expressing male. If the sgRNA is X-linked, the females inherit the sgRNA transgene 
(Table 10). If the sgRNA is Y-linked, the males inherit the sgRNA transgene (Table 11). 
In each case, there are four offspring genotypes. Inheritance of both the sgRNA and Cas9 
components, either genetically or by maternally deposited transcripts, results in mutations 
in the target locus, inducing non-viability (or fertility). One-quarter of the litter/half of 

















(maternally loaded Cas9 




















(maternally loaded Cas9 
mRNA, embryonic lethal) 
Table 11. Y-linked sgRNA mating with heterozygous R26-Cas9 to generate wildtype 
offspring 
 
There is still public and political discussion as to the safety and efficacy of genetically 
modified animals or animal products for human consumption. The main advantage of the 
CRISPR-Cas9 system described in this thesis, is that the X- or Y-linked Cas9 
endonuclease gene is lost with the embryonic-lethal population. The surviving population 
carries only the sgRNA transgene, which is not protein-coding. The fact that the surviving 
population carry a genetic modification which is not protein-coding, may provide an 
acceptable alternative for consumption of genetically modified animals. I have also 
described in this thesis alternative methods for inducing sex-specific lethality, whilst 
retaining half of the surviving litter completely wildtype, by utilising maternally 
deposited mRNAs. The feasibility of the wildtype-generating bi-component system 
warrants further investigation for my long-term future experiments. Furthermore, my 
long-term future experiments also include the generation of X-linked sgRNA transgenic 
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animals, including the Top1 sgRNA transgene, and the Sry sgRNA transgene. These two 
mouse models can be utilised as earlier described. 
 
In the short-term future I believe it will also be important to follow up on the Y-Cas9 
experimental matings, using the sgRNA mouse line. It will be important to investigate 
further the number of live births of males that are genotype Y-Cas9/sgRNA, to determine 
if co-inheritance of these two alleles results in non-viability of males and female-bias sex 
skew. Furthermore, if it is shown that the Y-Cas9 is functional to reduce the number of 
males born, thereby skewing offspring ratios, exactly when in development the Y-Cas9 
transgene is functional. Y-Cas9 transgene expression timing can be investigated using 
immunofluorescence techniques. Next, it will be essential to investigate the functionality 
of the X-Cas9 transgene, by setting up mouse matings between X-Cas9 hemizygous 
males, and homozygous sgRNA females. If the X-Cas9 transgene is functional, I predict 
that these matings will produce all-male litters. It may be necessary to determine that the 
X-linked Cas9 transgene is expressed during multiple stages of embryonic development 
by molecular biology techniques. Lastly, it may be required to investigate the position of 
the H11 Top1 sgRNA transgene, for example by performing CRISPR-Cas9 enhanced 
Nanopore sequencing.   
 
In summary, I have shown in this thesis that it is possible to utilise a bi-component system 
to generate single-sex litters, and have made significant progress towards generating the 
genetic tools for a CRISPR-Cas9 bi-component system. Utilising a CRISPR-Cas9 bi-
component system carries strengths in that the mouse models can be simply bred and 
maintained as standard breedings. Therefore, the models generated here may be 
immediately applicable to laboratory use for generating single-sex litters, in line with the 
Home Office 3Rs, if the sex chromosome linked Cas9 transgenes are shown to be 
functional. In this laboratory application the CRISPR-Cas9 bi-component strategy 
strengths is that the Cas9 and sgRNA lines can be maintained and bred separately, to 
ensure transmission of the transgenes, or in experimental matings to produce single-sex 
litters. Furthermore, different sgRNA transgenic mouse lines may be generated to target 
any gene of interest, thereby becoming applicable to many research groups to knock-out 
genes in a sex-specific manner. However for the agricultural approach, transgenic 
Chapter 7. Discussion 
 
 190 
breeders carrying a Cas9 or sgRNA transgene would first have to be generated, thereby 
creating a challenge for immediate translation of the technology. However once 
generated, it may be possible to sell Cas9-transgenic sperm to livestock breeders, to 
generate sex-selected offspring by in vitro fertilisation with sgRNA-carrying oocytes. In 
this strategy, farmers can maintain sgRNA and wildtype females, and buy Cas9-carrying 
sperm as required. However the main weakness of the agricultural translation is the use 
of GM animals to generate animal produce, which may be unpopular with the consumer. 
More realistically however, the CRISPR-Cas9 bi-component system may be more 
relevant to pest control. Many invasive species are rodents, and therefore genetically 
modified bi-component rodents may be released into the natural population at high 






Chapter 8. Appendices 
8.1 Appendix A: Media and buffers 
 Concentration (mM) 
Components Follicle holding medium 
(FHM) 
Potassium simplex optimised 
medium (KSOM) 
NaCl 95 95 
KH2PO4 2.5 2.5 
MgSO4 0.2 0.2 
Lactate 10 10 
Pyruvate 0.2 0.2 
Glucose 0.2 0.2 




EDTA 0.01 0.01 
NaHCO3 4 25 
HEPES 20 - 
CaCl2 1.71 1.71 






Medium Components Volume Final conc Product code 
2i + LIF NDiff227 489ml - Cellartis/Takara-
Clontech (Y40002) 





Glutamax 5ml 2mM Thermo Fisher 
Scientific 
(35050038) 
Human recombinant LIF 50µl 1000U/ml Merck-Millipore 
(ESG1107) 
CHIR99021 160µl 1uM Axon Medchem 
(1386) 
PD0325901 160µl 3uM Axon Medchem 
(1408) 
Human recombinant serum 
albumin 
500µl 50µg/ml Sigma-Aldrich 
(A9731) 







1ml  20%  




Fetal calf serum  2%  
2i+LIF  98%  






Medium Components Concentration Volume Final conc 
Bradley lysis buffer Tris-HCl (pH7.5) 1M 5ml 10mM 
EDTA 0.5M 10ml 10mM 
SDS 10% 25ml 0.5% 
NaCl 5M 1ml 10mM 
H2O - 459ml - 
+Proteinase K ProteinaseK 20mg/ml  1mg/ml 
 
10X KT buffer Tris-HCl (pH9.1) 670mM   
(NH4)2SO4 160mM   
MgCl2 35mM   
BSA 1.5mg/ml   
 
KT lysis buffer 10X KT buffer  10µl 1X 
NP40 10% 5µl 1% 
ProteinaseK 20mg/ml 4µl 1mg/ml 
H2O  81µl  





S.O.C. medium Concentration Total for 10 litres 
Part A (autoclave sterilise)   
Bacto Tryptone 20g 200g 
NaCl 0.584g 5.840g 
KCl 0.186g 1.860g 
Water 0.800 l 8 l 
   
Part B (filter sterilise)   
MgCl2.6H2O 2.033g 20.330g 
MgSO4.7H2O 2.464g 24.640g 
Glucose 3.603g 36.030g 
Water 0.2 l 2l 
   
Final product   
Part A 8ml  
Part B 2ml  





Medium Components Concentration 
Radioimmunoprecipitation 
assay (RIPA) buffer 
Tris-Cl (pH8) 10mM 
EDTA 1mM 
EGTA 0.5mM 
Triton-X 100 1% 
Sodium deoxycholate 0.1% 
Sodium dodecyl sulphate (SDS) 0.1% 
NaCl 140mM 




Protein extraction buffer RIPA buffer 10ml 
Phosphatase inhibitor 1x tablet 
Protease inhibitor 1x tablet 
PMSF 100µl 
 




Bromophenol blue 0.01% 
 








TBS-Tween Tris-Cl (pH7.5) 20mM 
NaCl 150mM 
Tween-20 0.2% 





Medium Components Final conc Product code 
Depurination buffer HCl 0.25M  
Water   
    
Denaturation buffer NaCl 1.5M  
NaOH 0.5M  
Water   
    
Neutralisation buffer (pH 7.5) NaCl 1.5M  
Tris  0.5M  
    
Hybridisation buffer   #11603558001 
Roche DIG 
Easy Hyb 
    
Washing buffer Maleic acid buffer 1x  
Tween-20 0.3%  
    
Maleic acid buffer Maleic acid 0.1M M0375 Sigma 
NaCl 0.15M  
NaOH pellets To pH 7.5  
    
10 X Blocking buffer Blocking powder 10% (w/v) #11363514910 
detection kit 
Roche 
    
Detection buffer Tris-HCl 0.1M  
NaCl 0.1M  





8.2 Appendix B: Oligonucleotides 
Name Sequence Reference 
Sly_F CAGTTACCAATCAACACATCAC  
Sly_R CTGGAGCTCTACAGTGATGA  
Myog_F TTACGTCCATCGTGGACAGCAT  
Myog_R TGGGCTGGGTGTTAGTCTTAT  
Hprt_Cre_F TTCATAGAGACAAGGAATGTGTCC  




R26_DTA_F AAAGTCGCTCTGAGTTGTTAT (Soriano, 1999) 
(Srinivas et al., 2001) R26_DTA_MutR GCGAAGAGTTTGTCCTCAACC 
R26_DTA_wtR GGAGCGGGAGAAATGGATATG 
Cas9_RT_F AAACAGCAGATTCGCCTGGA (Ran et al., 2013b) 
Cas9_RT_R TCATCCGCTCGATGAAGCTC 


































Top1_g1_F GAAGGAGAGACGGCAGACAC  









Top1_g2_F ACCACAAATGGCTGAGAACTGA  









Top1_g3_F TTGAGGCAAGGCAATGGGAT  




































X-Cas9_5’F GAAACCTGGGTGTGATAGGCTT  
X-Cas9_5’R AGGTCATGTACTGGGCACAA  
X-Cas9_3’F GACAACCAGGAATAGCCAGTACATC  

















Y-Cas9_F GACAACCAGGAATAGCCAGTACATC  














8.3 Appendix C: TaqMan probes 








Gene (copy number assay)  




Table 19. TaqMan probes 
8.4 Appendix D: Antibodies 
Protein Product code  
CAS9 Novus Bio NBP2-36440 
TOP1 (N-terminal) Abcam Ab109374 
TOP1 (C-terminal) Abcam Ab245432 
TUBULIN Sigma T9026 
GAPDH Santa Cruz Biotechnology Sc-25778 
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